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Absttractt 
 Despffitte a rffisffing demand for anttffi-obesffitty ttTherapeuttffics, few efecttffive pTharmacologffical opttffions 
are clffinfficaly avaffilable ttThatt ttargett ttThe synttThesffis and accumulattffion  of  body fatt.  Moderatte 
ffinThffibffittffion  of  mammalffian glycerol-3-pThospThatte acylttransferase (GPAT)  wffittTh  2-
(alkanesulfonamffido)benzoffic acffids  Thas recenttly  been  descrffibed ffin vffittro, accompanffied  by 
promffisffing  weffigThtt loss ffin vffivo. Dockffing sttudffies  wffittTh  2-(octtanesulfonamffido)benzoffic acffid 
modeled ffintto ttThe acttffive sffitte  of squasTh GPAT revealed an  unoccupffied volume lffined  wffittTh 
ThydropThobffic resffidues proxffimal tto C–4 and C–5 of ttThe benzoffic acffid rffing. In an efortt tto produce 
more  pottentt  GPAT ffinThffibffittors, a serffies  of  4- and  5-substtffittutted analogs  were  desffigned, 
synttThesffized, and evaluatted for ffinThffibffittory acttffivffitty. In general, compounds conttaffinffing 
ThydropThobffic substtffittuentts att ttThe  4- and  5-posffittffions, sucTh as  bffipThenyl and alkylpThenyl 
Thydrocarbons, exThffibffitted an ffimproved ffinThffibffittory acttffivffitty agaffinstt GPAT ffin vffittro. TThe mostt acttffive 
compound, a p-bffipThenylketto-substtffittutted analog, demonsttratted an IC50 of 8.5 μM and representts 
ttThe bestt GPAT ffinThffibffittor dffiscovered tto datte. Conversely, furttTher substtffittuttffion wffittTh polar Thydroxyl 
or fluoro groups led tto a  3-fold  decrease ffin acttffivffitty.  TThese resultts are consffisttentt  wffittTh ttThe 
presence  of a  ThydropThobffic  pockett and  may supportt ttThe  bffindffing  model as a  pottenttffial ttool for 
developffing more pottentt ffinThffibffittors. 
 TThe desffign and synttThesffis of ffindole analogs based on ttThe sulfonamffidobenzoffic scafold was 
also  underttaken.  Sffince exffisttffing  mettThods for ttTheffir  preparattffion  were ffinsuffficffientt, a flexffible and 
effficffientt routte tto substtffittutted  7-amffino-5-cyanoffindoles from  pyrole-3-carboxaldeThydes  was 
developed. TThe routte commences  wffittTh a  one-pott, ttThree-componentt  Wffittttffig reacttffion  of ttThe 
aldeThydes  wffittTh fumaronffittrffile and a ttrffialkylpThospThffine. TThe  predomffinanttly E-alkene  productt 
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posffittffions ttThe alylffic nffittrffile for facffile ffinttramolecular Hoeben-HoescTh reacttffion ffin ttThe presence of 
BF3•OEtt2. SynttTheses of 2,5- and 3,5-dffisubsttffittutted 7-amffinoffindoles are ffilusttratted. Addffittffionaly, 
dffianffion alkylattffion  of ttThe alylffic  nffittrffile ffis  demonsttratted tto furnffisTh, aftter cyclffizattffion,  5,6-
dffisubsttffittutted 7-amffinoffindoles. 
 Isostteres  of ffindole,  N-fused  Thetteroaromattffic  bfficycles  were also  desffired as ffinThffibffittor 
candffidattes. An effficffientt routte tto ttThese Thetterocycles, ffincludffing ffindolffizffines, ffimffidazo[1,2-
a]pyrffidffines, and ffimffidazo[1,5-a]pyrffidffines from azole aldeThydes  was  developed  usffing a relatted 
butt  mecThanffisttfficaly  dffisttffinctt  mettThod. A sffimffilar ttThree-componentt  Wffittttffig  olefffinattffion  of ttThe 
aldeThydes  was  opttffimffized tto aford predomffinanttly E-alkenes ttThatt,  upon ffin sffittu ttreattmentt  wffittTh 
cattalyttffic  KOH,  undergo rapffid cycloaromattffizattffion.  Substtffittuentt conttrol  of ttThe  1-,  2-, and  3-
posffittffions of ttThe resulttffing Thetteroaromattffic bfficycles ffis demonsttratted. Altternattffively, ttThe ffisolable E-
alkene Wffittttffig productt from  pyrole-2-carboxaldeThyde,  under  dffianffionffic condffittffions,  undergoes 
selecttffive alkylattffion  wffittTh varffious electtropThffiles, folowed  by ffin sffittu annulattffion tto ffindolffizffines 
addffittffionaly substtffittutted att ttThe  6-posffittffion. TThese routtes alow for ttThe rapffid generattffion  of 
Thetterocyclffic lffibrarffies for evaluattffion of GPAT ffinThffibffittffion. 
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CThaptter 1 
Inttroducttffion tto Currentt Anttffiobesffitty TTherapeuttffics 
1.1 Inttroducttffion 
TThe ffincffidence of obesffitty, defffined as Thavffing a Body Mass Index (BMI) of 30.0 or ThffigTher, Thas 
been stteadffily ffincreasffing  wffittTh approxffimattely  400  mffilffion adultts  beffing afectted  worldwffide. A 
recentt sttudy esttffimatted ttThatt 68.0% of U.S. adultts are overweffigThtt (BMI greatter ttThan 25.0) wffittTh 
33.8% classffifffied as  obese att an annual costt approacThffing  $300  bffilffion.1 Obesffitty  Thas  been 
ffimplfficatted ffin multtffiple dffiseases ffincludffing Theartt dffisease2,3, ttype 2 dffiabettes4, sttroke5, nonalcoTholffic 
fatttty lffiver dffisease4, ffinferttffilffitty6, and certtaffin ttypes of cancer7. In factt, of ttThe fffive leadffing causes of 
deattTh ffin ttThe U.S. ffin 2010, as sThown ffin Fffig. 1.1, four carffied some assocffiattffion wffittTh obesffitty. Every 
year, obesffitty resultts ffin Thundreds of ttThousands of lffives lostt and bffilffions of dolars wastted, makffing 
pTharmacologffical ffintterventtffion for ttThe dffisease an attttracttffive opttffion. 
	  
Fffigure 1.1 Leadffing causes of deattTh ffin ttThe Unffitted Sttattes ffin 2010 
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1.2 Anttffiobesffitty TTherapffies Targettffing Food Inttake (CNS) 
Despffitte ttThe rffisffing  demand for anttffiobesffitty ttTherapeuttffics, few drugs  Thave  been cleared for 
clffinffical ttreattmentt (Fffig. 1.2). TThe majorffitty of ttThese drugs ttargett recepttors ffin ttThe centtral nervous 
systtem (CNS) and  were  orffigffinaly sttudffied for neurologffical  dffisorders sucTh as  depressffion and 
drug dependence. For many of ttThese centtraly-acttffing drugs, anttffiobesffitty ttTherapy was consffidered 
only aftter researcThers  observed anorecttffic sffide efectts ffin clffinffical  pattffientts.  As  wffittTh  many  drugs 
ttargettffing ttThe CNS, several of ttThese ttTherapffies Thave also been lffinked tto severe sffide efectts, leadffing 
tto lffimffitted or dffisconttffinued clffinffical use. 
	  
Fffigure 1.2 Anttffiobesffitty drugs ttargettffing ttThe centtral nervous systtem 
Sffibuttramffine actts as a serottonffin-norepffinepThrffine reupttake ffinThffibffittor (SNRI) and  was 
orffigffinaly ttestted as an anttffidepressantt, butt ffitts abffilffitty tto suppress appettffitte caused a reducttffion ffin 
food ffinttake and led tto weffigThtt loss ffin pattffientts.8 Itt was approved for ttreattmentt of obesffitty ffin ttThe 
U.S. ffin 1997. Folowffing several reportts of cardffiovascular eventts sucTh as sttrokes and Theartt attttacks, 
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Lorcaserffin, developed by Arena PTharmaceuttfficals, actts as a 5HT2C recepttor agonffistt.11 WThffile 
ttThe cascadffing efectts  of ttThe serottonergffic acttffivffitty are  poorly  understtood, lorcaserffin ttreattmentt 
resultted ffin an ffincrease ffin anorecttffic acttffivffitty and subsequentt  decrease ffin weffigThtt. Inffittffial sttudffies 
ffindfficattffing ffincreased ttumor formattffion ffin ratts led ttThe FDA ffin 2010 tto rejectt ffitts approval for ttThe 
ttreattmentt of obesffitty.12 Aftter addffittffional sttudffies, Thowever, ttThe FDA ffin 2012 approved lorcaserffin 
for clffinffical use ffin resttrffictted subsetts of obese pattffientts.13 PsycThffiattrffic dependency ffin pattffientts led 
ttThe  drug tto  be cattegorffized as a  ScThedule IV substtance  by ttThe  Drug  Enforcementt  Agency ffin 
2013.14 
Rffimonabantt actts as an ffinverse agonffistt tto ttThe cannabffinoffid recepttor CB1 and was sttudffied as a 
ttTherapy for substtance abuse for cocaffine, marffijuana, ttobacco, and alcoThol dependency.15 WThffile 
ttettraThydrocannabffinol, ttThe psycThoacttffive componentt of marffijuana, actts as a pottenttffial agonffistt of 
CB1 leadffing tto, among  ottTher efectts, ffincreased appettffitte, ttThe ffinverse agonffism  of  Rffimonabantt 
resultts ffin appettffitte suppressffion and weffigThtt loss.16 For ttThffis reason, Sanofffi-Aventtffis won approval 
for  Rffimonabantt as an anttffiobesffitty  drug ffin ttThe  European  Unffion ffin  2006. In ttThe  U.S., ttThe  FDA 
denffied approval, cffittffing ffincreased  psycThffiattrffic  problems sucTh as  depressffion and sufficffidal 
ttThougThtts.17 Because of ttThese sffide efectts, ffitt was wffittThdrawn from ttThe European marketts ffin 2009. 
TThe combffinattffion ttTherapy Qsymffia™ ffincludes ttThe ampThettamffine derffivattffive pThenttermffine along 
wffittTh ttThe anttfficonvulsantt ttopffiramatte. PThenttermffine Thas sThown prevffious weffigThtt loss efectts wThen 
combffined wffittTh fenfluramffine, a combffinattffion popularly refered tto as fen-pThen.18 Fen-pThen was 
wffittThdrawn aftter beffing dffirecttly lffinked tto fattal Theartt valve defectts and pulmonary Thyperttensffion.19 
PThenttermffine ffittself, Thowever, Thas nott yett been sThown tto Thave sffignffiffficantt ttoxfficffitty and, combffined 
wffittTh ttopffiramatte, actts as an appettffitte suppressantt. Qsymffia™ was approved by ttThe FDA ffin 2012 butt 
Thas so far been denffied approval by ttThe European Unffion owffing tto ffincreased cardffiovascular rffisk.20 
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Fffinaly, ttThe combffinattffion ttTherapy  Conttrave™ combffines ttThe  opffioffid recepttor anttagonffistt 
nalttrexone  wffittTh ttThe anttffidepressantt  bupropffion tto acThffieve a sffignffiffficantt reducttffion ffin  body 
weffigThtt.21 BottTh drugs  Thave ffindffivffidualy  demonsttratted anorecttffic acttffivffitty and are  belffieved tto 
synergffisttfficaly  work tto suppress appettffitte.  TThe  FDA approved ttThe combffinattffion ttTherapy for 
obesffitty ffin latte  2014 along  wffittTh  boxed  warnffings  of ffincreased  mood  dffisorder and sufficffidal 
ttThougThtts.22 
1.3 Anttffiobesffitty TTherapffies Targettffing BffiocThemffical Processes aftter Food Inttake (PerffipTheral) 
Compared tto ttThe  plettThora  of anttffiobesffitty ttTherapffies ttargettffing ttThe  CNS for appettffitte 
suppressffion, relattffively few  drugs  Thave  been  developed ttThatt ttargett ttThe  myrffiad  bffiocThemffical 
processes ttThatt ttake  place aftter food ffinttake.  Because ttThese  processes  occur ffin ttThe  perffipTheral 
ttffissues, pTharmacologffical ffintterventtffion carffies a lower rffisk of psycThffiattrffic sffide efectts sucTh as ttThose 
observed ffin centtraly-acttffing drugs. Orlffisttatt, for example, ffis a satturatted derffivattffive of ttThe nattural 
productt lffipsttattffin and actts as a  pottentt  pancreattffic lffipase ffinThffibffittor.23 Typfficaly, ttrffiacylglycerol 
(TAG) from ttThe  dffiett,  wThfficTh ffittself ffis  poorly absorbed, ffis  Thydrolyzed  by  pancreattffic lffipases ffintto 
ttwo equffivalentts  of fatttty acffid and  one equffivalentt  of  monoacylglycerol (MAG) wThfficTh can  be 
absorbed  by entterocyttes along ttThe ffinttesttffinal  wal and eventtualy convertted ffintto  body fatt (Fffig. 
1.3A). TThe β-lacttone of orlffisttatt functtffions as an acylglycerol mffimffic and acylattes ttThe nucleopThffilffic 
Thydroxyl moffietty on ttThe cattalyttffic serffine of pancreattffic lffipases (Fffig. 1.3B). TThffis covalentt ffinThffibffittffion 
preventts ttThe breakdown of dffiettary TAG, decreasffing ttThe amountt of fatt absorbed and excrettffing 
ttThe remaffinffing fatt ffin ttThe sttools. Pattffientts ttreatted wffittTh orlffisttatt demonsttratted 3.5% greatter ffincrease 
ffin  weffigThtt loss compared  wffittTh ttThe  placebo conttrol aftter 1 year.24 TThe  weffigThtt loss ffin ttreatted 
pattffientts corelatted wffittTh a mffild decrease ffin ffincffidence of ttype-2 dffiabettes and a reducttffion ffin blood 
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pressure levels.25,  26 WThffile  orlffisttatt ffis  moderattely efecttffive as a  weffigThtt loss ttTherapeuttffic, ttThe 
unabsorbed dffiettary fatt causes undesffirable sffide efectts sucTh as stteattorThea and fecal ffinconttffinence. 
Also, ttThe fatt-soluble vffittamffins  A,  D,  E, and  K  bffind tto and are excretted  wffittTh ttThe  unabsorbed 
dffiettary fatt necessffittattffing addffittffional vffittamffin supplementtattffion.27 
	  
Fffigure 1.3 A) Lffipolysffis of TAG by pancreattffic lffipases; B) MecThanffism of lffipase ffinThffibffittffion by orlffisttatt 
AnottTher ttTherapeuttffic approacTh tto obesffitty ffinvolves exploffittffing ttThe enzymattffic mecThanffisms of 
fatttty acffid bffiosynttThesffis. Fatttty acffid synttThase (FAS) ffin Thumans ffis a large, multtffi-domaffinal protteffin 
responsffible for cattalyzffing ttThe  bffiosynttThesffis  of long cThaffin fatttty acffids, sucTh as  palmffittatte, from 



































































A) MecThanffism for Pancreattffic Lffipolysffis of Dffiettary Trffiacylglycerol
B) MecThanffism of Lffipase InThffibffittffion by Orlffisttatt
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ffitts sttructture ffincludffing ttThe acyl carffier  protteffin (ACP), acettyl-CoA:ACP ttransacylase (AT), 
malonyl-CoA:ACP ttransacylase (MAT), β-kettoacyl:ACP synttThase (KS), β-kettoacyl:ACP 
reducttase (KR), β-Thydroxyacyl:ACP  deThydrattase (DH), enoyl:ACP reducttase (ER), and 
acyl:ACP ttThffioestterase domaffins. Fatttty acffid bffiosynttThesffis commences by ttransttThffioestterffiffficattffion of 
acettyl-CoA  ontto ttThe  ACP pThospThopanttettTheffine arm cattalyzed  by ttThe  AT  domaffin, folowed  by 
ttrans-ttThffioestterffiffficattffion tto load ttThe acettyl group ontto ttThe acttffive sffitte cystteffine of ttThe KS domaffin. 
Malonyl-CoA ffis ttThen loaded  ontto ttThe  ACP pThospThopanttettTheffine arm cattalyzed  by ttThe  MAT 
domaffin, and a  decarboxylattffive  Claffisen condensattffion  occurs tto form a β-kettoacyl:ACP 
ffinttermedffiatte. NADPH-dependentt reducttffion of ttThe β-kettone ffis ttThen cattalyzed by ttThe KR domaffin 
tto aford a β-Thydroxyacyl:ACP ffinttermedffiatte, wThfficTh undergoes deThydrattffion cattalyzed by ttThe DH 
domaffin.  TThe resulttffing  ACP-bound α,	  β-unsatturatted ttThffioestter  undergoes anottTher  NADPH-
dependentt reducttffion, cattalyzed by ttThe ER domaffin, tto gffive ttThe fuly satturatted C4 ffinttermedffiatte. 
TThffis ffinttermedffiatte ffis loaded  back  ontto ttThe  KS and ttThe four-sttep cThaffin 
exttensffion/reducttffion/deThydrattffion/reducttffion sequence ffis repeatted  unttffil a  C16 satturatted fatttty 
acyl:ACP ffinttermedffiatte ffis formed.  Fffinaly, ttThe  TE  domaffin cattalyzes ttThe  Thydrolysffis of ttThffis 
ffinttermedffiatte tto release ttThe free fatttty acffid palmffittatte. 
Because  FAS ffis ttThe enzyme responsffible for ttThe de novo bffiosynttThesffis  of fatttty acffids, ffitts 
domaffins  Thave attttractted ffintterestt as ttargetts for anttffiobesffitty  drugs.  Cerulenffin (Fffig.  1.5), for 
example, ffis a nattural  productt ffisolatted from CepThalosporffium caerulens ttThatt  bffinds tto ttThe  KS 
domaffin of FAS, preventtffing cThaffin exttensffion and ffinThffibffittffing fatttty acffid synttThesffis.28, 29 ResearcThers 
reportted up tto 30% weffigThtt loss ffin mffice ttreatted wffittTh 60 mg/kg/day of cerulenffin aftter 1 week.30 
TThe lostt weffigThtt was recovered upon cessattffion of ttreattmentt wffittTh no reportted ttoxfficffitty. 
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Fffigure 1.4 BffiosynttThesffis of fatttty acffids by FAS 
	  
Fffigure 1.5 Sttructture of FAS ffinThffibffittor cerulenffin 
1.4 Glycerol-3-PThospThatte Acylttransferase as an Anttffiobesffitty Drug Targett 
TThe lffipolysffis of dffiettary TAG and bffiosynttThesffis of fatttty acffids from acettyl- and malonyl-CoA 
are only ttwo stteps along ttThe complex pattThway tto convertt food tto TAG. WThffile dffisrupttffion of any 
of ttThese  processes could, ttTheorettfficaly,  preventt ttThe formattffion  of  body fatt, ffin realffitty,  negattffive 
feedback loops  oftten  preventt susttaffined  weffigThtt loss. One  pottenttffial  mettThod  of  overcomffing ttThffis 
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TThe acttffivffitty of GPAT appears tto be coupled tto ttThe acttffivffitty of carnffittffine palmffittoylttransferase-
1 (CPT1), ttThe enzyme responsffible for ttThe ratte-lffimffittffing sttep ffin ttThe β-oxffidattffion of fatttty acffids. 
CPT1 cattalyzes ttThe acylattffion of carnffittffine wffittTh long cThaffin fatttty acyl CoAs. TThe acylatted carnffittffine 
productt ffis ttThen able tto dffifuse across ttThe outter mffittocThondrffial membrane wThere ffitt ffis ttranslocatted 
by carnffittffine-acylcarnffittffine ttranslocase (CACT) ffintto ttThe mffittocThondrffial mattrffix, and ttThe fatttty acffid 
eventtualy undergoes β-oxffidattffion. GPAT and CPT1 are colocatted on ttThe outter mffittocThondrffial 
membrane and compette for fatttty acyl-CoA substtrattes.32 For example, GPAT overexpressffion ffin 
ratt Thepattocyttes sThowed an 80% decrease ffin ttThe ratte of fatttty acffid oxffidattffion accompanffied by an 
ffincrease ffin glycerolffipffid synttThesffis.33 Conversely, wThen GPAT-knockoutt mffice were fed a ThffigTh-fatt, 
ThffigTh-sugar dffiett tto ffinduce obesffitty, elevatted rattes of fatttty acffid oxffidattffion were observed.34 TThese 
fffindffings suggestt ttThatt GPAT appears tto  play a  major role ffin ttThe  parttffittffionffing  of fatttty acyl-CoA 
substtrattes  bettween ttThe glycerolffipffid  bffiosynttThesffis and β-oxffidattffion  pattThways. TThe  decreased 
producttffion  of  TAG and concomffittantt ffincrease ffin β-oxffidattffion accompanyffing lower GPAT 
acttffivffitty make ttThe enzyme an attttracttffive ttargett for anttffiobesffitty ttTherapy. InThffibffittffion of GPAT by a 
smal  molecule ffinThffibffittor  Thas ttThe  pottenttffial tto lffimffitt de novo synttThesffis  of  TAG  wThffile sThuttttlffing 
exffisttffing fatttty acyl-CoA sttores ttoward CPT1-medffiatted fatt oxffidattffion. 
Recentt  work ffin  our lab Thas ffinvolved ttThe  developmentt  of smal  molecule ffinThffibffittors  of 
GPAT.35 TThe ffinffittffial class of ffinThffibffittors was rattffionaly desffigned tto mffimffic ttThe enzymattffic ttransffittffion 
sttatte (Fffig.  1.7). TThe  benzoffic and  pThospThonffic acffid  moffiettffies  of ttThese compounds,  wThfficTh are 
deprottonatted att  pThysffiologffical  pH,  were cThosen tto  mffimffic ttThe anffionffic  pThospThatte group  of ttThe 
nattffive substtratte. TThe sulfonamffide  was cThosen tto  mffimffic  bottTh ttThe geomettry  of ttThe ttettraThedral 
ffinttermedffiatte and ttThe cTharge  densffitty of ttThe  oxyanffion. TThe relattffively acffidffic aryl sulfonamffide 
Thydrogen ffis proposed tto ffintteractt wffittTh ttThe cattalyttffic Thffisttffidffine responsffible for deprottonattffing ttThe 
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prffimary  Thydroxyl group  of  G3P prffior tto acylattffion.  Fffinaly, ttThe long alkyl cThaffin  of ttThe 
sulfonamffide was desffigned tto bffind ttThe lffipopThffilffic palmffittoyl-CoA bffindffing sffitte. 
	  
Fffigure 1.7 Fffirstt generattffion GPAT ffinThffibffittors desffigned as mffimffics of enzymattffic ttransffittffion sttatte 
Of ttThe compounds ttestted, o-substtffittutted alkylsulfonamffidobenzoffic acffids were ttThe mostt acttffive 
agaffinstt  GPAT ffin vffittro.  One compound, nonyl  derffivattffive 1,  possessed a  modestt ffinThffibffittory 
acttffivffitty of 24.7 ± 2.1 µM agaffinstt GPAT ffin vffittro and was cThosen for furttTher ttesttffing ffin vffivo.36 Dffiett-
ffinduced obese (DIO) mffice ffinjectted wffittTh 5 mg/kg/d of 1 over nffine days sThowed a 12.1 ± 3.6% 
declffine ffin weffigThtt compared wffittTh ttThe veThfficle conttrol. Aftter cessattffion of ttreattmentt on day 9, ttThe 
ttreatted mffice maffinttaffined a weffigThtt loss of 15.6-17.6% for ttThe remaffinder of ttThe 15-day sttudy. TThe 
sttudy concluded ttThatt compound 1, ffin addffittffion tto ttThe ffinThffibffittffion of GPAT, caused a cThange tto 
ttThe  mettabolffic  profffile ttThatt alowed for sffignffiffficantt and susttaffined  weffigThtt loss.  TThffis observattffion 
justtffifffies  bottTh  GPAT as a ttargett and ttThe sulfonamffidobenzoffic acffid ttransffittffion sttatte  mffimffic 
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1.5 Summary 
Obesffitty and obesffitty-relatted dffiseases are a growffing global epffidemffic wffittTh Thuge medffical and 
economffic costts.  Exffisttffing  mettThods  of combattffing  obesffitty  Thave  demonsttratted lffimffitted effficacffies 
wThffile beffing plagued by severe sffide efectts. By lffimffittffing de novo bffiosynttThesffis of TAG, ffinThffibffittffion of 
GPAT  ofers a  new  mecThanffisttffic sttrattegy for combattffing ttThe accumulattffion  of  body fatt. Modestt 
ffinThffibffittffion  of  GPAT  Thas  been sThown tto  drasttfficaly altter ttThe  mettabolffic  profffile away from fatt 
synttThesffis and ttoward fatt  mettabolffism, ttThereby  demonsttrattffing ttThe ttTherapeuttffic  pottenttffial  of ttThffis 
approacTh. More pottentt GPAT ffinThffibffittors may gffive us betttter ffinsffigThtt ffintto ttThe bffiologffical processes 
ffinvolved and serve as ttTherapeuttffic agentts agaffinstt obesffitty and relatted mettabolffic dffisorders. 
1.6 TThesffis Goals 
TThe prffimary goal of ttThffis ttThesffis ffis tto rattffionaly desffign and synttThesffize more pottentt ffinThffibffittors 
of  GPAT for ttThe ttreattmentt  of  obesffitty. InThffibffittors conttaffinffing a sulfonamffidobenzoffic acffid  mottffif 
Thave sThown promffisffing weffigThtt loss ffin mouse models despffitte only moderatte acttffivffitty ffin vffittro. We 
would lffike tto buffild from ttThffis scafold tto develop a sttructture-acttffivffitty relattffionsThffip (SAR) of ttThe 
ffinThffibffittors  wffittTh  GPAT.  SAR analysffis could ttThen affid ffin ttThe  drug  desffign  of futture classes  of 
ffinThffibffittors and lead tto ffincreased pottency. More pottentt ffinThffibffittors would, ffin tturn, promotte ThffigTher 
fatt reducttffion as partt of a vffiable obesffitty ttTherapy. 
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CThaptter 2 
Desffign, SynttThesffis, and Evaluattffion of o-(Octtanesulfonamffido)benzoffic Acffids 
as InThffibffittors of Glycerol-3-pThospThatte Acylttransferase 
2.1 Inttroducttffion 
Obesffitty, defffined as Thavffing a Body Mass Index (BMI) of 30.0 or ThffigTher, Thas been ffimplfficatted 
ffin  multtffiple dffiseases, ffincludffing cardffiovascular  dffisease1, ttype-2  dffiabettes2,  Thyperttensffion, 
nonalcoTholffic fatttty lffiver dffisease3, ffinferttffilffitty4, and certtaffin ttypes of cancer.5 Accordffing tto ttThe World 
HealttTh Organffizattffion, ffitt afectts approxffimattely 500 mffilffion adultts and ffis ttThe fffifttTh leadffing rffisk of 
deattThs globaly, accounttffing for att leastt 2.8 mffilffion deattThs a year. Despffitte an ffincrease ffin obesffitty 
and  obesffitty-relatted  dffiseases, few efecttffive  pTharmacologffical ttTherapffies curenttly exffistt tto combatt 
ttThe  pThysffiologffical source  of  obesffitty, ttThe accumulattffion  of ttrffiacylglycerol (TAG).  One approacTh 
ffinvolves exploffittffing ttThe mecThanffisms of ttThe lffipffid mettabolffic pattThway, effittTher by decreasffing ttThe ratte 
of fatt synttThesffis, as sThown wffittTh ttThe smal molecule fatttty acffid synttThase (FAS) ffinThffibffittors C756 and 
cerulenffin7, or ffincreasffing ttThe ratte of fatttty acffid oxffidattffion.8 GPAT cattalyzes ttThe ttransestterffiffficattffion 
of fatttty acyl-CoAs  wffittTh ttThe  prffimary  Thydroxyl group  of glycerol-3-pThospThatte (G3P), ttThe fffirstt 
commffitttted and ratte-lffimffittffing sttep ffin ttThe  bffiosynttThesffis  of  TAG.9 In  mammals, mffittocThondrffial 
GPAT (mttGPAT) ffis an ffinttegral membrane protteffin ttThatt co-localffizes on ttThe mffittocThondrffion wffittTh 
carnffittffine-palmffittoyl ttransferase I (CPT1), ttThe ratte-lffimffittffing enzyme ffin β-oxffidattffion.  TThese 
enzymes are co-regulatted and compette for fatttty acyl-CoA substtrattes.10 InThffibffittffion of GPAT by a 
smal molecule ffinThffibffittor Thas ttThe pottenttffial tto reduce de novo synttThesffis of TAG and tto dffivertt ttThe 
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flux  of fatttty acyl-CoAs tto β-oxffidattffion  medffiatted  by  CPT1, ttThus  makffing  GPAT an attttracttffive 
ttTherapeuttffic ttargett agaffinstt obesffitty. 
2.2 InThffibffittor Desffign and Molecular Modelffing 
Recenttly, ffitt  Thas  been  demonsttratted ttThatt o-(alkanesulfonamffido)benzoffic acffids sucTh as 1a-b 
(Fffig.  2.1)  possess  moderatte ffinThffibffittory acttffivffitty agaffinstt  mammalffian  GPAT ffin vffittro.11 TThe  8-
carbon derffivattffive 1c Thas also been synttThesffized and exThffibffitts an ffinThffibffittory acttffivffitty comparable tto 
1b. TThe benzoffic acffid moffietty of ttThese compounds, wThfficTh ffis deprottonatted att pThysffiologffical pH, ffis 
belffieved tto  mffimffic ttThe anffionffic  pThospThatte group  of ttThe  nattffive substtratte.  TThe acffidffic aryl 
sulfonamffide protton ffis proposed tto ffintteractt  wffittTh ttThe cattalyttffic  Thffisttffidffine responsffible for 
deprottonattffing ttThe prffimary Thydroxyl group of G3P necessary for acylattffion. Fffinaly, ttThe long alkyl 
cThaffin of ttThe sulfonamffide was desffigned tto bffind ttThe lffipopThffilffic palmffittoyl-CoA bffindffing sffitte. 
 
Fffigure 2.1 Sttructture of o-(alkanesulfonamffido)benzoffic acffid GPAT ffinThffibffittors 
WThffile sttructtural ffinformattffion regardffing mammalffian GPAT ffis lffimffitted, X-ray crysttal sttructtures 
of squasTh GPAT revealed ttThe conserved cattalyttffic HXXXXD mottffif presentt ffin al GPATs as wel 
as a  puttattffive  G3P  bffindffing sffitte comprffised  of conserved cattffionffic resffidues  Lys193,  Arg235, and 
Arg237.12a-b A complex nettwork of relattffively ThydropThobffic pocketts and ttunnels emanattffing from 




























1a (x = 16) IC50 = 18.3 ± 1.9 µM
1b (x = 9) IC50 = 24.7 ± 2.1 µM




acylttransferases, ffincludffing  AGPAT1,  AGPAT2, and  AGPAT9,  wffittTh ttThe squasTh  GPAT crysttal 
sttructture sThowed ttThatt,  despffitte low sequence  Thomology, ttThe  Thuman enzymes are sffimffilar ffin 
predffictted secondary sttructture and  ThydropThobffic resffidue  dffisttrffibuttffion.13 TThese fffindffings suggestt 
ttThatt, alttThougTh ttThe prffimary sequences of ttThe acylttransferase Thomologs dffifer, ttThe arcThffittecttures of 
ttThe acttffive sffittes may be quffitte sffimffilar. An ffin sffilffico dockffing sffimulattffion of 1c wffittTh squasTh GPAT, as 
sThown ffin  Fffig. 2.2,  dffisplayed ttThe ffinThffibffittor  bound att ttThe  puttattffive  G3P  bffindffing  pockett  wffittTh ttThe 
carboxylatte anffion posffittffioned att ttThe pThospThatte bffindffing sffitte and ttThe long alkyl cThaffin resffidffing ffin 
ttThe puttattffive palmffittoyl-CoA bffindffing sffitte descrffibed by Turnbul ett al.12a FurttThermore, ttThe dockffing 
model sThowed a second ThydropThobffic ttunnel, descrffibed prevffiously by Tamada ett al.,12b exttendffing 
away from ttThe G3P bffindffing sffitte and presenttffing from C-4 and C-5 of ttThe benzoffic acffid rffing of ttThe 
docked ffinThffibffittor.  TThffis volume  was lffined  by  ThydropThobffic and aromattffic resffidues ffincludffing 
PThe98, Gly99, Tyr102, Ile103, Ala143, Leu176, Pro179, and PThe180. 
 
Fffigure 2.2 A) Compound 1c (yelow) docked ffintto ttThe acttffive sffitte of squasTh GPAT; B) Compound 14b 
manualy docked ffintto ttThe bffindffing sffitte obttaffined for compound 1c 
In an attttemptt tto ffimprove upon ttThe ffinThffibffittory acttffivffitty of 1c, a serffies of pottenttffial ffinThffibffittors, 
sThown ffin  Fffig.  2.3, was  desffigned and synttThesffized  wffittTh varffious aryl substtffittuentts effittTher  dffirecttly-
bound tto ttThe 4- or 5-posffittffions of 1c or coupled vffia one of several lffinkers (ketto-, vffinyl-, or ettThyl-). 
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TThe aryl substtffittuentts  were cThosen tto  promotte π-sttackffing  wffittTh ttThe aromattffic resffidues ffin ttThe 
pottenttffial ThydropThobffic cThannel as wel as for synttThettffic accessffibffilffitty. TThe lffinkers were cThosen tto 
examffine ttThe efectts of pTharmacopThore separattffion and conformattffional rffigffidffitty versus flexffibffilffitty. 
TThe  8-carbon cThaffin  of 1c was cThosen for ffitts ready commercffial avaffilabffilffitty and,  wffittThffin 
experffimenttal eror, essenttffialy uncThanged GPAT ffinThffibffittory acttffivffitty compared tto ttThe 9-carbon 
analog reportted prevffiously.11 TThe candffidattes were ttestted for GPAT ffinThffibffittffion ffin vffittro tto develop 
a sttructture-acttffivffitty relattffionsThffip and assess ttThe valffidffitty of ttThe dockffing model as a ttool tto dffirectt 
futture medfficffinal cThemffisttry efortts. 
 
Fffigure 2.3 InThffibffittor desffign for 4- and 5-substtffittutted derffivattffives of 1c 
2.3 SynttThesffis of 4- and 5-Substtffittutted Analogs 
An effficffientt, dffivergentt routte was devffised tto access ttThe 4- and 5-substtffittutted derffivattffives of 1c 
as sThown ffin Fffig. 2.4. Sulfonamffide couplffing of 4- and 5-bromoanttThranffilattes 2 and 3, respecttffively, 
wffittTh  octtanesulfonyl cThlorffide generatted sulfonamffides 4 and 5.  Suzukffi-Mffiyaura couplffing 
reacttffions  wffittTh varffious aryl  boronffic acffids  were ttThen  performed effittTher  under argon tto aford 
couplffing  productts 6a-l and 7a-l or  under an attmospThere  of carbon  monoxffide tto aford ketto-


















































X = -CO2H, -PO3H2
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lffinker precursors 8a-b and 9a-d. Altternattffively, couplffing of 4 and 5 wffittTh varffious ttrans-arylvffinyl 
boronffic acffids  under an argon attmospThere  provffided vffinyl-lffinker  precursors 10a-b and 11a-b. 
EacTh of ttThe benzoattes was ttThen Thydrolyzed, effittTher under Gassman condffittffions14 or ffin aqueous 1 
M  NaOH, tto aford analogs 12a-l, 13a-l, 14a-b, 15a-d, 16a-b, and 17a-b.  Altternattffively, 
Thydrogenattffion of 10a-b and 11a-b prffior tto Thydrolysffis aforded ettThyl-lffinked analogs 18a-b and 
19a-b. 
 
Fffigure  2.4 SynttThesffis  of  GPAT ffinThffibffittor analogs.  Reagentts and condffittffions: (a)  ClSO2C8H17,  NEtt3, 
CH2Cl2, 62–76%; (b) Pd(PPTh3)4, Ar-B(OH)2, Na2CO3, PThMe/MeOH, 90 °C, 45–80%; (c) Pd(PPTh3)4, 
Ar-B(OH)2,  K2CO3,  dffioxane,  90 °C,  CO (1 attm),  28–46%; (d)  Pd(PPTh3)4, (E)-Ar-(CH)2B(OH)2, 
K2CO3, PThCH3, 105 °C, 58–83%; (e) Pd/C, H2 (1 attm), MeOH, 80–91%; (f) KOttBu, H2O, Ett2O, 0 °C-





























































































2.4 InThffibffittffion Datta 
 TThe ffinThffibffittory datta for ttThe 4- and 5-aryl-substtffittutted analogs are presentted ffin Table 2.1. 
Several  of ttThese compounds exThffibffitted  marked ffimprovementt  over 1c. In general,  ThydropThobffic 
substtffittuentts sucTh as p-n-buttylpThenyl (12d),  bffipThenyl (12e,f), and  mettThoxypThenyl (12g,Th) 
exThffibffitted a  moderatte ffincrease ffin ffinThffibffittory acttffivffitty  of  up tto ttwo-fold.  CThloropThenyl analogs 
(12a-c) also  demonsttratted  markedly  more  pottentt ffinThffibffittffion,  parttfficularly ttThe m-cThloro analog 
wThfficTh also was aboutt 2-fold more acttffive ttThan 1c. Conversely, Thydroxyl- and fluoro-conttaffinffing 
analogs (12ffi-l) caused a  modestt  decrease ffin ffinThffibffittory acttffivffitty.  TThe p-Thydroxyl analog, for 
ffinsttance, sThowed a nearly ttThree-fold declffine ffin ffinThffibffittffion. 
TThe sttructture-acttffivffitty relattffionsThffip  of 5-aryl-substtffittutted class  mffirors ttThatt  of ttThe  4-aryl 
derffivattffives.  For ffinsttance, several  of ttThe compounds sThowed  nottable ffimprovementt  over 1c, 
parttfficularly ttThose conttaffinffing cThloropThenyl and ThydropThobffic substtffittuentts. Specffiffficaly, bottTh ttThe 
m-cThloro (13b) and p-n-buttyl (13d) analogs efectted a  2.9-fold ffincrease ffin ffinThffibffittory acttffivffitty. 
Also sffimffilar tto ttThe 4-aryl class, ThydroxypThenyl and fluoropThenyl groups were nott wel ttoleratted, 










Table 2.1 GPAT InThffibffittffion by 4- and 5-Substtffittutted Derffivattffives 
 
 
Enttry Compound R IC50 (µM) ± SD 
1 12a o-Cl 26.9 ± 4.1 
2 12b m-Cl 13.8 ± 2.5 
3 12c p-Cl 18.1 ± 3.5 
4 12d p-n-C4H9 15.7 ± 1.6 
5 12e o-C6H5 17.1 ± 0.8 
6 12f p-C6H5 13.5 ± 3.2 
7 12g o-OCH3 16.1 ± 0.5 
8 12Th p-OCH3 13.3 ± 1.1 
9 12ffi o-F 47.2 ± 2.0 
10 12j m-F 32.6 ± 3.6 
11 12k o-OH 63.1 ± 5.5 
12 12l p-OH 64.8 ± 3.8 
13 13a o-Cl 14.4 ± 1.3 
14 13b m-Cl 8.9 ± 0.9 
15 13c p-Cl 9.2 ± 0.7 
16 13d p-n-C4H9 9.0 ± 0.4 
17 13e o-C6H5 10.1 ± 0.7 
18 13f p-C6H5 29.1 ± 6.3 
19 13g o-OCH3 27.6 ± 2.0 
20 13Th p-OCH3 19.5 ± 5.5 
21 13ffi o-F 34.6 ± 2.0 
22 13j m-F 37.6 ± 9.7 
23 13k o-OH 61.7 ± 13.8 


















Fffigure 2.5 4- and 5-Substtffittutted analogs wffittTh lffinkers: sttructtures and IC50 datta 
TThe  datta for ttThe  4- and  5-aryl analogs are consffisttentt  wffittTh ttThe  presence  of a  ThydropThobffic 
bffindffing pockett exttendffing from C-4 and C-5 of ttThe benzoffic acffid of 1c. BottTh stterffic and electtronffic 
facttors may be afecttffing bffindffing ffin ttThffis pockett. Stterfficaly, ttThe pockett ffis large enougTh around ttThe 

















































































































12e and 12f.  TThe regffion  near ttThe  5-posffittffion,  Thowever, appears  more consttraffined ffin sffize. 
Consequenttly, ttThe p-bffipThenyl analog 13f sThows a large decrease ffin acttffivffitty, possffibly due tto stterffic 
ffintteracttffions  wffittTh resffidues  on ttThe edge  of ttThe  bffindffing  pockett.  TThe o-bffipThenyl analog 13e, 
Thowever,  may  orffientt ttThe ttermffinal  pThenyl substtffittuentt away from ttThe edge and  back ffintto ttThe 
bffindffing  pockett resulttffing ffin a  2.5-fold ffincrease ffin acttffivffitty.  Van  der  Waals and π-sttackffing 
ffintteracttffions seem tto  be favored  wffittThffin ttThe  pockett as  pThenyl- alkylpThenyl-, and alkoxypThenyl 
substtffittuentts sThowed an ffincrease ffin acttffivffitty. Conversely, ttThe more polarffized fluorffine-conttaffinffing 
analogs demonsttratted moderattely dffimffinffisThed acttffivffitty possffibly due tto bffindffing att a sffitte ffinttolerantt 
of ttThe ffinThffibffittor’s  ThffigTh cTharge densffitty  or  dffisrupttffion  of key π–π ffintteracttffions  wffittThffin ttThe 
ThydropThobffic cThannel. 
WThffile ttThe  3-fold ffincrease ffin  observed acttffivffitty for ttThe  4-aryl and  5-aryl  derffivattffives  was 
promffisffing, we worffied ttThatt ttThe kffinked natture of ttThe ThydropThobffic ttunnel observed ffin ttThe dockffing 
model  was  preventtffing ttThe analogs from exttendffing fuly ffintto ffitt.  TTherefore,  we  nextt sougThtt tto 
ffincorporatte varffious lffinker regffions on a subsett of ttThe more promffisffing ThydropThobffic leads. Ketto, 
vffinyl, and ettThyl lffinkers were cThosen tto examffine ttThe efectt of separattffing ttThe substtffittuentts from ttThe 
pTharmacopThore and tto explore conformattffional rffigffidffitty versus flexffibffilffitty ffin exttendffing ttThe 
substtffittuentts ffintto ttThe  ThydropThobffic ttunnel. InThffibffittffion  datta for ttThe  4- and  5-substtffittutted analogs 
are sThown ffin  Table  2.2. In general, ttThe analogs  possessffing a ketto lffinker  were slffigThttly tto 
moderattely less pottentt ttThan ttThe corespondffing sttructtures wffittThoutt a lffinker. For example, 5-ketto-
substtffittutted p-n-buttyl analog 15a exThffibffitted a  3.5-fold  decrease ffin ffinThffibffittffion compared tto 
compound 13d.  TThe p-bffipThenyl analogs 14b and 15b, Thowever,  were  nottable excepttffions. 
Compound 14b sThowed a 2-fold more pottentt ffinThffibffittffion compared tto ttThe lffinker-free analog 13f. 
WThffile ttThe rffigffid lffinear carbon skeletton of 13f may stterfficaly ffintterfere wffittTh resffidues on ttThe face of 
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ttThe  ThydropThobffic  pockett, ttThe kettone lffinker ffin 15b could  pottenttffialy  dffirectt ttThe large  bffipThenyl 
moffietty back ttowards ttThe cavffitty. Compound 14b, wffittTh an IC50 of 8.5 μM, was 3-fold more pottentt 
ttThan 1c and, tto our knowledge, representts ttThe mostt acttffive GPAT ffinThffibffittor dffiscovered tto datte. 
TThe benzopThenone moffietty presentt ffin ttThffis derffivattffive ffimpartts pottenttffial uttffilffitty as a bffiocThemffical 
ttool. BenzopThenones Thave been sThown tto undergo a pThotto-ffinduced n→π* ttransffittffion tto form a 
dffiradffical specffies,  wThfficTh can crosslffink  wffittTh  nearby  protteffins.15 PThottocrosslffinkffing sttudffies  wffittTh a 
benzopThenone-conttaffinffing ffinThffibffittor could  ofer ffinsffigThtt ffintto ffitts  bffindffing locattffion  wffittThffin ttThe 
GPAT enzyme. Addffittffionaly, pThottocrosslffinkffing could pottenttffialy affid ffin ffidenttffifyffing ttThe of-ttargett 
bffindffing of ottTher protteffins. 
TThe more rffigffid vffinyl and conformattffionaly flexffible ettThyl lffinkers  were generaly  nott  wel 
ttoleratted. For example, 16b, a vffinyl-lffinked p-mettThoxypThenyl analog, produced an acttffivffitty of 37.5 
µM compared tto 13.3 µM for ttThe lffinker-free derffivattffive 12Th. No sffignffiffficantt benefffitt was apparentt 
from ttThe ffincorporattffion  of ttThe conformattffionaly flexffible ettThyl lffinkers.  TThe same p-
mettThoxypThenyl substtffittuentt wffittTh a lffinker regffion ffin compound 18b demonsttratted an IC50 of 43.0 
µM or 3.2-fold lower acttffivffitty ttThan ttThe corespondffing compound 12Th. 
2.5 Conclusffions 
Several  4- and  5-substtffittutted analogs  of  GPAT ffinThffibffittor (octtanesulfonamffido)benzoffic acffid 
were synttThesffized and analyzed for ffin vffittro ffinThffibffittory acttffivffitty. In general,  ThydropThobffic 
substtffittuentts led tto an ffincrease ffin ffinThffibffittory acttffivffitty  wThffile  more  polar and  Thydrogen-bondffing 
substtffittuentts sThowed a  decrease ffin ffinThffibffittory acttffivffitty, consffisttentt  wffittTh ttThe  presence  of a 
ThydropThobffic pockett ffidenttffifffied by ffin sffilffico sttudffies. Takffing advanttage of ttThe ThydropThobffic pockett, 
p-bffipThenylkettone-substtffittutted 14b ffimproved ttThe ffinThffibffittory acttffivffitty  3-fold tto  8.5 μM, 
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representtffing ttThe  mostt  pottentt  GPAT ffinThffibffittor tto  datte. TThe  benzopThenone  moffietty ffin ttThffis 
compound lends ffitt  pottenttffial as a  bffiocThemffical ttool for  pThottocrosslffinkffing experffimentts. Futture 
sttudffies wffil affim tto dettermffine wThettTher furttTher exttensffion of aryl and alkyl substtffittuentts ffintto ttThffis 
cThannel confers addffittffional ffinThffibffittory acttffivffitty and ffif ttThe observed ffincreases ffin vffittro corelatte wffittTh 
ffin vffivo TAG bffiosynttThesffis and overal fatt mettabolffism ffin keepffing wffittTh earlffier sttudffies.16 
2.6 Experffimenttal 
General Informattffion. Al reagentts and solventts  were  obttaffined from commercffial sources, and 
used as supplffied  unless  ottTherwffise ffindfficatted.  Reacttffions requffirffing anThydrous condffittffions  were 
conductted under an ffinertt attmospThere of argon usffing anThydrous solventts. CH2Cl2, ttoluene and 
MeOH were dffisttffiled over CaH2. Ett2O and THF were dffisttffiled over Na and benzopThenone. Al 
reacttffions  were  monffittored  by analyttffical ttThffin-layer cThromattograpThy (TLC)  usffing ffindfficatted 
solventt systtems  on  AnalttecTh  Unffiplatte  Sffilffica  Gel  TLC  plattes (250  mfficrons).  TLC  plattes  were 
vffisualffized  usffing  UV lffigThtt (254  nm) and/or  by sttaffinffing ffin  pottassffium  permanganatte, cerffium 
ammonffium  molybdatte,  or  pThospThomolybdffic acffid folowed  by  Theattffing.  Al  NMR specttra  were 
recorded on effittTher Bruker Advance 400 MHz or 300 MHz specttrometters as ffindfficatted. CThemffical 
sThffiftts (δ H) are quotted ffin ppm (partts per mffilffion) and referenced tto resffidual solventt sffignals: 1H 
δ = 7.26 (CDCl3), 2.50 (DMSO-d6), 3.31 (CD3OD), 13C δ = 77.0 (CDCl3), 39.43 (DMSO-d6), 
49.05 (CD3OD). Couplffing consttantts (J) are gffiven ffin Hz. Elementtal analyses were performed by 





Preparattffion of 2-(octtanesulfonamffido)benzoffic acffid (1c) 
 
MettThyl  2-(octtanesulfonamffido)benzoatte. To a sttffirffing soluttffion  of  mettThyl 
anttThranffilatte (2.5  mL,  19.3  mmol) ffin  CH2Cl2 att  0 °C  was added 
octtanesulfonyl cThlorffide (4.5  mL,  23.2  mmol)  dropwffise folowed  by fresThly  dffisttffiled 
ttrffiettThylamffine (8.1  mL,  57.9  mmol).  TThe reacttffion  mffixtture  was alowed tto  warm tto room 
ttemperatture and sttffired for  16  Th, ttThen  quencThed  wffittTh satturatted  NH4Cl and exttractted  wffittTh 
CH2Cl2 (×3). TThe combffined organffic exttractts were wasThed wffittTh brffine, drffied over Na2SO4, and 
concenttratted ffin vacuo tto  provffide  6.0 g  of a crude  of-wThffitte solffid.  Recrysttalffizattffion from  warm 
EttOAc/Thexanes aforded ttThe desffired sulfonamffide as a wThffitte solffid (5.6 g, 17.1 mmol, 89%). 1H-
NMR (400 MHz; CDCl3): δ 8.07 (ddd, J = 8.0, 1.7, 0.4 Hz, 1H), 7.76 (ddd, J = 8.4, 1.2, 0.5 Hz, 
1H), 7.64 (ddd, J = 8.4, 7.3, 1.7 Hz, 1H), 7.19 (ddd, J = 8.0, 7.3, 1.2 Hz, 1H), 3.95 (s, 3H), 3.29-
3.25 (m, 2H), 1.79-1.71 (m, 2H), 1.39 (s, 2H), 1.23 (s, 8H), 0.85 (tt, J = 7.0 Hz, 3H); 13C-NMR 
(101 MHz; DMSO-d6): δ 167.8, 139.8, 134.7, 131.0, 123.0, 118.5, 116.1, 52.6, 51.2, 31.0, 28.7, 
28.6, 28.0, 22.8, 21.9, 13.9. 
2-(Octtanesulfonamffido)benzoffic acffid (1c). To a sttffirffing soluttffion of mettThyl 
2-(octtanesulfonamffido)benzoatte (5.6 g,  17.1  mmol) ffin  THF (86  mL) att 
room ttemperatture  was added  1  M  NaOH (171  mL,  171  mmol).  TThe reacttffion  mffixtture  was 
sttffired att  40 °C for  18  Th, ttThen ttThe reacttffion  was  quencThed  wffittTh  1  M  HCl and exttractted  wffittTh 
EttOAc (×3). TThe combffined organffic exttractts were wasThed wffittTh brffine, drffied over Na2SO4, and 





































EttOAc/Thexanes aforded ttThe desffired carboxylffic acffid as a wThffitte solffid (5.0 g, 16.0 mmol, 93%). 
1H-NMR (400  MHz; acettone-d6): δ 10.67 (s,  1H),  8.14 (ddd, J =  8.0,  1.7,  0.4  Hz,  1H),  7.76 
(ddd, J = 8.4, 1.2, 0.4 Hz, 1H), 7.65 (ddd, J = 8.4, 7.3, 1.7 Hz, 1H), 7.21-7.18 (m, 1H), 3.28-3.24 
(m, 2H), 1.75 (m, 2H), 1.39 (m, 2H), 1.29-1.23 (m, 7H), 0.85 (tt, J = 7.0 Hz, 3H); 13C-NMR 
(101 MHz, DMSO-d6): δ 170.19, 141.04, 134.73, 131.85, 122.52, 117.42, 115.79, 51.26, 31.32, 
28.55,  28.52,  27.42,  23.16,  22.23,  13.94;  HRMS (FAB) calcd for  C15H24NO4S [M+H]+, 
314.14260; found, 314.14278. 
 
Preparattffion of mettThyl 2-amffino-4-bromobenzoatte (2) 
 
 MettThyl  4-bromo-2-nffittrobenzoatte. To a sttffirffing soluttffion  of 4-bromo-2-
nffittrobenzoffic acffid (5.0 g, 21.7  mmol) ffin  DMF (33  mL) att  0 °C  was added  DBU 
(3.91  mL,  26.1  mmol) folowed  by ffiodomettThane (2.04  mL,  32.8  mmol).  TThe 
reacttffion mffixtture was alowed tto warm tto room ttemperatture and sttffired for 12 Th, ttThen quencThed 
wffittTh  NaHCO3, and exttractted  wffittTh  Ett2O (3 ×  100  mL).  TThe combffined  organffic layers  were 
wasThed  wffittTh  brffine,  drffied  over  Na2SO4, and concenttratted ffin vacuo.  Purffiffficattffion  by flasTh 
cThromattograpThy (10%  EttOAc ffin  Thexanes) aforded  mettThyl  4-bromo-2-nffittrobenzoatte (98%). 
Specttral datta mattcTh lffitteratture values.17 
 MettThyl 2-amffino-4-bromobenzoatte 2. To a sttffirffing soluttffion of mettThyl 4-bromo-2-

























ttemperatture was added SnCl2•2H2O (20.6 g, 91.3 mmol). TThe reacttffion mffixtture was sttffired att 
room ttemperatture for 16 Th, ttThen quencThed wffittTh NaHCO3. TThe gelattffinous mffixtture was fffilttered 
over  Celffitte, and ttThe fffilttratte  was exttractted  wffittTh  DCM (3 ×  100  mL).  TThe combffined  organffic 
layers  were  wasThed  wffittTh  brffine,  drffied  over  Na2SO4, and concenttratted ffin vacuo.  Purffiffficattffion  by 
flasTh cThromattograpThy (10% EttOAc ffin Thexanes) aforded anffilffine 2 (95%). Specttral datta mattcTh 
lffitteratture values.17 
 
Preparattffion of Sulfonamffides 4 and 5. 
 
General Procedure. To a sttffirffing soluttffion of ttThe sttarttffing anffilffine (6.6 mmol) ffin DCM (24 mL) 
att 0 °C was added pyrffidffine (4 mL). Octtanesulfonyl cThlorffide (1.2 equffiv) was ttThen added slowly 
vffia syrffinge. TThe soluttffion was sttffired and alowed tto warm tto room ttemperatture. Reacttffion 
progress was monffittored by TLC (20 % EttOAc ffin Thexanes). Upon complettffion, ttThe reacttffion was 
poured ffintto satturatted NaHCO3 soluttffion (50 mL), exttractted wffittTh DCM (3 × 30 mL), and 
wasThed wffittTh 1 M HCl (50 mL). TThe combffined organffic layers were concenttratted ffin vacuo and 
purffifffied by flasTh cThromattograpThy (10% EttOAc ffin Thexanes). 
MettThyl  4-bromo-2-(octtanesulfonamffido)benzoatte (4). (62% yffield from 
anffilffine 2). 1H-NMR (400 MHz; CDCl3): δ 10.47 (s, 1H), 7.94 (d, J = 2.0 Hz, 
1H), 7.89 (d, J = 8.4 Hz, 1H), 7.23 (dd, J = 2.0, 8.4 Hz, 1H), 3.93 (s, 3H), 






























NMR (100  MHz; CDCl3): δ  167.8,  142.0,  132.5,  129.7,  125.7,  120.4,  113.5,  52.6,  52.4,  31.5, 
28.8, 28.7, 27.9, 23.2, 22.5, 13.9. 
MettThyl-5-bromo-2-(octtanesulfonamffido)benzoatte (5). (76% yffield 
from anffilffine 3 (>99%, TCI Amerffica)). 1H-NMR (400 MHz; CDCl3): δ 
10.33 (s, 1H), 8.17 (d, J = 2.4 Hz, 1H), 7.66 (m, 2H), 3.95 (s, 3H), 3.11(tt, J = 8.0 Hz, 2H), 
1.78(m, 2H), 1.26(m, J = 10H ),0.89 (tt, J = 6.8Hz, 3H); 13C-NMR (100 MHz; CDCl3): δ 167.2, 
140.1, 137.5, 134.0, 119.5, 116.5, 115.0, 52.8, 52.3, 31.6, 28.8, 28.8, 28.0, 23.3, 22.5, 14.0. 
 
Preparattffion of Suzukffi Couplffing Productts 6a-l and 7a-l 
 
General  Procedure. Aryl  bromffide 4 or 5 (0.247  mmol)  was  placed ffintto a vffial flusThed  wffittTh 
argon, and a soluttffion of 10 mg Pd(PPTh3)4 ffin 0.40 mL ttoluene was added, folowed by 0.25 mL 2 
M Na2SO3 soluttffion. TThe soluttffion was sttffired att room ttemperatture for 5 mffin, and ttThen a soluttffion 
of ttThe  boronffic acffid (0.318  mmol,  1.25 equffiv.) ffin  0.40  mL  MeOH  was added.  TThe vffial  was 
capped and Theatted tto 90 °C for 24 Th. TThe reacttffion was ttThen cooled tto room ttemperatture and 
dffilutted wffittTh CH2Cl2, ttThe organffic pThase was separatted from ttThe aqueous pThase, and ttThe organffic 
pThase was concenttratted ffin vacuo. TThe crude productt was purffifffied by column cThromattograpThy 


































2-CThloro-3-(octtanesulfonamffido)-bffipThenyl-4-carboxylffic acffid  mettThyl 
estter (6a). 76% yffield; 1H-NMR (400 MHz; CDCl3): δ 10.46 (s, 1H), 8.04 
(d, J = 8.4 Hz, 1H), 7.77 (s, 1H), 7.41 (m, 1H), 7.27 (m, 3H), 7.09 (d, J = 
8.4 Hz, 1H), 3.85 (s, 3H), 3.14 (tt, J = 8.0 Hz, 2H), 1.75 (m, 2H), 1.31 (m, 2H), 1.18 (m, 8H), 
0.80 (tt, J = 6.8  Hz,  3H); 13C-NMR (100  MHz; CDCl3): δ  168.1,  145.8,  140.7,  138.6,  132.0, 
131.2,  130.9,  130.0,  129.4,  127.0,  123.4,  118.4,  113.8,  52.5,  52.0,  31.5,  28.7,  28.7,  27.9,  23.2, 
22.4, 13.9. 
3-CThloro-3-(octtanesulfonamffido)-bffipThenyl-4-carboxylffic acffid 
mettThyl estter (6b). 74% yffield; 1H-NMR (400 MHz; CDCl3): δ 10.51 
(s,  1H),  8.11 (d, J = 8.4  Hz,  1H),  7.97 (d, J = 1.6  Hz,  1H),  7.59 (s, 
1H), 7.51 (m, 1H), 7.39 (m, 2H), 7.29 (dd, J = 1.6, 8.4 Hz, 1H), 3.97 (s, 3H), 3.18 (tt, J = 8.0 Hz, 
2H), 1.82 (m, 2H), 1.37 (m, 2H), 1.25 (m, 8H), 0.86 (tt, J = 6.8 Hz, 3H); 13C-NMR (100 MHz; 
CDCl3): δ  168.1,  145.9,  141.5,  140.9,  134.8,  132.0,  130.2,  128.6,  127.2,  125.4,  121.1,  116.1, 
114.1, 52.5, 52.2, 31.5, 28.8, 28.7, 27.9, 23.3, 22.4, 13.9. 
4-CThloro-3-(octtanesulfonamffido)-bffipThenyl-4-carboxylffic acffid 
mettThyl estter (6c). 74% yffield; 1H-NMR (400 MHz; CDCl3): δ 10.49 
(s,  1H),  8.10 (d, J = 8.4  Hz,  1H),  7.97 (s,  1H),  7.56 (d, J = 6.8  Hz, 
2H), 7.43 (d, J = 6.8 Hz, 2H), 7.29 (d, J = 8.4 Hz, 1H), 3.96 (s, 3H), 3.16 (tt, J = 8.0 Hz, 2H), 
1.82 (m,  2H),  1.36 (m,  2H),  1.22 (m,  8H),  0.84 (tt, J = 6.8  Hz,  3H); 13C-NMR (100  MHz; 
CDCl3): δ 168.1, 146.1, 141.5, 137.4, 134.9, 132.0, 129.1, 128.5, 120.9, 115.9, 113.9, 52.5, 52.2, 





















mettThyl estter (6d). 72% yffield; 1H-NMR (400 MHz; CDCl3): δ 10.65 
(s, 1H), 8.22 (d, J = 8.3 Hz, 1H), 8.16 (d, J = 1.7 Hz, 1H), 7.70 (d, J 
= 8.2 Hz, 2H), 7.46 (dd, J = 8.3, 1.7 Hz, 1H), 7.42 (d, J = 8.2 Hz, 2H), 4.08 (s, 3H), 3.33-3.29 
(m, 2H), 2.81 (tt, J = 7.7 Hz, 2H), 2.00-1.90 (m, 2H), 1.80-1.76 (m, 2H), 1.59-1.45 (m, 4H), 
1.45-1.30 (m,  8H),  1.10 (tt, J = 7.3  Hz,  3H),  1.00 (tt, J = 6.9  Hz,  3H).; 13C-NMR (101  MHz, 
CDCl3): δ 168.54,  147.68,  144.00,  141.67,  136.55,  132.07,  129.25,  127.31,  121.14,  115.94, 
113.57, 52.63, 52.31, 35.51, 33.72, 31.83, 29.08, 29.00, 28.20, 23.55, 22.73, 22.53, 14.20, 14.12. 
2-PThenyl-3-(octtanesulfonamffido)-bffipThenyl-4-carboxylffic acffid  mettThyl 
estter (6e). 67% yffield; 1H-NMR (400 MHz; CDCl3): δ 10.41 (s, 1H), 8.00 
(d, J = 8.0 Hz, 1H), 7.45 (m, 5H), 7.25 (m, 5H), 7.03 (dd, J = 8.4, 1.6 Hz, 
1H), 3.93 (s, 3H), 2.67 (tt, J = 7.6 Hz, 2H), 1.67 (m, 2H), 1.32 (m, 2H), 0.92 (tt, J = 6.8 Hz, 3H); 
13C-NMR (100 MHz; CDCl3): δ 168.2, 148.6, 141.0, 140.5, 140.3, 138.7, 131.2, 130.8, 130.2, 
129.8,  128.3,  128.0,  127.5,  126.6,  123.6,  118.9,  112.7,  52.3,  51.2,  31.6,  28.9,  28.8,  27.8,  23.3, 
22.5, 13.9. 
4-PThenyl-3-(octtanesulfonamffido)-bffipThenyl-4-carboxylffic acffid 
mettThyl estter (6f). 71% yffield; 1H-NMR (400 MHz; DMSO-d6): δ 
10.28 (s, 1H), 8.06 (d, J = 8.4 Hz, 1H), 7.90 (s, 1H), 7.81 (q, J = 
8.4 Hz, 4H), 7.73 (d, J = 8.4 Hz, 2H), 7.57 (d, J = 8.4 Hz, 1H), 7.49 (tt, J = 7.6 Hz, 2H), 7.40 (tt, J 
= 7.2 Hz, 1H), 3.91 (s, 3H), 3.37 (tt, J = 8.0 Hz, 2H), 1.64 (m, 2H), 1.32 (m, 2H), 1.20 (m, 8H), 
0.80 (tt, J = 6.8 Hz, 3H); 13C-NMR (100 MHz; DMSO-d6): δ 167.7, 145.5, 140.5, 140.4, 139.2, 
137.2, 131.8, 128.9, 127.7, 127.5, 127.3, 126.6, 121.2, 116.0, 114.8, 52.7, 51.4, 31.0, 28.2, 28.2, 


















2-MettThoxy-3-(octtanesulfonamffido)-bffipThenyI-4-carboxylffic acffid  mettThyl 
estter (6g). 70% yffield; 1H-NMR (400 MHz; CDCl3): δ 10.48 (s, 1H), 8.07 
(d, J = 8.4 Hz, 1H), 7.98 (s, 1H), 7.37 (m, 2H), 7.28 (d, J = 8.4 Hz, 1H), 
7.05 (m, 2H), 3.95 (s, 3H), 3.84 (s, 3H), 3.20 (tt, J = 8.0 Hz, 2H), 1.82 (m, 2H), 1.40 (m, 2H), 
1.23 (m, 8H), 0.86 (tt, J = 7.2 Hz, 3H); 13C-NMR (100 MHz; CDCl3): δ 168.3, 156.3, 145.2, 
140.6, 130.9, 130.5, 129.8, 128.6, 123.6, 120.9, 118.6, 113.1, 111.3, 55.5, 52.3, 51.8, 31.5, 28.8, 
28.7, 27.9, 23.2, 22.4, 13.9. 
4-MettThoxy-3-(octtanesulfonamffido)-bffipThenyl-4-carboxylffic acffid 
mettThyl estter (6Th). 71% yffield; 1H-NMR (400 MHz; CDCl3): δ 10.47 
(s, 1H), 8.04 (d, J = 8.4 Hz, 1H), 7.96 (d, J = 1.6 Hz, 1H), 7.57 (dd, J 
= 6.8, 2.0 Hz, 2H), 7.28 (dd, J = 8.4, 1.6 Hz, 1H), 6.97 (dd, J = 6.8, 2.0 Hz, 2H), 3.93 (s, 3H), 
3.84 (s, 3H), 3.14 (tt, J = 8.0 Hz, 2H), 1.80 (m, 2H), 1.23 (m, 10H), 0.86 (tt, J = 7.2 Hz, 3H); 13C-
NMR (100 MHz; CDCl3): δ 168.3, 160.2, 147.0, 141.4, 131.8, 131.3, 128.4, 120.5, 115.4, 114.3, 
113.0, 55.3, 52.4, 52.0, 31.5, 28.8, 28.7, 27.9, 23.2, 22.4, 13.9. 
2-Fluoro-3-(octtanesulfonamffido)-bffipThenyl-4-carboxylffic acffid  mettThyl 
estter (6ffi). 69% yffield; 1H-NMR (400 MHz; CDCl3): δ 10.51 (s, 1H), 8.12 
(d, J = 8.4 Hz, 1H), 7.96 (d, J = 1.6 Hz, 1H), 7.48 (dtt, J = 7.6, 2.0 Hz, 1H), 
7.40 (m, 1H), 7.28 (m, 1H), 7.19 (m, 1H), 3.97 (s, 3H), 3.21 (tt, J = 8.0 Hz, 2H), 1.83 (m, 2H), 
1.37 (m, 2H), 1.25 (m, 8H), 0.87 (tt, J = 6.8 Hz, 3H); 13C-NMR (100 MHz; CDCl3): δ 168.1, 
159.6 (d, J = 249 Hz), 142.3 (d, J = 1.4 Hz), 141.1, 131.4, 130.5 (d, J = 2.9 Hz), 130.2 (d, J = 8.4 
Hz), 127.3, 124.6 (d, J = 3.7 Hz), 123.0 (d, J = 3.6 Hz), 117.9 (d, J = 3.5 Hz), 116.2 (d, J = 22.5 




















3-Fluoro-3-(octtanesulfonamffido)-bffipThenyl-4-carboxylffic acffid  mettThyl 
estter (6j). 70% yffield; 1H-NMR (400 MHz; CDCl3): δ 10.49 (s, 1H), 
8.10 (d, J = 8.4 Hz, 1H), 7.98 (d, J = 1.6 Hz, 1H), 7.41 (m, 2H), 7.30 
(m, 2H), 7.10 (m, 1H), 3.96 (s, 3H), 3.16 (tt, J = 8.0 Hz, 2H), 1.81 (m, 2H), 1.36 (m, 2H), 1.21 
(m, 8H), 0.86 (tt, J = 6.8 Hz, 3H); 13C-NMR (100 MHz; CDCl3): δ 168.1, 163.0 (d, J = 246 Hz), 
146.0 (d, J = 2.2 Hz), 141.5, 141.3 (d, J = 7.3 Hz), 132.0, 130.5 (d, J = 8.0 Hz), 122.9 (d, J = 2.9 
Hz), 121.0, 116.1, 115.4 (d, J = 21.1 Hz), 114.1, 114.1 (d, J = 22.4 Hz), 52.5, 52.2, 31.5, 28.8, 
28.7, 27.9, 23.3, 22.4, 13.9. 
2-Hydroxy-3-(octtanesulfonamffido)-bffipThenyl-4-carboxylffic acffid  mettThyl 
estter (6k). 45% yffield; 1H-NMR (400 MHz; CDCl3): δ 10.50 (s, 1H), 8.11 
(d, J = 8.4 Hz, 1H), 7.94 (d, J = 1.6 Hz, 1H), 7.29 (m, 3H), 6.99 (m, 2H), 
5.90 (br s, 1H), 3.96 (s, 3H), 3.20 (tt, J = 8.0 Hz, 2H), 1.80 (m, 2H), 1.33 (m, 10H), 0.88 (tt, J = 
6.8 Hz, 3H); 13C-NMR (100 MHz; CDCl3): δ 168.2, 152.7, 144.6, 141.1, 131.7, 130.2, 129.9, 
126.4, 123.1, 121.0, 118.2, 116.4, 113.5, 52.5, 52.2, 31.6, 28.8, 28.7, 27.9, 23.3, 22.5, 13.9. 
 2-CThloro-4-(octtanesulfonamffido)-bffipThenyl-3-carboxylffic acffid  mettThyl 
estter (7a). 74% yffield; 1H-NMR (400  MHz; CDCl3): δ  10.51 (s,  1H), 
8.15 (d, J = 2.0 Hz, 1H), 7.82 (d, J = 8.8 Hz, 1H), 7.64 (dd, J = 8.8, 2.4 Hz, 
1H), 7.48 (m, 1H), 7.33 (m, 3H), 3.94 (s, 3H), 3.20 (tt, J = 8.0 Hz, 2H), 1.85 (m, 2H), 1.26 (m, 
10H),  0.87 (tt, J = 6.8  Hz,  3H); 13C-NMR (100  MHz; CDCl3): δ  168.2,  140.4,  138.4,  135.8, 
133.5,  132.3,  132.3,  131.0,  130.0,  128.9,  127.0,  117.2,  114.6,  52.5,  52.3,  31.5,  28.8,  28.7,  27.9, 





















mettThyl estter (7b). 78% yffield; 1H-NMR (400 MHz; CDCl3): δ 10.45 
(s, 1H), 8.23 (d, J = 2.4 Hz, 1H), 7.83 (d, J = 8.4 Hz, 1H), 7.71 (dd, J = 
2.4, 8.8 Hz, 1H), 7.53 (m, 1H), 7.43 (m, 1H), 7.35 (m, 2H), 3.98 (s, 3H), 3.17 (tt, J = 8.0 Hz, 
2H), 1.82 (m, 2H), 1.37 (m, 2H), 1.24 (m, 8H), 0.85 (tt, J = 6.8 Hz, 3H); 13C-NMR (100 MHz; 
CDCl3): δ  168.0,  140.8,  140.5,  134.7,  133.8,  133.0,  130.1,  129.7,  127.5,  126.6,  124.7,  118.1, 
115.2, 52.5, 52.2, 31.5, 28.7, 28.7, 27.9, 23.2, 22.4, 13.8. 
 4-CThloro-4-(octtanesulfonamffido)-bffipThenyl-3-carboxylffic acffid 
mettThyl estter (7c). 80% yffield; 1H-NMR (400 MHz; CDCl3): δ 10.43 
(s, 1H), 8.24 (d, J = 2.4 Hz, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.72 (dd, J 
= 2.4, 8.8 Hz, 1H), 7.50 (d, J = 8.8 Hz, 2H), 7.42 (d, J = 8.8 Hz, 2H), 3.97 (s, 3H), 3.17 (tt, J = 
8.0 Hz, 2H), 1.82 (m, 2H), 1.36 (m, 2H), 1.23 (m, 8H), 0.85 (tt, J = 6.8 Hz, 3H); 13C-NMR (100 
MHz; CDCl3): δ 168.1, 140.3, 137.5, 134.2, 133.7, 133.0, 129.6, 129.0, 127.8, 118.3, 115.4, 52.6, 
52.2, 31.5, 28.8, 28.7, 27.9, 23.3, 22.5, 13.9. 
 4'-Buttyl-4-(octtanesulfonamffido)-[1,1'-bffipThenyl]-3-carboxylffic 
acffid mettThyl estter (7d). 74% yffield; 74% yffield; 1H-NMR (400 MHz, 
CDCl3): δ 0.87 (tt, 3H, J = 6.8), 0.96 (tt, 3H, J = 7.2), 1.24 (m, 8H), 
1.39 (m, 4H), 1.65 (m, 2H), 1.83 (m, 2H), 2.66 (tt, 2H, J = 8.0), 3.18 (tt, 2H, J = 8.0), 3.97 (s, 
3H), 7.27 (d, 2H, J = 8.4), 7.49 (d, 2H, J = 8.0), 7.75 (d, 1H, J = 8.4), 7.83 (d, 1H, J = 8.8), 8.28 
(s, 1H), 10.42 (s, 1H); 13C-NMR (100 MHz, CDCl3): δ 14.0, 14.1, 22.4, 22.6, 23.4, 28.1, 28.9, 
29.0,  31.7,  33.3,  33.6,  35.3,  52.2,  52.6,  115.5,  118.4,  126.6,  129.1,  129.6,  133.2,  135.7,  136.5, 




















2-PThenyl-4-(octtanesulfonamffido)-bffipThenyl-3-carboxylffic acffid  mettThyl 
estter (7e). 65% yffield; 1H-NMR (400 MHz; CDCl3): δ 10.37 (s, 1H), 7.93 
(d, J = 2.0 Hz, 1H), 7.55 (d, J = 8.8 Hz, 1H), 7.43 (m, 4H), 7.22 (m, 4H), 
7.13 (m, 2H), 3.87 (s, 3H), 3.11 (tt, J = 8.0 Hz, 2H), 1.77 (m, 2H), 1.36 (m, 2H), 1.25 (m, 8H), 
0.88 (tt, J = 6.8  Hz,  3H); 13C-NMR (100  MHz; CDCl3): δ  168.2,  140.9,  140.6,  139.4,  138.4, 
136.2, 135.8, 132.5, 130.6, 130.0, 129.8, 128.0, 127.9, 127.6, 126.7, 117.1, 114.6, 52.3, 52.0, 31.6, 
28.8, 28.8, 28.0, 23.2, 22.5, 14.0. 
4-PThenyl-4-(octtanesulfonamffido)-bffipThenyl-3-carboxylffic acffid 
mettThyl estter (7f). 72% yffield; 1H-NMR (400  MHz; CDCl3): δ 
10.45 (s,  1H),  8.34 (d, J = 2.4  Hz,  1H),  7.85 (m,  2H),  7.67 (m, 
6H), 7.48 (tt, J = 7.6 Hz, 2H), 7.40 (m, 1H), 3.99 (s, 3H), 3.19 (tt, J 
= 8.0 Hz, 2H), 1.84 (m, 2H), 1.39 (m, 2H), 1.24 (m, 8H), 0.87 (tt, J = 6.8 Hz, 3H); 13C-NMR 
(100 MHz; CDCl3): δ 168.3, 140.5, 140.3, 140.1, 138.0, 135.0, 133.1, 129.6, 128.8, 127.6, 127.5, 
127.0, 126.9, 118.3, 115.4, 52.6, 52.2, 31.6, 28.9, 28.8, 28.0, 23.3, 22.5, 14.0. 
2-MettThoxy-4-(octtanesulfonamffido)-bffipThenyl-3-carboxylffic acffid mettThyl 
eser (7g). 67% yffield; 1H-NMR (400 MHz; CDCl3): δ 10.46 (s, 1H), 8.22 
(d, J = 2.8 Hz, 1H), 7.80 (d, J = 8.8 Hz, 1H), 7.74 (dd, J = 2.0, 8.8 Hz, 1H), 
7.32 (m, 2H), 7.03 (m, 2H), 3.94 (s, 3H), 3.83 (s, 3H), 3.19 (tt, J = 8.0 Hz, 2H), 1.84 (m, 2H), 
1.36 (m, 2H), 1.26 (m, 8H), 0.87 (tt, J = 7.2 Hz, 3H); 13C-NMR (100 MHz; CDCl3): δ 168.4, 
156.2, 139.6, 135.9, 132.9, 132.1, 130.3, 129.0, 128.4, 120.8, 117.2, 114.7, 111.1, 55.4, 52.4, 52.1, 



















mettThyl estter (7Th). 71% yffield; 1H-NMR (400 MHz; CDCl3): δ 10.37 
(s, 1H), 8.22 (d, J = 2.4 Hz, 1H), 7.81 (d, J = 8.8 Hz, 1H), 7.71 (dd, J 
= 2.4, 8.8 Hz, 1H), 7.50 (d, J = 8.8 Hz, 2H), 6.99 (d, J = 8.8 Hz, 2H), 3.96 (s, 3H), 3.85 (s, 3H), 
3.16 (tt, J = 8.0 Hz, 2H), 1.81 (m, 2H), 1.37 (m, 2H), 1.23 (m, 8H), 0.85 (tt, J = 6.8 Hz, 3H); 13C-
NMR (100 MHz; CDCl3): δ 168.3, 159.3, 139.5, 135.3, 132.8, 131.6, 129.2, 127.7, 118.4, 115.4, 
114.3, 55.3, 52.5, 52.1, 31.6, 28.8, 28.8, 28.0, 23.3, 22.5, 13.9. 
2-Fluoro-4-(octtanesulfonamffido)-bffipThenyl-3-carboxylffic acffid  mettThyl 
estter (7ffi). 73% yffield; 1H-NMR (400 MHz; CDCl3): δ 10.48 (s, 1H), 8.24 
(s, 1H), 7.83 (d, J = 8.8 Hz, 1H), 7.72 (ttd, J = 8.8, 2.0 Hz, 1H), 7.41 (dtt, J 
= 7.6, 2.0 Hz, 1H), 7.32 (m, 1H), 7.22 (m, 1H), 7.15 (m, 1H), 3.94 (s, 3H), 3.18 (tt, J = 8.0 Hz, 
2H), 1.82 (m, 2H), 1.38 (m, 2H), 1.24 (m, 8H), 0.86 (tt, J = 7.2 Hz, 3H); 13C-NMR (100 MHz; 
CDCl3): δ 168.1, 159.5 (d, J = 248 Hz), 140.3, 135.1 (d, J = 3.3 Hz), 131.7 (d, J = 3.0 Hz), 130.2 
(d, J = 3.0 Hz), 130.0, 129.3 (d, J = 8.1 Hz), 127.0 (d, J = 13.0 Hz), 124.5 (d, J = 3.7 Hz), 117.7, 
116.1 (d, J = 22.6 Hz), 115.0, 52.5, 52.2, 31.5, 28.8, 28.7, 27.9, 23.2, 22.4, 13.9. 
3-Fluoro-4-(octtanesulfonamffido)-bffipThenyI-3-carboxylffic acffid mettThyl 
estter (7j). 77% yffield; 1H-NMR (400 MHz; CDCl3): δ 10.46 (s, 1H), 
8.27 (d, J = 2.4 Hz, 1H), 7.85 (d, J = 8.8 Hz, 1H), 7.74 (dd, J = 8.4, 2.4 
Hz, 1H), 7.41 (dd, J = 8.0, 6.0 Hz, 1H), 7.35 (d, 7.6 Hz, 1H), 7.26 (d, J = 8.8 Hz, 1H), 7.06 (m, 
1H), 3.99 (s, 3H), 3.19 (tt, J = 8.0 Hz, 2H), 1.83 (m, 2H), 1.39 (m, 2H), 1.24 (m, 8H), 0.86 (tt, J 
= 7.6 Hz, 3H); 13C-NMR (100 MHz; CDCl3): δ 168.1, 163.1 (d, J = 246 Hz), 141.2 (d, J = 7.3 
Hz), 140.5, 134.0, 133.0, 130.4 (d, J = 8.2 Hz), 129.7, 122.2 (d, J = 2.8 Hz), 118.2, 115.3, 114.3 




















2-Hydroxy-4-(octtanesulfonamffido)-bffipThenyl-3-carboxylffic acffid  mettThyl 
estter (7k). 48% yffield; 1H-NMR (400 MHz; CDCl3): δ 10.47 (s, 1H), 8.22 
(d, J = 2.0 Hz, 1H), 7.83 (d, J = 8.4 Hz, 1H), 7.71 (dd, J = 8.4, 2.0 Hz, 1H), 
7.26 (m, 2H), 7.01 (tt, J = 7.6 Hz, 1H), 6.96 (d, J = 8.0 Hz, 1H), 5.31 (s, 1H), 3.94 (s, 3H), 3.19 
(tt, J = 8.0 Hz, 2H), 1.82 (m, 2H), 1.27 (m, 2H), 1.25 (m, 8H), 0.88 (tt, J = 6.8 Hz, 3H); 13C-
NMR (100 MHz; CDCl3): δ 168.2, 152.4, 140.2, 135.6, 132.0, 131.8, 130.3, 129.3, 126.4, 121.1, 
118.0, 116.1, 115.2, 52.6, 52.4, 31.6, 28.9, 28.8, 28.0, 23.3, 22.5, 14.0. 
4-Hydroxy-4-(octtanesulfonamffido)-bffipThenyl-3-carboxylffic acffid 
mettThyl estter (7l). 51% yffield; 1H-NMR (400 MHz; CDCl3): δ 10.37 
(s, 1H), 8.21 (d, J = 2.4 Hz, 1H), 7.80 (d, J = 8.8 Hz, 1H), 7.70 (dd, J 
= 8.4, 2.4 Hz, 1H), 7.44 (d, J = 8.4 Hz, 2H), 6.93 (d, J = 8.4 Hz, 2H), 3.96 (s, 3H), 3.16 (tt, J = 
8.0 Hz, 2H), 1.81 (m, 2H), 1.36 (m, 2H), 1.21 (m, 8H), 0.84 (tt, J = 7.2 Hz, 3H); 13C-NMR (100 
MHz; CDCl3): δ 168.3, 155.7, 139.4, 135.4, 132.8, 131.6, 129.2, 127.9, 118.4, 115.8, 115.5, 52.6, 
52.2, 31.6, 28.8, 28.8, 28.0, 23.3, 22.5, 13.9. 
 
Preparattffion of Carboxylffic Acffids 12a-l and 13a-l 
 
General  Procedure. To a sttffirffing suspensffion of pottassffium ttertt-buttoxffide (5.88 mmol) ffin Ett2O 
(15 mL) cooled tto 0 °C, was added watter (1.4 mmol) vffia syrffinge. TThe slury was sttffired for 5 






































sttarttffing  matterffial  dffisappeared  by  TLC analysffis (20%  EttOAc ffin  Thexanes). Ice  watter  was added 
unttffil 2 clear layers formed. TThe aqueous layer was separatted and acffidffifffied wffittTh 1 M HCl. TThe 
productt  was ttThen exttractted  wffittTh  EttOAc (3 ×  20  mL), evaporatted ffin vacuo, and recrysttalffized 
(EttOAc/Thexanes) or purffifffied by column cThromattograpThy (3:17:80 AcOH:EttOAc:Thexanes). 
2-CThloro-3-(octtanesulfonamffido)-bffipThenyl-4-carboxylffic acffid (12a). 
89% yffield; mp = 200-201 °C; 1H-NMR (400 MHz; DMSO-d6): δ 8.00 (d, J 
= 8.0 Hz, 1H), 7.56 (d, J = 8.0 Hz, 1H), 7.48 (s, 1H), 7.42 (m, 3H), 6.96 
(d, J = 8.0 Hz, 1H), 3.08 (tt, J = 7.6 Hz, 2H), 1.62 (m, 2H), 1.20 (m, 10H), 0.80 (tt, J = 7.2 Hz, 
3H); 13C-NMR (100  MHz; MeOD): δ  171.1,  146.8,  142.0,  140.0,  133.0,  133.0,  132.1,  131.1, 
130.7,  128.4,  124.7,  119.6,  115.9,  52.3,  32.7,  29.8,  29.8,  28.7,  24.3,  23.5,  14.4.  Anal. 
(C21H26ClNO4S) C, H, N. 
3-CThloro-3-(octtyIsulfonamffido)-bffipThenyI-4-carboxylffic acffid (12b). 
90% yffield; mp = 120-121 °C; 1H-NMR (400 MHz; MeOD): δ 8.21 (d, 
J = 8.4 Hz, 1H), 7.98 (s, 1H), 7.68 (s, 1H), 7.62 (d, J = 7.6 Hz, 1H), 
7.46 (m, 3H), 3.25 (tt, J = 7.6 Hz, 2H), 1.78 (m, 2H), 1.38 (m, 2H), 1.23 (m, 8H), 0.87 (tt, J = 7.2 
Hz,  3H); 13C-NMR (100  MHz; MeOD): δ  171.2,  146.7,  142.9,  142.6,  135.9,  133.8,  131.6, 
129.6,  128.0,  126.6,  122.3,  117.1,  116.7,  52.5,  32.8,  29.9,  29.8,  28.8,  24.4,  23.6,  14.4.  Anal. 
(C21H26ClNO4S) C, H, N. 
4-CThloro-3-(octtanesulfonamffido)-bffipThenyl-4-carboxylffic acffid (12c). 
86% yffield; mp = 162-163 °C; 1H-NMR (400 MHz; MeOD): δ 8.15 (d, 
J = 8.0 Hz, 1H), 7.89 (d, J = 1.6 Hz, 1H), 7.65 (d, J = 6.8 Hz, 2H), 7.48 
(d, J = 6.8 Hz, 2H), 7.35 (dd, J = 2.0, 8.0 Hz, 1H), 3.14 (tt, J = 8.0 Hz, 2H), 1.76 (m, 2H), 1.35 




















142.9,  139.3,  135.9,  133.8,  130.2,  129.7,  122.3,  117.0,  115.2,  52.5,  32.8,  29.9,  29.8,  28.8,  24.5, 
23.6, 14.3. Anal. (C21H26ClNO4S) C, H, N. 
4'-Buttyl-4-(octtanesulfonamffido)-[1,1'-bffipThenyl]-3-carboxylffic acffid 
(12d). 85% yffield; mp = 134-135 °C; 1H-NMR (400 MHz; CDCl3): δ 
10.23 (s, 1H), 8.19 (d, J = 8.4 Hz, 1H), 8.03 (d, J = 1.6 Hz, 1H), 7.58 
(d, J = 8.1 Hz, 2H), 7.39 (dd, J = 8.4, 1.6 Hz, 1H), 7.30 (d, J = 8.1 Hz, 2H), 3.22 (tt, J = 7.9 Hz, 
2H), 2.68 (tt, J = 7.7 Hz, 2H), 1.87-1.83 (m, 2H), 1.68-1.61 (m, 2H), 1.42-1.35 (m, 4H), 1.23 (s, 
9H), 0.96 (tt, J = 7.3 Hz, 3H), 0.84 (tt, J = 6.8 Hz, 3H); 13C-NMR (101 MHz, CDCl3): δ 172.82, 
148.92,  144.30,  142.16,  136.30,  133.16,  129.27,  127.33,  121.37,  115.83,  112.26,  52.45,  35.47, 
33.65, 31.76, 29.03, 28.96, 28.16, 23.50, 22.66, 22.47, 14.14, 14.05; Anal. (C25H35NO4S) C, H, 
N. 
2-PThenyl-3-(octtanesulfonamffido)-bffipThenyl-4-carboxylffic acffid (12e). 
84% yffield; mp = 110-111 °C: 1H-NMR (400 MHz; MeOD): δ 8.06 (d, J = 
8.4 Hz, 1H), 7.45 (m, 5H), 7.23 (m, 5H), 7.12 (dd, J = 8.0, 1.2 Hz, 1H), 
2.61 (tt, J = 8.0 Hz, 2H), 1.56 (m, 2H), 1.26 (m, 10H), 0.91 (tt, J = 7.2 Hz, 3H); 13C-NMR (100 
MHz; MeOD): δ  171.3,  149.8,  142.6,  141.8,  141.8,  140.4,  133.1,  131.8,  131.2,  130.9,  129.5, 
129.3,  128.7,  127.9,  124.9,  120.1,  114.9,  51.5,  32.8,  30.0,  29.9,  28.7,  24.5,  23.6,  14.4.  Anal. 
(C27H31NO4S) C, H, N. 
4-PThenyl-3-(octtanesulfonamffido)-bffipThenyl-4-carboxylffic acffid 
(12f). 83% yffield; mp = 220-221 °C; 1H-NMR (400 MHz; DMSO-
d6): δ 8.08 (d, J = 8.4 Hz, 1H), 7.81 (m, 7H), 7.49 (m, 3H), 7.39 (tt, J 
= 7.2 Hz, 1H), 3.31 (tt, J = 8.0 Hz, 2H), 1.64 (m, 2H), 1.31 (m, 2H), 1.18 (m, 8H), 0.79 (tt, J = 


















132.3,  128.9,  127.7,  127.4,  127.3,  126.6,  120.5,  115.3,  114.9,  51.0,  31.0,  28.2,  28.1,  27.0,  23.0, 
21.9, 13.8. HRMS (FAB) calcd for C27H31NO4S [M]+, 465.19738; found, 465.19692. 
2-MettThoxy-3-(octtanesulfonamffido)-bffipThenyl-4-carboxylffic acffid (12g). 
89% yffield; mp = 100-101 °C; 1H-NMR (400 MHz; MeOD): δ 8.12 (d, J = 
8.4 Hz, 1H), 7.93 (s, 1H), 7.40 (m, 2H), 7.28 (d, J = 8.4 Hz, 1H), 7.11 (m, 
2H), 3.85 (s, 3H), 3.25 (tt, J = 7.8 Hz, 2H), 1.71 (m, 2H), 1.22 (m, 10H), 0.87 (tt, J = 6.9 Hz, 
3H); 13C-NMR (100  MHz; MeOD): δ  173.9,  157.9,  146.4,  132.7,  131.4,  131.0,  130.0,  124.8, 
122.0,  119.9,  119.2,  112.8,  112.3,  56.1,  51.8,  32.8,  29.8,  29.8,  28.8,  24.4,  23.5,  14.3.  Anal. 
(C22H28NNaO5S) C, H, N. 
4-MettThoxy-3-(octtanesulfonamffido)-bffipThenyl-4-carboxylffic acffid 
(12Th). 94% yffield; mp = 144 °C; 1H-NMR (400 MHz; MeOD): δ 8.12 
(d, J = 8.4 Hz, 1H), 7.94 (d, J = 1.6 Hz, 1H), 7.60 (d, J = 6.8 Hz, 2H), 
7.37 (dd, J = 1.6, 8.4 Hz, 1H), 7.02 (dd, J = 2.0, 6.8 Hz, 2H), 3.84 (s, 3H), 3.20 (tt, J = 7.6 Hz, 
2H), 1.73 (m, 2H), 1.34 (m, 2H), 1.20 (m, 8H), 0.86 (tt, J = 6.8 Hz, 3H); 13C-NMR (100 MHz; 
MeOD): δ 171.4, 161.8, 148.2, 142.9, 133.6, 132.7, 129.3, 121.8, 116.3, 115.5, 115.2, 55.8, 52.3, 
32.8, 29.9, 29.8, 28.8, 24.4, 23.6, 14.4. Anal. (C22H29NO5S) C, H, N. 
2-Fluoro-3-(octtanesulfonamffido)-bffipThenyl-4-carboxylffic acffid (12ffi). 91% 
yffield; mp = 117-118 °C; 1H-NMR (400 MHz; MeOD): δ 8.16 (dd, J = 2.8, 
8.4 Hz, 1H), 7.92 (d, J = 1.6 Hz, 1H), 7.53 (m, 1H), 7.42 (m, 1H), 7.31 (m, 
2H), 7.24 (m, 1H), 3.21 (tt, J = 7.6 Hz, 2H), 1.73 (m, 2H), 1.33 (m, 2H), 1.24 (m, 8H), 0.85 (tt, J 
= 7.2  Hz,  3H); 13C-NMR (100  MHz; MeOD): δ  171.2,  161.0 (d, J = 250  Hz),  143.3,  142.5, 




















Hz), 119.1 (d, J = 3.5 Hz), 117.2 (d, J = 22.4 Hz), 116.1, 52.3, 32.7, 29.8, 29.8, 28.8, 24.4, 23.5, 
14.3. Anal. (C21H26FNO4S) C, H, N. 
3-Fluoro-3-(octtanesulfonamffido)-bffipThenyl-4-carboxylffic acffid (12j). 
86% yffield; mp = 128-129 °C; 1H-NMR (400 MHz; MeOD): δ 8.19 (d, J 
= 8.4 Hz, 1H), 7.97 (d, J = 1.6 Hz, 1H), 7.50 (m, 2H), 7.43 (m, 2H), 
7.16 (m, 1H), 3.22 (tt, J = 7.6 Hz, 2H), 1.76 (m, 2H), 1.39 (m, 2H), 1.23 (m, 8H), 0.87 (tt, J = 7.2 
Hz, 3H); 13C-NMR (100 MHz; MeOD): δ 171.7, 164.5 (d, J = 243.8 Hz), 146.3 (d, J = 2.0 Hz), 
143.1, 142.7, 133.7, 131.8 (d, J = 8.6 Hz), 124.0 (d, J = 2.7 Hz), 122.2, 118.2, 117.1, 116.1 (d, J = 
21.3  Hz),  114.8 (d, J = 22.5  Hz),  52.4,  32.7,  29.9,  29.8,  28.8,  24.4,  23.5,  14.3.  Anal. 
((C21H26FNO4S)·0.5(AcOH)) C, H, N. 
2-Hydroxy-3-(octtanesuIfonamffido)-bffipThenyl-4-carboxylffic acffid (12k). 
74% yffield; mp = 45 °C; 1H-NMR (400 MHz; MeOD): δ 8.12 (d, J = 8.4 
Hz, 1H), 8.00 (s, 1H), 7.34 (m, 2H), 7.21 (m, 1H), 6.92 (m, 2H), 3.26 (d, J 
= 8.0 Hz, 2H), 1.73 (m, 2H), 1.35 (m, 2H), 1.18 (m, 8H), 0.86 (tt, J = 6.8 Hz, 3H); 13C-NMR 
(100  MHz; MeOD): δ  175.2,  155.7,  146.5,  141.8,  132.7,  131.3,  130.6,  128.0,  124.5,  121.0, 
119.5, 117.1, 116.4, 51.7, 32.7, 29.8, 29.8, 28.8, 24.3, 23.5, 14.3. Anal. ((C21H27NO5S)·(H2O)) 
C, H, N. 
4-Hydroxy-3-(octtanesulfonamffido)-bffipThenyl-4-carboxylffic acffid 
(12l). Estter 6Th (0.3  mmol)  was  dffissolved ffin  13  mL  CH2Cl2, ttThe 
soluttffion  was cooled tto -78 °C, and  1M  BBr3 soluttffion ffin  CH2Cl2 (4 
equffiv) was added slowly. TThe soluttffion was sttffired and warmed tto room ttemperatture, and wThen 
complette  by  TLC (30%  EttOAc ffin  Thexanes), ttThe soluttffion  was acffidffifffied  wffittTh  1M  HCl and 




















recrysttalffized (EttOAc/Thexanes)  or  purffifffied  by column cThromattograpThy (3:17:80 
AcOH:EttOAc:Thexanes). 69% yffield; mp = 61-62 °C; 1H-NMR (400 MHz; MeOD): δ 8.11 (d, J 
= 8.0 Hz, 1H), 7.92 (s, 1H), 7.52 (d, J = 8.8 Hz, 2H), 7.37 (m, 1H), 6.89 (d, J = 8.8 Hz, 2H), 
3.19 (tt, J = 7.6 Hz, 2H), 1.72 (m, 2H), 1.34 (m, 2H), 1.19 (m, 8H), 0.86 (tt, J = 6.8 Hz, 3H); 13C-
NMR (100 MHz; MeOD): δ 171.5, 159.5, 148.4, 142.8, 133.6, 131.6, 129.3, 121.6, 116.9, 116.2, 
110.7, 52.2, 32.8, 29.9, 29.8, 28.8, 24.4, 23.5, 14.3. Anal. ((C21H27NO5S)·0.3(AcOH)) C, H, N. 
2-CThloro-4-(octtanesulfonamffido)-bffipThenyl-3-carboxyIffic acffid (13a). 
85% yffield; mp = 74-75 °C; 1H-NMR (400 MHz; MeOD): δ 8.17 (d, J = 2.4 
Hz, 1H), 7.76 (d, J = 8.4 Hz, 1H), 7.60 (dd, J = 8.4, 2.4 Hz, 1H), 7.49 (d, J 
= 8.0 Hz, 1H), 7.37 (m, 3H), 3.21 (tt, J = 8.0 Hz, 2H), 1.76 (m, 2H), 1.20 (m, 10H), 0.86 (tt, J = 
7.2 Hz, 3H); 13C-NMR (100 MHz; MeOD): δ 172.1, 141.6, 140.3, 135.6, 135.0, 133.9, 133.4, 
132.3,  131.0,  130.0,  128.3,  118.4,  115.4,  52.2,  32.8,  29.9,  29.9,  28.9,  24.4,  23.6,  14.3.  Anal. 
((C21H26ClNO4S)·0.3(AcOH)) C, H, N.  
 
3-CThloro-4-(octtanesulfonamffido)-bffipThenyl-3-carboxylffic acffid (13b). 
89% yffield; mp = 133-134 °C; 1H-NMR (400 MHz; MeOD): δ 8.29 (s, 
1H), 7.81 (m, 2H), 7.57 (m, 1H), 7.52 (d, J = 7.6 Hz, 1H), 7.42 (tt, J = 
8.0 Hz, 1H), 7.34 (d, J = 8.0 Hz, 1H), 3.22 (tt, J = 8.0 Hz, 2H), 1.72 (m, 2H), 1.23 (m, 10H), 
0.83 (tt, 7.2 Hz, 3H); 13C-NMR (100 MHz; MeOD): δ 171.1, 142.4, 142.1, 135.9, 135.2, 134.0, 
131.5, 131.2, 128.5, 127.5, 126.0, 119.4, 117.4, 52.4, 32.8, 29.9, 29.9, 28.8, 24.4, 23.6, 14.3. Anal. 














4-CThloro-4-(octtanesulfonamffido)-bffipThenyl-3-carboxylffic acffid (13c). 
91% yffield; mp = 143-144 °C; 1H-NMR (400 MHz; MeOD): δ 8.31 (d, 
J = 2.0 Hz, 1H), 7.81 (m, 2H), 7.58 (d, J = 8.8 Hz, 2H), 7.43 (d, J = 8.4 
Hz, 2H), 3.22 (tt, J = 7.6 Hz, 2H), 1.73 (m, 2H), 1.35 (m, 2H), 1.22 (m, 8H), 0.86 (tt, J = 7.2 Hz, 
3H); 13C-NMR (100  MHz; MeOD): δ  171.1,  141.8,  139.1,  135.5,  134.7,  133.8,  131.0,  130.1, 
129.1, 119.5, 117.5, 52.4, 32.8, 29.9, 29.9, 28.8, 24.5, 23.6, 14.4. Anal. (C21H26ClNO4S) C, H, N. 
4’-Buttyl-4-(octtanesulfonamffido)-bffipThenyl]-3-carboxylffic acffid 
(13d). 93% yffield; mp = 103-104 °C; 1H-NMR (300 MHz, CDCl3): δ 
0.85 (tt, 3H, J = 6.8), 0.97 (tt, 3H, J = 7.2), 1.25 (m, 8H), 1.41 (m, 4H), 
1.66 (m, 2H), 1.87 (m, 2H), 2.68 (tt, 2H, J = 7.8), 3.24 (tt, 2H, J = 7.5), 7.30 (d, 2H, J = 7.5), 7.52 
(d, 2H, J = 7.8), 7.86 (m, 2H), 8.41 (s, 1H), 10.22 (s, 1H); 13C-NMR (75 MHz, CDCl3): δ 14.0, 
14.0, 22.4, 22.6, 23.4, 28.1, 28.9, 28.9, 31.7, 33.6, 35.3, 52.4, 114.5, 118.3, 126.5, 129.1, 130.6, 
134.2, 135.9, 136.1, 140.3, 142.8, 172.4; Anal. (C25H35NO4S) C, H, N. 
2-PThenyl-4-(octtanesulfonamffido)-bffipThenyl-3-carboxylffic acffid (13e). 
88% yffield; mp = 114-115 °C; 1H-NMR (400 MHz; MeOD): δ 7.89 (d, J = 
2.0 Hz, 1H), 7.51 (d, J = 8.8 Hz, 1H), 7.38 (m, 4H), 7.19 (m, 4H), 7.09 (m, 
2H), 3.10 (tt, J = 8.0 Hz, 2H), 1.65 (m, 2H), 1.21 (m, 10H), 0.86 (tt, J = 6.8 Hz, 3H); 13C-NMR 
(100  MHz; MeOD): δ  171.3,  142.5,  141.9,  140.8,  139.9,  137.5,  137.0,  134.3,  131.2,  130.9, 
129.0,  129.0,  128.8,  127.7,  118.4,  116.9,  52.2,  32.8,  29.9,  29.9,  28.9,  24.4,  23.6,  14.4;  Anal. 





















(13f). 92% yffield; mp = 175-176 °C; 1H-NMR (400 MHz; DMSO-
d6): δ 10.79 (br s, 1H), 8.31 (d, J = 2.4 Hz, 1H), 8.01 (dd, J = 2.4, 
8.8 Hz, 1H), 7.75 (m, 7H), 7.48 (tt, J = 8.0 Hz, 2H), 7.37 (m, 1H), 
3.33 (tt, J = 7.6 Hz, 2H), 1.65 (m, 2H), 1.33 (m, 2H), 1.20 (m, 8H), 0.81 (tt, J = 7.2 Hz, 3H); 13C-
NMR (100  MHz; DMSO-d6): δ  169.8,  139.9,  139.4,  139.2,  137.3,  133.7,  132.6,  129.1,  128.9, 
127.5,  127.3,  126.8,  126.5,  118.2,  116.4,  51.0,  31.0,  28.2,  28.2,  27.0,  22.9,  21.9,  13.8;  HRMS 
(FAB) calcd for C27H31NO4S [M]+, 465.19738; found, 465.19766. 
2-MettThoxy-4-(octtanesulfonamffido)-bffipThenyl-3-carboxylffic acffid (13g). 
91% yffield;  mp  =  104-105 °C; 1H-NMR (400  MHz; MeOD): δ  8.24 (s, 
1H), 7.71 (m, 2H), 7.28 (m, 2H), 6.98 (m, 2H), 3.77 (s, 3H), 3.17 (tt, J = 
8.0  Hz,  2H),  1.70 (m,  2H),  1.19 (m,  10H),  0.83 (tt, J = 7.2  Hz,  3H); 13C-NMR (100  MHz; 
MeOD): δ  171.5,  157.7,  140.9,  136.6,  134.5,  133.8,  131.2,  130.1,  129.8,  122.0,  118.3,  116.9, 
112.5, 55.9, 52.2, 32.7, 29.9, 29.8, 28.8, 24.4, 23.5, 14.4. Anal. (C22H29NO5S) C, H, N. 
4-MettThoxy-4-(octtanesulfonamffido)-bffipThenyl-3-carboxylffic acffid 
(13Th). 91% yffield; mp = 114-115 °C; 1H-NMR (400MHz; MeOD): δ 
8.26 (s, 1H), 7.71 (m, 2H), 7.46 (d, J = 8.8 Hz, 2H), 6.93 (d, J = 8.8 
Hz, 2H), 3.79 (s, 3H), 3.15 (tt, J = 8.0 Hz, 2H), 1.70 (m, 2H), 1.20 (m, 10H), 0.81 (tt, J = 7.2 Hz, 
3H); 13C-NMR (100  MHz; MeOD): δ  171.5,  160.8,  140.8,  136.5,  133.2,  132.7,  130.5,  128.5, 




















2-Fluoro-4-(octtanesulfonamffido)-bffipThenyl-3-carboxylffic acffid (13ffi). 90% 
yffield; mp = 91-92 °C; 1H-NMR (400 MHz; MeOD): δ 8.27 (s, 1H), 7.78 
(d, J = 8.4 Hz, 1H), 7.70 (d, J = 8.4 Hz, 1H), 7.42 (tt, J = 8.0 Hz, 1H), 7.32 
(m, 1H), 7.21 (tt, J = 7.6 Hz, 1H), 7.15 (m, 1H), 3.19 (tt, J = 7.6 Hz, 2H), 1.73 (m, 2H), 1.32 (m, 
2H), 1.17 (m, 8H), 0.81 (tt, J = 7.2 Hz, 3H); 13C-NMR (100 MHz; MeOD): δ 171.3, 160.9 (d, J 
= 245 Hz), 141.7, 135.7 (d, J = 3.4 Hz), 133.3 (d, J = 3.3 Hz), 131.3 (d, J = 3.0 Hz), 130.5 (d, J = 
8.4 Hz), 128.4, 128.2, 125.7 (d, J = 3.6 Hz), 118.7, 117.5, 117.0 (d, J = 22.8 Hz), 52.4, 32.7, 29.8, 
29.8, 28.8, 24.4, 23.5, 14.3. Anal. (C21H26FNO4S) C, H, N. 
3-Fluoro-4-(octtanesulfonamffido)-bffipThenyl-3-carboxylffic acffid (13j). 
82% yffield; mp = 102-103 °C; 1H-NMR (400 MHz; MeOD): δ 8.31 (s, 
1H),  7.79 (s,  2H),  7.41 (m,  2H),  7.30 (d, J = 10.4  Hz,  1H),  7.05 (m, 
1H), 3.20 (tt, J = 7.6 Hz, 2H), 1.73 (m, 2H), 1.33 (m, 2H), 1.21 (m, 8H), 0.82 (tt, J = 6.8 Hz, 
3H); 13C-NMR (100  MHz; MeOD): δ  171.3,  164.6 (d, J = 243  Hz),  142.9 (d, J = 7.4  Hz), 
141.9, 135.2, 133.6, 131.7 (d, J = 8.4 Hz), 131.2, 123.3 (d, J = 2.9 Hz), 119.3, 118.1, 115.1 (d, J = 
21.1  Hz),  114.2 (d, J = 22.3  Hz),  52.4,  32.8,  29.9,  29.9,  28.8,  24.4,  23.5,  14.3.  Anal. 
(C21H26FNO4S) C, H, N. 
2-Hydroxy-4-(octtanesulfonamffido)-bffipThenyl-3-carboxylffic acffid (13k). 
71% yffield; mp = 59 °C; 1H-NMR (400 MHz; MeOD): δ 8.33 (s, 1H), 7.75 
(dd, J = 8.4, 2.4 Hz, 1H), 7.69 (d, J = 8.4 Hz, 1H), 7.28 (dd, J = 8.0, 1.6 Hz, 
1H), 7.15 (dtt, J = 7.6, 1.6 Hz, 1H), 6.90 (m, 2H), 3.17 (tt, J = 8.0 Hz, 2H), 1.75 (m, 2H), 1.23 
(m, 10H), 0.86 (tt, J = 7.2 Hz, 3H); 13C-NMR (100 MHz; MeOD): δ 173.0, 155.4, 140.3, 135.1, 
134.8,  133.6,  131.2,  129.6,  128.4,  120.9,  120.8,  118.4,  116.9,  51.9,  32.7,  29.9,  29.9,  28.9,  24.4, 





















(13l). 71% yffield; mp = 142 °C; 1H-NMR (400 MHz; MeOD): δ 8.26 
(s, 1H), 7.73 (m, 2H), 7.43 (d, J = 8.7 Hz, 2H), 6.87 (d, J = 8.7 Hz, 
2H), 3.17 (tt, J = 8.0 Hz, 2H), 1.69 (m, 2H), 1.34 (m, 2H), 1.24 (m, 8H), 0.82 (tt, J = 7.2 Hz, 
3H); 13C-NMR (100  MHz; MeOD): δ  175.2,  158.3,  140.5,  137.0,  133.2,  131.7,  130.3,  128.6, 
119.4, 117.7, 116.7, 52.1, 32.7, 29.8, 29.8, 28.7, 24.3, 23.5, 14.3. Anal. (C21H27NO5S) C, H, N. 
 
Preparattffion of Suzukffi Couplffing productts 8a-b and 9a-d 
 
General  Procedure. To an round bottttom flask flusThed wffittTh carbon monoxffide was added 1.23 
mmol of aryl bromffide 4 or 5, dffioxane (9 mL), Pd(PPTh3)4 (10 mol%), K2CO3 (3.0 equffiv), and 
boronffic acffid (1.1 eq). TThe cattalystt was loaded by bubblffing CO ttThrougTh ttThe soluttffion, and ttThe 
reacttffion  mffixtture  was  Theatted tto  90 °C and sttffired  under  1 attm  of carbon  monoxffide.  Reacttffion 
progress  was  monffittored  by  TLC (10%  EttOAc ffin  Thexanes)  unttffil  dffisappearance  of sttarttffing 
matterffial was observed (approx. 24 Th). Upon complettffion, ttThe reacttffion was quencThed wffittTh 1 M 
HCl soluttffion, and ttThe crude  productt  was exttractted  wffittTh  EttOAc (3 ×  20  mL).  TThe combffined 
organffic exttractts  were  wasThed  wffittTh  brffine,  drffied  wffittTh  MgSO4, and concenttratted ffin vacuo. 
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Suzukffi productts 8a-b or 9a-d as wel as dffirecttly-coupled Suzukffi sffide productts wffittThoutt carbonyl 
ffinserttffion. 
MettThyl  4-(4-n-buttylbenzoyl)-2-(octtanesulfonamffido)benzoatte 
(8a). 25% yffield (48%  dffirecttly-coupled  productt); 1H-NMR (400 
MHz; CDCl3): δ 10.46 (s, 1H), 8.15 (d, J = 8.2 Hz, 1H), 8.03 (d, J 
= 1.5 Hz, 1H), 7.75 (d, J = 8.3 Hz, 2H), 7.43 (dd, J = 8.2, 1.5 Hz, 1H), 7.30 (d, J = 8.3 Hz, 2H), 
3.98 (s, 3H), 3.17-3.14 (m, 2H), 2.69 (tt, J = 7.8 Hz, 2H), 1.84-1.77 (m, 2H), 1.65-1.50 (m, 2H), 
1.40-1.35 (m, 4H), 1.28-1.22 (m, 8H), 0.94 (tt, J = 7.3 Hz, 3H), 0.85 (tt, J = 6.9 Hz, 3H); 13C-
NMR (101  MHz,  CDCl3): δ 194.89,  167.90,  149.35,  143.67,  140.99,  133.75,  131.59,  130.47, 
128.65,  122.94,  121.12, 118.61,  52.91,  52.83,  35.81,  33.22,  31.68,  28.96,  28.89,  28.06,  23.42, 
22.59, 22.39, 14.07, 13.93. 
MettThyl 4-([1,1'-bffipThenyl]-4-carbonyl)-2-
(octtanesulfonamffido)benzoatte (8b). 35% yffield (44%  dffirecttly-
coupled  productt); 1H-NMR (400  MHz;  CDCl3): δ 10.48 (s, 
1H), 8.18 (d, J = 8.2 Hz, 1H), 8.09 (d, J = 1.5 Hz, 1H), 7.93-7.90 (m, 2H), 7.73-7.71 (m, 2H), 
7.66-7.64 (m,  2H),  7.55-7.40 (m,  4H),  3.99 (s,  3H),  3.20-3.16 (m,  2H),  1.86-1.78 (m,  2H), 
1.39-1.35 (m, 2H), 1.28-1.22 (m, 8H), 0.86 (tt, J = 6.9 Hz, 3H); 13C-NMR (101 MHz, CDCl3): δ 
194.94, 168.01, 146.31, 143.48, 141.19, 139.81, 134.94, 131.04, 129.14, 127.47, 127.36, 123.13, 
118.85, 117.52, 53.08, 53.06, 31.81, 29.10, 29.02, 28.22, 23.57, 22.72, 14.20. 
MettThyl  5-(4-n-buttylbenzoyl)-2-(octtanesulfonamffido)benzoatte 
(9a). 40% yffield (37%  dffirecttly-coupled  productt); 1H-NMR (300 
MHz, CDCl3): δ 0.85 (tt, 3H, J = 6.3), 0.94 (tt, 3H, J = 7.2), 1.23 






















3.94 (s, 3H), 7.30 (d, 2H, J = 8.1), 7.70 (d, 2H, J = 7.8), 7.83 (d, 1H, J = 8.7), 7.97 (d, 1H, J = 
8.7),  8.55 (s,  1H),  10.76 (s,  1H); 13C-NMR (75  MHz,  CDCl3): δ 13.9,  14.0,  22.4,  22.6,  23.4, 
28.0,  28.9,  28.9,  31.7,  33.3,  35.7,  52.8,  52.8,  114.3,  116.6,  128.6,  130.1,  131.7,  133.8,  134.5, 
136.3, 144.3, 148.6, 168.0, 194.1. 
MettThyl 5-([1,1'-bffipThenyl]-4-carbonyl)-2-
(octtanesulfonamffido)benzoatte (9b). 32% yffield (42%  dffirecttly-
coupled productt); 1H-NMR (400 MHz, CDCl3): δ 0.87 (tt, 3H, J 
= 6.8), 1.15-1.30 (m, 8H), 1.35-1.45 (m, 2H), 1.80-1.90 (m, 2H), 3.24 (tt, 2H, J = 8.0), 3.95 (s, 
3H), 7.38-7.55 (m, 3H), 7.66 (d, 2H, J = 8.0), 7.73 (d, 2H, J = 8.0), 7.84-7.89 (m, 3H), 8.03 (d, 
1H, J = 8.8), 8.59 (s, 1H); 13C-NMR (100 MHz, CDCl3): δ 14.0, 22.5, 23.3, 28.0, 28.8, 28.9, 
31.6, 52.8, 52.8, 114.2, 116.7, 127.1, 127.2, 128.3, 129.0, 130.5, 131.4, 133.9, 135.6, 136.3, 139.7, 
144.5, 145.5, 167.9, 194.1. 
MettThyl  5-(2-mettThoxybenzoyl)-2-(octtanesulfonamffido)benzoatte 
(9c). 28% yffield (57% dffirecttly-coupled productt); 1H-NMR (400 MHz, 
CDCl3): δ 0.82 (tt, 3H, J = 6.8), 1.20 (m, 8H), 1.34 (m, 2H), 1.79 (m, 
2H), 3.18 (tt, 2H, J = 8.0), 3.69 (s, 3H), 3.89 (s, 3H), 6.98 (tt, 1H, J = 8.0), 7.04 (d, 1H, J = 7.6), 
7.33 (d, 1H, J = 7.6), 7.47 (tt, 1H, J = 7.6), 7.74 (d, 1H, J = 7.2), 7.89 (dd, 1H, J1=8.8, J2=2.0), 
8.53 (d, 1H, J = 2.0), 10.77 (s, 1H); 13C-NMR (100 MHz, CDCl3): δ 14.0, 22.5, 23.4, 28.0, 28.8, 
28.9, 31.6, 52.7, 52.8, 55.6, 111.6, 114.2, 116.4, 120.8, 128.0, 129.7, 129.7, 132.4, 133.5, 136.3, 
144.7, 157.2, 168.1, 194.1. 
MettThyl 5-(4-mettThoxybenzoyl)-2-





















coupled productt); 1H-NMR (400  MHz,  CDCl3): δ 0.84 (tt,  3H, J = 6.8),  1.10-1.30 (m,  8H), 
1.35-1.40 (m, 2H), 1.70-1.85 (m, 2H), 3.20 (tt, 2H, J = 8.0), 3.88 (s, 3H), 3.93 (s, 3H), 6.97 (d, 
2H, J = 8.8), 7.77 (d, 2H, J = 8.8), 7.81 (d, 1H, J = 8.4), 7.93 (d, 1H, J = 8.4), 8.48 (s, 1H), 10.72 
(s, 1H); 13C-NMR (100 MHz, CDCl3): δ 13.9, 22.5, 23.3, 27.9, 28.7, 28.8, 31.5, 52.6, 52.7, 55.5, 
113.7, 114.1, 116.6, 129.5, 131.9, 132.2, 133.5, 136.0, 144.0, 163.3, 167.9, 193.1 
 
Preparattffion of Compounds 10a-b and 11a-b 
 
General Procedure. To a vffial flusThed wffittTh argon was placed 0.247 mmol of aryl bromffide 4 or 5, 
folowed by 10 mol% Pd(PPTh3)4, 0.40 mL of ttoluene, and 0.25 mL of a 2 M Na2CO3 soluttffion. 
TThe soluttffion was sttffired att room ttemperatture for 5 mffin, and ttThen a soluttffion of ttThe boronffic acffid 
(40 mg, 1.25 equffiv) ffin 0.40 mL MeOH was added. TThe vffial was capped and Theatted tto 90 °C for 
24 Th. TThe reacttffion was ttThen cooled tto room ttemperatture and dffilutted NaHCO3. TThe reacttffion 
mffixtture  was exttractted  wffittTh  CH2Cl2 (3 ×  5  mL) and ttThe combffined  organffic layers  were 
concenttratted ffin vacuo.  TThe crude  productt  was  purffifffied  by column cThromattograpThy 
(EttOAc/Thexanes) tto yffield ttThe desffired Suzukffi couplffing productt. 
(E)-MettThyl  2-(octtanesulfonamffido)-4-sttyrylbenzoatte (10a). 64% 
yffield; 1H-NMR (400 MHz, CDCl3): δ 0.88 (tt, 3H, J = 6.8), 1.31 (m, 
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6H), 7.55 (d, 2H, J = 8.0), 7.88 (s, 1H), 8.02 (d, 1H, J = 8.0), 10.52 (s, 1H); 13C-NMR (100 
MHz,  CDCl3): δ 13.9,  22.4,  23.2,  27.9,  28.7,  28.8,  31.5,  51.9,  52.3,  113.5,  115.5,  120.0,  126.8, 
126.9, 128.4, 128.7, 131.6, 132.5, 136.2, 141.3, 143.7, 168.1. 
(E)-MettThyl 4-(4-mettThoxysttyryl)-2-
(octtanesulfonamffido)benzoatte (10b). 58% yffield; 1H-NMR 
(300 MHz, CDCl3): δ 0.87 (tt, 3H, J = 7.2), 1.33 (m, 10H), 1.80 
(m, 2H), 3.15 (tt, 2H, J = 8.1), 3.82 (s, 3H), 3.91 (s, 3H), 6.88 (m, 3H), 7.20 (m, 2H), 7.46 (d, 
2H, J = 8.7), 7.82 (s, 1H), 7.97 (d, 1H, J = 8.4), 10.48 (s, 1H); 13C-NMR (75 MHz, CDCl3): δ 
13.9, 22.5, 23.2, 27.9, 28.7, 28.8, 31.4, 51.8, 52.2, 55.1, 113.1, 114.1, 115.2, 119.8, 124.7, 128.2, 
128.9, 131.6, 132.1, 141.4, 144.2, 159.9, 168.1. 
(E)-MettThyl  2-(octtanesulfonamffido)-5-sttyrylbenzoatte (11a). 83% 
yffield; 1H-NMR (300 MHz, CDCl3): δ 0.87 (tt, 3H, J = 7.2), 1.23 (m, 
10H), 1.81 (m, 2H), 3.16 (tt, 2H, J = 8.1), 3.97 (s, 3H), 7.04 (d, 2H, J 
= 2.1), 7.28 (m, 1H), 7.37 (tt, 2H, J = 7.5), 7.51 (d, 2H, J = 7.2), 7.66 (dd, 1H, J = 2.1, 8.7), 7.76 
(d, 1H, J = 8.7), 8.15 (d, 1H, J = 2.1), 10.43; 13C-NMR (75 MHz, CDCl3): δ 13.9, 22.4, 23.1, 
27.8,  28.6,  28.7,  31.4,  52.0,  52.4,  115.1,  117.9,  126.3,  126.3,  127.7,  128.5,  128.8,  129.3,  131.8, 
132.1, 136.6, 139.8, 168.0. 
(E)-MettThyl 5-(4-mettThoxysttyryl)-2-
(octtanesulfonamffido)benzoatte (11b). 73% yffield; 1H-NMR 
(400 MHz, CDCl3): δ 0.85 (tt, 2H, J = 7.2), 1.26(m, 10H), 1.77 
(m, 2H), 3.14 (tt, 2H, J = 7.8), 3.77 (s, 3H), 3.94 (s, 3H), 6.82-7.01 (m, 4H), 7.42 (d, 2H, J = 



















MHz, CDCl3): δ 13.8, 22.3, 23.1, 27.8, 28.6, 28.7, 31.4, 51.9, 52.4, 55, 113.9, 115.0, 117.9, 124.1, 
127.5, 128.3, 128.9, 129.3, 131.8, 132.2, 139.4, 159.3, 168.3. 
 
Preparattffion of Compounds 20a-b and 21a-b. 
 
General  Procedure. TThe alkene (0.5 mmol) was dffissolved ffin anThydrous MeOH (5 mL), 10% 
Pd/C cattalystt (30 mg) was added, and ttThe soluttffion was Thydrogenatted att 30 psffi for 5Th. WThen 
complette, ttThe cattalystt  was removed  by fffilttrattffion and ttThe reduced  productt  was  purffifffied  by 
column cThromattograpThy (10% EttOAc ffin Thexanes). 
MettThyl  2-(octtanesulfonamffido)-4-pThenettThylbenzoatte (20a). 89% 
yffield; 1H-NMR (400 MHz; CDCl3): δ 10.43 (s, 1H), 7.95 (d, J = 8.1 
Hz, 1H), 7.54 (s, 1H), 7.31-7.15 (m, 5H), 6.92 (d, J = 8.1 Hz, 1H), 
3.93 (s, 3H), 2.99 (m, 6H), 1.77 (m, 2H), 1.30 (m, 10H), 0.88 (tt, J = 7.2 Hz, 3H); 13C-NMR 
(100 MHz; CDCl3): δ 168.2, 149.5, 141.0, 140.6, 131.3, 128.3, 128.2, 126.0, 122.8, 117.5, 112.7, 
52.2, 51.7, 37.7, 36.8, 31.5, 28.8, 28.7, 27.9, 23.2, 22.4, 13.9. 
MettThyl 4-(4-mettThoxypThenettThyl)-2-
(octtanesulfonamffido)benzoatte (20b). 87% yffield; 1H-NMR 
(400 MHz; CDCl3): δ 10.42 (s, 1H), 7.93 (d, J = 8.1 Hz, 1H), 
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3H), 3.77 (s, 3H), 3.01 (tt, J = 8.1 Hz, 2H), 2.92 (m, 4H), 1.75 (m, 2H), 1.26 (m, 10H), 0.86 (tt, J 
= 7.2 Hz, 3H); 13C-NMR (100 MHz; CDCl3): δ 168.2, 157.7, 149.5, 140.9, 132.5, 131.3, 129.2, 
122.9, 117.5, 113.6, 112.6, 55.0, 52.2, 51.5, 37.9, 35.9, 31.5, 28.7, 28.6, 27.8, 23.1, 22.4, 13.8. 
MettThyl  2-(octtanesulfonamffido)-5-pThenettThylbenzoatte (21a). 91% 
yffield; 1H-NMR (400 MHz; CDCl3): δ 10.32 (s, 1H), 7.88 (d, J = 2.1 
Hz, 1H), 7.69 (d, J = 8.4 Hz, 1H), 7.31 (m, 3H), 7.20 (m, 3H), 3.95 
(s, 3H), 3.14 (tt, J = 7.8 Hz, 2H), 2.93 (s, 4H), 1.80 (m, 2H), 1.32 (m, 10H), 0.89 (tt, J = 7.2 Hz, 
3H); 13C-NMR (100  MHz; CDCl3): δ  168.2,  140.8,  138.8,  136.0,  134.9,  130.9,  128.2,  128.2, 
125.9, 117.9, 115.0, 52.3, 51.8, 37.4, 36.7, 31.5, 28.7, 28.6, 27.8, 23.1, 22.4, 13.9. 
MettThyl 5-(4-mettThoxypThenettThyl)-2-
(octtanesulfonamffido)benzoatte (21b). 80% yffield; 1H-NMR 
(400 MHz; CDCl3): δ 10.29 (s, 1H), 7.84 (d, J  = 1.8 Hz, 1H), 
7.65 (d, J = 8.4 Hz, 1H), 7.30 (dd, J = 2.1, 8.7 Hz, 1H), 7.07 (d, J = 8.4 Hz, 2H), 6.82 (d, J = 8.4 
Hz, 2H), 3.93 (s, 3H), 3.79 (s, 3H), 3.11 (tt, J = 8.0 Hz, 2H), 2.85 (s, 4H), 1.77 (m, 2H), 1.30 
(m, 10H), 0.85 (tt, J = 7.2 Hz, 3H); 13C-NMR (100 MHz; CDCl3): δ 168.3, 157.8, 138.9, 136.1, 
135.0, 133.0, 131.0, 129.2, 117.9, 115.0, 113.7, 55.1, 52.4, 51.8, 37.0, 36.6, 31.5, 28.8, 28.7, 27.9, 














Preparattffion of Benzoffic Acffids 14a-b, 15a-d, 16a-b, 17a-b, 18a-b, and 19a-b 
 
General  Procedure. To ttThe sttarttffing estter (0.5  mmol)  dffissolved ffin  THF (3  mL) att room 
ttemperatture was added 1 M NaOH (3 mL). TThe reacttffion mffixtture was Theatted tto 40 °C unttffil ttThe 
sttarttffing  matterffial  Thad  dffisappeared  by  TLC (20%  EttOAC ffin  Thexanes). WThen complette, ttThe 
soluttffion  was acffidffifffied  wffittTh  1  M  HCl and exttractted  wffittTh  3 ×  10  mL  EttOAc.  TThe combffined 
organffic exttractts were drffied over Na2SO4, concenttratted ffin vacuo, and ttThe resulttffing productt was 
purffifffied  by recrysttalffizattffion (EttOAc/Thexanes)  or column cThromattograpThy (3:7:90 
AcOH:EttOAc:Thexanes). 
4-(4-n-Buttylbenzoyl)-2-(octtanesulfonamffido)benzoffic acffid 
(14a). 85% yffield; mp = 149-150 °C; 1H-NMR (400 MHz, CDCl3): 
δ 10.27 (s, 1H), 8.23 (d, J = 8.2 Hz, 1H), 8.04 (d, J = 1.5 Hz, 1H), 
7.76-7.74 (m, 2H), 7.45 (dd, J = 8.2, 1.5 Hz, 1H), 7.30 (d, J = 8.3 Hz, 2H), 3.21-3.17 (m, 2H), 
2.69 (tt, J = 7.7 Hz, 2H), 1.85-1.77 (m, 2H), 1.67-1.60 (m, 2H), 1.40-1.35 (m, 4H), 1.32-1.20 





















20a-b R1=H,   R2=
21a-d R1=            , R2=H
Ar
Ar
10a-b R1=H,   R2=









18a-b R1=H,   R2=
19a-d R1=            , R2=H
Ar
Ar
16a-b R1=H,   R2=

















195.11, 178.03, 172.12, 149.64, 144.50, 141.52, 133.71, 132.72, 130.63, 128.79, 123.15, 118.54, 
116.61, 52.99, 35.91, 33.30, 31.78, 29.05, 28.99, 28.18, 23.50, 22.68, 22.48, 14.16, 14.02; Anal. 
(C26H35NO5S) C, H, N. 
4-([1,1'-BffipThenyl]-4-carbonyl)-2-
(octtanesulfonamffido)benzoffic acffid (14b). 87% yffield; mp = 188-
189 °C; 1H-NMR (400 MHz; CDCl3): δ 8.27 (d, J = 8.2 Hz, 1H), 
8.10 (d, J = 1.4 Hz, 1H), 7.92 (d, J = 8.3 Hz, 2H), 7.73 (d, J = 8.3 Hz, 2H), 7.67-7.64 (m, 2H), 
7.51-7.42 (m, 4H), 3.21 (tt, J = 7.9 Hz, 2H), 1.87-1.79 (m, 2H), 1.40-1.35 (m, 2H), 1.27-1.22 
(m,  8H),  0.85 (tt, J = 6.9  Hz,  3H); 13C-NMR (101  MHz,  CDCl3): δ  194.73,  146.30,  144.17, 
141.53, 139.64, 134.68, 132.69, 130.92, 129.01, 128.44, 127.34, 127.25, 123.08, 118.48, 52.98, 
31.65, 28.95, 28.86, 28.08, 23.42, 22.57, 14.05; Anal. (C28H31NO5S) C, H, N. 
 5-(4-n-Buttylbenzoyl)-2-(octtanesulfonamffido)benzoffic acffid 
(15a). 90% yffield;  mp  =  149-150 °C; 1H-NMR (400  MHz, 
CDCl3): δ 0.84 (tt, 3H, J = 6.8), 0.95 (tt, 3H, J = 7.2), 1.24 (m, 8H), 
1.40 (m, 4H), 1.65 (m, 2H), 1.85 (m, 2H), 2.71 (tt, 2H, J = 7.6), 3.25 (tt, 2H, J = 8.0), 7.32 (d, 
2H, J = 8.0), 7.72 (d, 2H, J = 8.0), 7.85 (d, 1H, J = 7.2), 8.05 (d, 1H, J = 7.2), 8.64 (s, 1H), 10.61 
(s, 1H); 13C-NMR (100 MHz, CDCl3): δ 13.9, 14.0, 22.4, 22.6, 23.4, 28.1, 28.9, 28.9, 31.6, 33.2, 
35.8,  53.0,  113.3,  116.8,  128.7,  130.2,  131.7,  134.3,  135.0,  137.2,  144.9,  148.9,  171.1,  194.5; 
Anal. (C26H35NO5S) C, H, N. 
5-([1,1'-BffipThenyl]-4-carbonyl)-2-
(octtanesulfonamffido)benzoatte (15b). 91% yffield; mp = 210-211 





















1.15-1.30 (m, 8H), 1.35-1.45 (m, 2H), 1.80-1.90 (m, 2H), 3.24 (tt, 2H, J = 8.0), 3.95 (s, 3H), 
7.40-7.55 (m, 3H), 7.70-7.90 (m, 7H), 8.06 (d, 1H, J = 8.8), 8.41 (s, 1H); 13C-NMR (100 MHz, 
DMSO-d6): δ 13.9, 22.0, 22.9, 27.1, 28.2, 28.3, 29.9, 31.1, 51.5, 115.1, 116.9, 126.8, 127.0, 128.4, 
129.1, 130.3, 130.5, 133.6, 135.6, 135.8, 138.8, 144.2, 144.4; Anal. (C28H31NO5S) C, H, N. 
5-(2-mettThoxybenzoyl)-2-(octtanesulfonamffido)benzoffic acffid (15c). 
81% yffield; mp = 125-126 °C; 1H-NMR (400 MHz, CDCl3): δ 0.83 (tt, 
3H, J = 6.8), 1.22 (m, 8H), 1.40 (m, 2H), 1.78 (m, 2H), 3.37 (tt, 2H, J = 
8.0), 3.74 (s, 3H), 7.11 (tt, 1H, J = 7.2), 7.18 (d, 1H, J = 7.6), 7.37 (dd, 1H, J1=7.6, J2=2.0), 7.55 
(tt, 1H, J = 7.6), 7.82 (d, 1H, J = 7.2), 7.99 (dd, 1H, J1=8.8, J2=2.0), 8.51 (d, 1H, J = 2.0), 11.00 
(s,  1H); 13C-NMR (100  MHz,  CDCl3): δ 13.4,  22.3,  23.3,  27.6,  28.7,  28.8,  31.5,  51.9,  55.1, 
111.8, 114.1, 116.6, 120.8, 128.5, 129.2, 131.6, 132.2, 133.7, 135.6, 145.3, 157.2, 169.2, 193.3; 
Anal. (C23H29NO6S) C, H, N. 
5-(4-MettThoxybenzoyl)-2-(octtanesulfonamffido)benzoffic acffid 
(15d). 83% yffield; mp = 132-133 °C; 1H-NMR (400 MHz, CDCl3): 
δ 0.84 (tt, 3H, J = 6.8), 1.10-1.30 (m, 8H), 1.35-1.40 (m, 2H), 1.75-
1.90 (m, 2H), 3.23 (tt, 2H, J = 8.0), 3.90 (s, 3H), 6.98 (d, 2H, J = 8.0), 7.79 (d, 2H, J = 8.4), 7.83 
(d,  1H, J = 8.8),  8.00 (d,  1H, J = 8.8),  8.58 (s,  1H),  10.63 (s,  1H); 13C-NMR (100  MHz, 
CDCl3): δ 14.0, 22.5, 23.3, 28.0, 28.8, 28.9, 31.6, 52.9, 55.5, 113.5, 113.8, 116.7, 129.4, 131.9, 
132.4, 134.7, 136.8, 144.6, 163.6, 171.3, 193.5; Anal. (C23H28NNaO6S•1/4(H2O)) C, H, N. 
(E)-2-(octtanesulfonamffido)-4-sttyrylbenzoffic acffid (16a). 80% yffield; 
mp = 91-92 °C; 1H-NMR (400 MHz, CDCl3): δ 0.86 (tt, 3H, J = 7.2), 




















J = 8.0), 7.10-7.44 (m, 7H), 7.57 (d, 2H, J = 11.2), 7.89 (s, 1H), 8.13 (d, 1H, J = 8.4), 10.28 (s, 
1H); 13C-NMR (100 MHz, CDCl3): δ 14.0, 22.5, 23.3, 28.0, 28.8, 28.9, 31.6, 52.2, 112.5, 115.6, 
120.3, 126.8, 127.0, 128.7, 128.8, 132.9, 133.3, 136.2, 142.0, 145.0, 172.5; Anal. (C23H29NO4S) 
C, H, N. 
(E)-4-(4-mettThoxysttyryl)-2-(octtanesulfonamffido)benzoffic acffid 
(16b). 91% yffield; mp = 98-98 °C; 1H-NMR (400 MHz, CDCl3): 
δ 0.84 (tt,  3H, J  = 7.2),  1.10-1.30 (m,  8H),  1.30-1.40 (m,  2H), 
1.75-1.85 (m, 2H), 3.20 (tt, 2H, J  = 8.0), 3.85 (s, 3H), 6.90-7.00 (m, 3H), 7.20-7.30 (m, 3H), 
7.49 (d, 2H, J = 8.8), 7.84 (s, 1H), 8.08 (d, 1H, J = 8.4), 10.25; 13C-NMR (100 MHz, CDCl3): δ 
14.0, 22.5, 23.4, 28.0, 28.8, 28.9, 31.6, 52.1, 55.4, 112.0, 114.3, 115.2, 120.1, 124.7, 128.5, 129.0, 
132.8, 132.9, 142.1, 145.4, 160.2, 172.2; Anal. (C24H30NNaO5S•1(H2O)) C, H, N. 
(E)-2-(Octtanesulfonamffido)-5-sttyrylbenzoffic acffid (17a). 92% yffield; 
mp = 94-95 °C; 1H-NMR (400 MHz, CDCl3): δ 0.86 (tt, 3H, J = 7.2), 
1.15-1.30 (m, 8H), 1.30-1.45 (m, 2H), 1.80-1.90 (m, 2H), 3.20 (tt, 2H, 
J = 8.0), 7.00-7.10 (m, 2H), 7.20-7.40 (m, 3H), 7.52 (d, 2H, J = 8.4), 7.70-7.80 (m, 2H), 8.25 (s, 
1H), 10.25 (s, 1H); 13C-NMR (100 MHz, CDCl3): δ 14.0, 22.5, 23.3, 28.0, 28.8, 28.9, 31.6, 52.3, 
114.6,  118.1,  126.3,  126.5,  128.0,  128.7,  129.3,  130.4,  132.3,  133.2,  136.7,  140.4,  169.1;  Anal. 
(C23H29NO4S•1/4(H2O)) C, H, N. 
(E)-5-(4-mettThoxysttyryl)-2-(octtanesulfonamffido)benzoffic acffid 
(17b). 90% yffield; mp = 98-99 °C; 1H-NMR (400 MHz, MeOD): 
δ 0.84 (tt,  3H, J  = 7.2),  1.15-1.25 (m,  8H),  1.30-1.40 (m,  2H), 



















7.46 (d, 2H, J = 8.8), 7.65-7.75 (m, 2H), 8.19 (s, 1H); 13C-NMR (100 MHz, MeOD): δ 14.4, 
23.6,  24.5,  28.8,  28.9,  29.9,  32.9,  52.3,  55.7,  115.2,  119.4,  121.1,  125.5,  128.9,  130.0,  130.8, 
131.2, 132.8, 134.3, 141.0, 161.0, 172.3; Anal. (C24H31NO5S) C, H, N. 
2-(Octtanesulfonamffido)-4-pThenettThylbenzoffic acffid (18a). 85% yffield; 
mp = 94-95 °C; 1H-NMR (400 MHz; MeOD): δ 7.97 (d, J  = 8.1 Hz, 
1H),  7.46 (s,  1H),  7.22 (m,  2H),  7.13 (m,  3H),  6.97 (d, J  = 8.1  Hz, 
1H), 2.94 (m, 6H), 1.64 (m, 2H), 1.23 (m, 10H), 0.89 (tt, J = 7.2 Hz, 3H); 13C-NMR (100 MHz; 
MeOD): δ 171.3, 150.7, 142.3, 142.0, 133.1, 129.4, 129.3, 127.0, 124.3, 118.7, 114.6, 51.9, 38.6, 
37.8, 32.7, 29.9, 29.9, 28.7, 24.4, 23.6, 14.4. Anal (C23H31NO4S) C, H, N. 
4-(4-MettThoxypThenettThyl)-2-(octtanesulfonamffido)benzoffic acffid 
(18b). 87% yffield;  mp  =  106-107 °C; 1H-NMR (400  MHz; 
MeOD): δ 7.95 (d, J = 8.1 Hz, 1H), 7.42 (s, 1H), 7.00 (d, J = 8.1 
Hz, 2H), 6.93 (d, J = 8.1 Hz, 1H), 6.75 (d, J = 8.1 Hz, 2H), 3.70 (s, 3H), 2.89 (m, 6H), 1.61 (m, 
2H), 1.17 (m, 10H), 0.85 (tt, J  = 7.2 Hz, 3H); 13C-NMR (100 MHz; MeOD): δ 171.3, 159.3, 
150.8,  142.3,  133.9,  133.0,  130.4,  124.2,  118.7,  114.7,  114.5,  55.5,  51.8,  38.8,  36.9,  32.7,  29.9, 
29.8, 28.7, 24.3, 23.5, 14.4. Anal. (C24H33NO5S) C, H, N. 
 2-(Octtanesulfonamffido)-5-pThenettThylbenzoffic acffid (19a). 89% yffield; 
mp = 92-93 °C; 1H-NMR (400 MHz; MeOD): δ 7.89 (d, J  = 2.1 Hz, 
1H), 7.60 (d, J = 8.7 Hz, 1H), 7.34 (dd, J = 2.1, 8.7 Hz, 1H), 7.23 (m, 
2H), 7.13 (m, 3H), 3.11 (tt, J = 8.0 Hz, 2H), 2.88 (s, 4H), 1.68 (m, 2H), 1.23 (m, 10H), 0.86 (tt, J 
= 7.2 Hz, 3H); 13C-NMR (100 MHz; MeOD): δ 171.3, 142.3, 140.3, 137.6, 135.9, 132.8, 129.4, 
129.2,  126.9,  119.0,  116.9,  52.0,  38.6,  37.9,  32.7,  29.8,  29.8,  28.8,  24.3,  23.5,  14.4.  Anal. 



















(19b). 89% yffield;  mp  =  102-103 °C; 1H-NMR (400  MHz; 
MeOD): δ 7.87 (d, J = 2.1 Hz, 1H), 6.60 (d, J = 8.4 Hz, 1H), 7.33 
(dd, J = 2.4, 8.4 Hz, 1H), 7.04 (d, J = 8.7 Hz, 2H), 6.78 (d, J = 8.7 Hz, 2H), 3.73 (s, 3H), 3.12 (tt, 
J = 8.0 Hz, 2H), 2.84 (s, 4H), 1.68 (m, 2H), 1.28 (m, 10H), 0.88 (tt, J = 7.2 Hz, 3H); 13C-NMR 
(100  MHz; MeOD): δ  171.3,  159.3,  140.2,  137.8,  135.9,  134.3,  132.8,  130.4,  119.8,  117.0, 
114.6, 55.5, 52.0, 38.1, 37.7, 32.7, 29.8, 29.8, 28.7, 24.3, 23.5, 14.3. Anal. (C24H33NO5S) C, H, N. 
 
Protteffin-Lffigand Dockffing 
TThe squasTh glycerol-3-pThospThatte acylttransferase coordffinattes  used  were from ttThe  PDB enttry 
1IUQ.12b TThe resoluttffion  of ttThe sttructture  was  1.55  Å.  BottTh ffin sffilffico vffiewffing and  manffipulattffion 
were carffied  outt  usffing  Accelrys  Dffiscovery  Sttudffio, versffion  2.1.  Glycerol, sulfatte, and  watter 
molecules were removed prffior tto lffigand dockffing experffimentts. TThe A cThaffin was ttThen desffignatted 
as ttThe recepttor and ttyped  wffittTh ttThe  CHARMm forcefffield.  A  model  of compound 1 was ttThen 
creatted as ttThe ffinputt lffigand and docked ffintto ttThe acttffive sffitte of ttThe recepttor usffing ttThe CDOCKER 
prottocol. TThe docked lffigand ffin Fffigure 2.2A ffin was one of ttThe resulttffing poses. Fffigure 2.2B was 




MffittocThondrffial  Preparattffion. TThe  mttGPAT assay  Thas  been reportted  prevffiously.18 TThe 
mffittocThondrffial preparattffion was performed wffittTh ttThe MffittocThondrffia Isolattffion Kffitt (Sffigma-AldrfficTh, 








fresThly-sacrffiffficed  BALB/c  mouse  was  Thomogenffized ffin  12  mL exttracttffion  bufer (ffisottonffic 
soluttffion, 10 mM HEPES, pH 7.5, conttaffinffing 200 mM mannffittol, 70 mM sucrose, 1 mM EGTA, 
24 mg albumffin), ttransfered tto a 2 mL mfficrocenttrffifuge ttube, and centtrffifuged att 1000 × RPM. 
TThe pelett was dffiscarded and ttThe supernattantt was centtrffifuged att 3500 × RPM. TThe pelett was 
resuspended ffin exttracttffion bufer, and ttThe prevffious ttwo centtrffifugattffion stteps were repeatted. Aftter 
ttThe fffinal 3500 × RPM spffin, ttThe pelett was resuspended ffin sttorage bufer (10 mM HEPES, pH 
7.4, conttaffinffing  250  mM sucrose,  1mM  ATP,  0.08  mM  ADP,  5  mM sodffium succffinatte,  2  mM 
K2HPO4, and 1 mM DTT) and used as ttThe mffittocThondrffial preparattffion ffin ttThe GPAT Assay 
GPAT Assay. TThe mffittocThondrffial preparattffion (3 µL) ffincludffing mttGPAT was added tto 200 µL 
of an ffincubattffion mffixtture conttaffinffing 75 mM Trffis/HCl, pH 7.4; 4 mM MgCl2; 2 mg/mL bovffine 
serum albumffin; 7.6 mCffi/mmol 14C-labeled glycerol-3-pThospThatte, 50 µM palmffittoyl-CoA, and 1 
µL  of varyffing ffinThffibffittor concenttrattffions (0,  0.625,  2.5,  10,  40 µg/mL ffin  DMSO) tto ffinffittffiatte ttThe 
reacttffion. Aftter 10 mffin, ttThe reacttffion was ttermffinatted by addffing 3 mL CHCl3:MeOH (1:2) and 
600 µL of 1% percThlorffic acffid. Aftter an addffittffional 5 mffin, 1 mL CHCl3 and 1 mL 1% percThlorffic 
acffid were added, and ttThe upper aqueous layer was removed. Aftter wasThffing ttThree ttffimes wffittTh 2 
mL of 1% percThlorffic acffid, ttThe organffic layer was evaporatted under nffittrogen, and ttThe amountt of 
14C  presentt  was  measured  by scffinttffillattffion counttffing tto  dettermffine ttThe exttentt  of reacttffion 
ffinThffibffittffion. Datta poffintts were recorded ffin ttrffiplfficatte, and IC50 values were calculatted based on ttThe 
amountt of ttestt ffinThffibffittor requffired tto produce 50% of mttGPAT acttffivffitty observed ffin ttThe absence 
of ffinThffibffittor butt ffin ttThe presence of DMSO veThfficle conttrol. 
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CThaptter 3 
A Practtffical Routte tto Substtffittutted 7-Amffinoffindoles from Pyrrole-3-
carboxaldeThydes 
3.1 Inttroducttffion 
Glycerol-3-pThospThatte acylttransferase (GPAT) cattalyzes ttThe fffirstt commffitttted and ratte-
lffimffittffing sttep ffin ttThe bffiosynttThesffis of glycerolffipffids. Moderatte ffinThffibffittffion of GPAT Thas prevffiously 
been acThffieved ffin vffittro usffing a varffietty of sulfonamffidobenzoffic acffids.1 Addffittffionaly, dffiett-ffinduced 
obese (DIO) mffice ttreatted wffittTh ttThese ffinThffibffittors demonsttratted sffignffiffficantt weffigThtt loss, wThfficTh was 
susttaffined aftter cessattffion  of ttreattmentt valffidattffing  GPAT as a ttargett for anttffiobesffitty ttTherapy.2 
Uttffilffizffing an energy-mffinffimffized  dockffing  model  of ttThese ffinThffibffittors ffin ttThe acttffive sffitte  of a  GPAT 
Thomolog, several ffinThffibffittor analogs  Thave been synttThesffized tto  bffind an  observed  ThydropThobffic 
pockett.3 TThese analogs ffincreased ttThe ffinThffibffittory acttffivffitty ffin vffittro by  up tto ttThree-fold,  butt low 
solubffilffitty precluded ffin vffivo analysffis. In order tto overcome poor solubffilffitty as wel as tto probe new 
scafolds for GPAT ffinThffibffittffion, we cThose a serffies of Thetteroaromattffic bfficycles, sThown ffin Fffig. 3.1, tto 
replace ttThe sffimple benzene rffing of ttThe fffirstt generattffion of ffinThffibffittors. TThe possffible locattffions of ttThe 
nffittrogen  wffittThffin ttThe  Thetteroaromattffic systtem provffide pottenttffial  H-bond  donattffing and accepttffing 
capabffilffittffies tto ffintteractt wffittTh ttThe enzyme and affid wffittTh solubffilffitty. In addffittffion, eacTh unffique scafold 
confers pertturbattffions tto ttThe electtronffic sttructture  of ttThe ffinThffibffittors,  wThfficTh  wffil afectt  bffindffing 
wffittThffin  GPAT. Because no suffittable  mettThods exffistt for ttThe rapffid generattffion  of lffibrarffies  of ttThese 
polysubsttffittutted  Thetteroaromattffic  bfficyclffic scafolds,  we electted tto  develop a  mettThod for ttTheffir 
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synttThesffis. In ttThffis cThaptter, sttrattegffies for ttThe synttThesffis of ffindoles are dffiscussed and a new general 
mettThod ffis developed. 
	  
Fffigure 3.1 Desffign of Thetteroaromattffic bfficyclffic ffinThffibffittors and general sttructture of ffindole scafold 
SynttThettffic routtes tto ffindoles Thave long been prffized owffing tto ttThe prevalence of ttThe aromattffic 
Thetterocycles ffin  nattural  productts as  wel as synttThettffic  medfficffinal agentts.4 Classffical ffindole 
synttTheses, ffincludffing ttThe  work  of  FffiscTher5, BffiscThler6,  Sugasawa7,  Larock8, Hegedus9,  Morffi10, 
Reffissertt11, Barttolffi12, and many ottThers13, remaffin bencThmarks ffin ttThe developmentt of Thetterocyclffic 
mettThodology.  TThe  majorffitty  of ttThese approacThes uttffilffize an aza-functtffionalffized  benzene rffing tto 
annulatte ttThe 5-membered pyrolffic porttffion of ttThe ffindole as sThown ffin Fffig. 3.2. TThe FffiscTher ffindole 
synttThesffis, for example, ffinvolves acffid-cattalyzed Thydrazone formattffion from a kettone wffittTh 
pThenylThydrazffine, folowed by [3,3]-sffigmattropffic rearangementt and cyclffizattffion wffittTh exttrusffion of 
ammonffia.5 OttTher acffidffic  mettThods  of annulattffion ffinclude ttThe  BffiscThler6 and  Sugasawa7 mettThods, 






























































folowed by annulattffion. BottTh of ttThese mettThods requffire TharsThly acffidffic condffittffions of BCl3/AlCl3 
for ttThe BffiscThler mettThod and HBr/200 °C for ttThe Sugasawa mettThod. Also usffing anffilffine sttarttffing 
matterffials, ttThe Larock8, Hegedus9, and Morffi-Ban10 mettThods uttffilffize paladffium or nffickel complexes 
tto promotte annulattffion  wffittTh a  pendantt alkynyl  or alyl  moffietty. OttTher  mettThods sttartt  wffittTh o-
substtffittutted  nffittrobenzenes.  TThe  Reffissertt  mettThod, for example, ffinvolves ttThe condensattffion  of o-
nffittrottoluene wffittTh a dffialkyl oxalatte, folowed by reducttffive cyclffizattffion wffittTh zffinc ffin acettffic acffid and 
decarboxylattffion tto ttThe ffindole.11 Also  usffing  nffittrobenzene, ttThe  Barttolffi  mettThod  begffins  wffittTh 
addffittffion  of a  Grffignard reagentt ffintto ttThe  nffittro  moffietty and elffimffinattffion tto a  nffittrosobenzene 
ffinttermedffiatte.12 Addffittffion  of anottTher equffivalentt  of ttThe  Grffignard reagentt, folowed  by [3,3]-
sffigmattropffic rearangementt, cyclffizattffion, and elffimffinattffion of watter afords ttThe ffindole.  
In conttrastt tto ttThe ffindole-formffing  mettThods sttarttffing from functtffionalffized  benzenes, few 



















































Fffigure 3.2 Promffinentt ffindole synttTheses from benzenoffid precursors 
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porttffion  of ttThe ffindole.14 TThe latttter sttrattegy can  benefffitt from ttThe  unffique cThemffisttry  of  pyroles, 
wThfficTh reactt wffittTh electtropThffiles preferenttffialy att C-2 butt exclusffively att C-3 wThen N-prottectted wffittTh 
ttThe stterfficaly cumbersome ttrffiffisopropylsffilyl group as sThown ffin Fffig. 3.3.15 TThffis ttunable reacttffivffitty 
alows for ready ffinttroducttffion  of ttThe  would-be  C-2 and  C-3 substtffittuentts  of ttThe ffindole  prffior tto 
annulattffion. FurttTher, ttThe ffinttrffinsffic reacttffivffitty of pyrroles att C-2 ffinttroduces a dffisconnecttffion opttffimal 
for ttThe ffindole-formffing cyclffizattffion ffittself. Tacttffical ffissues of symmettry and regffiocThemffisttry ffinTherentt 
tto routtes from substtffittutted benzene rffings are avoffided. 
	  
Fffigure 3.3 Tunable regffioselecttffivffitty for electtropThffilffic reacttffions of pyroles 
Our sttrattegy, sThown ffin Fffig.  3.4,  uttffilffizes a ttThree-componentt  Wffittttffig reacttffion  of  pyrole-3-
carboxaldeThydes  wffittTh fumaronffittrffile and a ttrffialkylpThospThffine tto generatte  predomffinanttly E-
alkenes.  TThese alylffic  nffittrffiles are  posffittffioned for ffinttramolecular cyclffizattffion  under  Houben-
HoescTh condffittffions tto furnffisTh, aftter aromattffizattffion, substtffittutted  7-amffinoffindoles.  An  opttffional 
ttaffilorffing sttep tto ffinsttal C-6 substtffittuentts prffior tto rffing closure can also be envffisffioned. TThffis scTheme 
would alow for conttrol of ttThe C-2, C-3, and C-6 ffindole substtffittuentts on ttThe resulttffing 7-amffino-5-
cyanoffindoles ttThatt are  nott readffily accessffible  usffing exffisttffing  mettThods.  TThe amffine (e.g.,  by 
sulfonylattffion, dffiazottffizattffion, acylattffion) and ttThe nffittrffile (e.g., by Thydrattffion, Thydrolysffis, reducttffion, 
ettc.) can be dffiferenttffialy modffifffied for rapffid sttructtural dffiversffiffficattffion. In addffittffion tto ttThe analogs 

































class  of  pottentt β-secrettase  1 (BACE1) ffinThffibffittors16 as  wel as a class  of  nfficottffinffic acettylcTholffine 




Fffigure 3.5 Representtattffive medfficffinal cThemffisttry ttargetts 



































































































Fffigure 3.4 Proposed routte tto substtffittutted 7-amffinoffindoles 
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3.2 One-Pott, TThree-Componentt Wffittttffig Reacttffion: Opttffimffizattffion 
Of fundamenttal ffimporttance tto ttThe planned synttThesffis was ttThe acquffisffittffion of E-alkenes sucTh 
as 2 (Fffig.  3.4).  TThe E-selecttffive  olefffinattffion  of aldeThydes  wffittTh estters  of fumaratte and  maleatte, 
maleffic anThydrffide,  or  maleffimffide and ttrffibuttyl- or ttrffipThenylpThospThffine  Thas  been  prevffiously 
descrffibed.18 We envffisffioned a sffimffilar  1,4-addffittffion  of a  pThospThffine tto fumaronffittrffile folowed by 
rapffid prottottropffic rearangementt of ttThe ffinffittffialy formed zwffitttterffion A tto ttThe ttThermodynamfficaly 
favored  pThospThonffium ylffide B,  wThfficTh ffis  poffised for ffin sffittu Wffittttffig  olefffinattffion  wffittTh  pyrole-3-
carboxaldeThydes sucTh as 1.  TrffimettThyl-, ttrffiettThyl-, ttrffibuttyl-, and ttrffipThenylpThospThffine, as  wel as 
ttrffimettThylpThospThffitte,  were evaluatted for ttThe effficffiency  of ttTheffir reacttffions  wffittTh fumaronffittrffile and 
aldeThyde 1a as sThown ffin  Table 3.1.  PPTh3 and  P(OMe)3 were  unreacttffive  under ttThe reacttffion 
condffittffions.  PMe3,  PEtt3, and  PBu3,  wThen  used ffin excess, exThffibffitted  understtandably sffimffilar 
reacttffivffitty, converttffing aldeThyde 1a tto alkene 2a ffin moderatte yffield (72-80%) butt wffittTh only slffigThtt 
E-selecttffivffitty (4:3) aftter exttended reacttffion ttffime (48  Th).  Concerned ttThatt ttThe excess  pThospThffine 
was addffing ffintto ttThe productt, ffittself an α,β-unsatturatted nffittrffile, and causffing ffisomerffizattffion of ttThe 
alkene,  we  nextt attttemptted ttThe reacttffion  wffittTh lffimffittffing  pThospThffine.  Att room ttemperatture, ttThese 
reacttffions gave ttThe desffired alkene 2a ffin ThffigTh yffield (91-99%) and good E/Z-rattffio (3:1) suggesttffing 
ttThatt ttThe excess pThospThffine was ffindeed causffing alkene ffisomerffizattffion. To amelffioratte ttThe sluggffisTh 
reacttffion ratte,  we  Theatted ttThe reacttffion  wffittTh  PEtt3 tto  65 °C.  TThese ffimproved condffittffions cutt ttThe 
reacttffion ttffime  6-fold  wThffile  maffinttaffinffing ttThe favorable yffield (97%) and E/Z-rattffio (3:1)  of ttThe 
room ttemperatture reacttffion. TThere are dffisttffinctt advanttages tto eacTh of ttThe pThospThffines ttestted. TThe 
volattffilffitty of PMe3 (bp 38 °C) alows for easy removal upon workup butt proThffibffitts Theattffing of ttThe 
reacttffion wffittThoutt a sealed vessel. PBu3 (bp 240 °C) requffires an addffittffional oxffidattffive workup sttep 
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butt ffis ttThe  mostt economffical cThoffice.  Fffinaly,  PEtt3 (bp  126 °C) aforded ttThe  ThffigThestt yffield and 
alows for Theattffing tto reflux wThffile maffinttaffinffing ttThe opttffion of low-pressure removal. 
Table 3.1	  Opttffimffizattffion of Wffittttffig Reacttffion wffittTh AldeThyde 1a 
 
enttry PR3 X ttemp (°C) ttffime (Th) yffield of 2a (%) E/Z 
1 PMe3 1.4 23 48 76 4:3 
2 PEtt3 1.4 23 48 80 4:3 
3 PBu3 1.4 23 48 72 4:3 
4 PPTh3 1.4 23 48 0  
5 P(OMe)3 1.4 23 48 0  
6 PEtt3 1.2 23 48 95 3:1 
7 PEtt3 1.2 23 48 99 3:1 
8 PEtt3 1.2 23 48 91 3:1 
9 PEtt3 1.2 65 8 97 3:1 
 
3.3 One-Pott, TThree-Componentt Wffittttffig Reacttffion: Scope 
To demonsttratte scope, ttThe opttffimffized condffittffions usffing PEtt3 att 65 °C were applffied tto varffious 
4- and  5-substtffittutted  pyrole-3-carboxaldeThydes 1a-g.  Alkenes  2a-g  were  obttaffined ffin generaly 
good tto excelentt yffield and moderatte dffiasttereoselecttffivffitty (Table 3.2). TThe reacttffion condffittffions 
were ttolerantt of a wffide range of substtffittuentts ffincludffing alkyl, aryl, Thalogen, and estter moffiettffies. 
Electtron-wffittThdrawffing substtffittuentts att ttThe  pyrolffic α-posffittffion led tto slower conversffion. 

















Table 3.2	  Scope of Wffittttffig Reacttffion 
 
enttry aldeThyde R2 R3 ttffime (Th) productt yffield (%) E/Z 
1 1a -H -H 8 2a 97 3:1 
2 1b -Br -H 10 2b 97 3:1 
3 1c -CO2Ett -H 8 2c 96 5:1 
4 1d -PTh -H 8 2d 88 3:1 
5 1e -H -Me 8 2e 85 4:1 
6 1f -H -Ett 8 2f 85 4:1 
7 1g -H -Br 8 2g 93 5:3 
        
3.4 Alkylattffion of C-6 
To furttTher dffiversffify ttThe lffibrary of E-alkenes, we nextt sougThtt tto functtffionalffize ttThe alylffic nffittrffile. 
To accomplffisTh ttThffis ttask wffittThoutt ttThe use of prottecttffing groups, we electted tto exploffitt ttThe relattffively 
more acffidffic  pyrole  N-H and  developed a  dffianffion approacTh tto alkylatte ttThe alylffic  posffittffion 
cThemoselecttffively (Table 3.3). Addffittffion of 2.1 equffivalentts of LDA folowed by ttThe addffittffion of 
varffious electtropThffiles, efectted selecttffive α-alkylattffion of nffittrffile 2a tto aford 4a-f wffittThoutt dettecttffion 
of N-alkylatted  pyrole sffide  productts 10a-f.  Analogous attttemptts  wffittTh ttThe electtropThffiles ettThyl 



















Table 3.3	  Alkylattffion of Alylffic Nffittrffile 3a 
 
enttry electtropThffile productt R6 yffield (%) 
1 MeI 4a -CH3 77 
2 EttI 4b -CH2CH3 80 
3 BnBr 4c -CH2PTh 75 
4 alyl-Br 4d -CH2CH=CH 67 
5 propargyl-Br 4e -CH2C≡CH 72 
6 BrCH2CO2Ett 4f -CH2CO2Ett 80 
 
3.5 Lewffis Acffid-Medffiatted Annulattffion: Opttffimffizattffion 
WffittTh reacttffion condffittffions esttablffisThed tto E-olefffinffic precursors 2a-g and 4a-f, we nextt sougThtt 
tto opttffimffize ffindole cyclffizattffion condffittffions as sThown ffin Table 3.4. Of ttThe Lewffis acffids ttestted, only 
BF3•OEtt2 successfuly efectted cyclffizattffion. Inffittffial attttemptts tto use a cattalyttffic amountt of BF3•OEtt2 
gave only sttofficThffiomettrffic yffield. Presumably, ttThffis ffis due tto cThelattffion of ttThe Lewffis acffid by ttThe 7-
amffinoffindole productt ttThereby preventtffing cattalyttffic tturnover. Sffimffilarly, usffing THF as ttThe solventt 
aforded no reacttffion, lffikely owffing tto assocffiattffion of ttThe Lewffis acffid wffittTh ttThe ettThereal solventt. TThe 
opttffimffized condffittffions used 2.5 equffivalentts of BF3•OEtt2 ffin 1,2-dfficThloroettThane att 90 °C for 12 Th, 




















Table 3.4	  Opttffimffizattffion of Cyclffizattffion tto Indole 3a 
 
enttry Lewffis acffid X solventt ttemp (°C) yffield of 3a (%) 
1 none  CH2Cl2 45 0 
2 AlCl3 0.2 CH2Cl2 45 0 
3 Sc(OTf)3 0.2 CH2Cl2 45 0 
4 TffiCl4 0.2 CH2Cl2 45 0 
5 BF3•OEtt2 0.2 CH2Cl2 45 19 
6 BF3•OEtt2 1.1 THF 70 0 
7 BF3•OEtt2 1.1 PThCH3 85 61 
8 BF3•OEtt2 2.5 DCE 90 91 
 
3.6 Lewffis Acffid-Medffiatted Annulattffion: Scope 
Applfficattffion  of ttThe annulattffion condffittffions tto ttThe E-alkenes 2a-g and 4a-f gave ffindoles 3a-g 
and 5a-f ffin good tto excelentt yffields (Table 3.5).  TThe reacttffion condffittffions  were amenable tto a 
wffide scope  of substtffittuentts.  Of  parttfficular ffintterestt tto  us, ttThe  bromo- and  propargyl-substtffittutted 
ffindoles can be furttTher functtffionalffized ttThrougTh couplffing reacttffions or clffick cThemffisttry, respecttffively, 
tto rapffidly generatte large lffibrarffies of compounds. TThe more electtron-deffficffientt pyroles (e.g. 2c, 
2g)  demonsttratted lower yffields, ttypffical  of electtropThffilffic aromattffic substtffittuttffion  wffittTh an electtron-
deffficffientt arene. TThe reacttffion ttffimes for ttThe 6-substtffittutted alkenes were slffigThttly sThortter ttThan for 
cyclffizattffion  of ttThe  2- and  3-substtffittutted examples.  TThffis  beThavffior  poffintts tto a  possffible  TThorpe-
Ingold efectt, wThereby ttThe  C-6 substtffittuentt ffincreases ttThe  populattffion  of ttThe reacttffive rottamer 
resulttffing ffin an ffincreased reacttffion ratte. Itt ffis lffikely ttThatt ttThffis ttacttffic can also be applffied tto pyroles 
















Table 3.5	  Scope of Indole Annulattffion 
 
enttry pyrole R2 R3 R6 productt ttffime (Th) yffield (%) 
1 2a -H -H -H 3a 12 91 
2 2b 0.2 -H -H 3b 12 67 
3 2c 0.2 -H -H 3c 12 62 
4 2d 0.2 -H -H 3d 12 87 
5 2e -H -CH3 -H 3e 12 94 
6 2f -H -CH2CH3 -H 3f 12 92 
7 2g -H -Br -H- 3g 12 75 
8 4a -H -H -CH3 5a 8 88 
9 4b -H -H -CH2CH3 5b 8 95 
10 4c -H -H -CH2PTh 5c 8 96 
11 4d -H -H -CH2CH=CH2 5d 8 93 
12 4e -H -H -CH2C≡CH 5e 8 92 
13 4f -H -H -CH2CO2Ett 5f 8 72 
 
3.7 One-Pott, Tandem Wffittttffig/Annulattffion Sequence 
In addffittffion, a functtffionaly one-pott reacttffion was run tto ffindole 3a, sThown ffin Fffig. 3.6, ffin wThfficTh 
pyrole-3-carboxaldeThyde and fumaronffittrffile  were reactted ffin  dry  THF  wffittTh  PMe3 as  before 
(Table  1).  Takffing advanttage  of ttThe relattffively low  boffilffing  poffintt  of  PMe3, ttThe solventt and any 
unreactted pThospThffine were removed by rottary evaporattffion and ttThe resffidue ttaken up ffin 1,2-DCE. 
Treattmentt  of ttThffis  mffixtture as above  wffittTh  BF3•OEtt2 gave ttThe  desffired ffindole ffin  77% yffield, 
approxffimattely ttThe ttTheorettffical lffimffitt from ttThe E-ffisomer, aftter crysttalffizattffion of ttThe productt from 






















Fffigure 3.6 One-pott synttThesffis of ffindole 3a 
3.8 Applfficattffion tto SynttThesffis of Benzofurans and BenzottThffiopThenes 
Encouraged  by ttThe success  of ttThffis approacTh,  we  nextt ttestted  wThettTher ttThe corespondffing 
furan- and ttThffiopThene-3-carboxaldeThydes could undergo a sffimffilar ttwo-sttep sequence tto ttThe 
corespondffing  7-amffino-5-cyanobenzofurans and  benzottThffiopThenes, respecttffively (Fffig.  3.7).  We 
ThypottThesffized ttThatt,  wffittTh  decreased  C-2  nucleopThffilfficffitty and ffincreased  Thetteroattomffic ffintteracttffion 
wffittTh ttThe  BF3•OEtt2, ttThe annulattffion  of ttThese  Thetterocycles  would  be less facffile.  Fffirstt,  Wffittttffig 
reacttffion usffing ttThe opttffimffized condffittffions aforded ttThe olefffins 12a-b ffin excelentt yffield and betttter 
dffiasttereoselecttffivffitty ttThan for ttThe analogous reacttffion wffittTh pyrole-3-carboxaldeThyde. Treattmentt 
wffittTh  BF3•OEtt2 efectted annulattffion tto  benzofuran 13a and  benzottThffiopThene 13b ffin low tto 
moderatte yffield.  As expectted, ttThe reacttffion rattes  were  mucTh slower  wffittTh conversffion sttalffing 
around 24 Th. NeffittTher addffittffional equffivalentts of Lewffis acffid nor longer reacttffion ttffimes ffimproved 
ttThe yffields. Itt ffis possffible ttThatt use of a less oxopThffilffic Lewffis acffid could ffimprove ttThe yffields for ttThese 
classes of Thetterocycles. 
	  
Fffigure 3.7 Applfficattffion tto ttThe synttThesffis of benzofuran and benzottThffiopThene derffivattffives 
ttThen BF3-OEtt2
1,2-DCE
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3.9 Functtffional Group Transformattffions 
Fffinaly, tto ffilusttratte practtffical applfficattffions of ttThffis mettThod we cThose tto demonsttratte functtffional 
group conversffions from ttThe  7-amffino-5-cyanoffindole ffinttermedffiattes tto readffily ffidenttffifffiable 
precursors  of ttThe  medfficffinal cThemffisttry ttargetts  notted above (Fffig.  3.5).   Fffirstt,  we  uttffilffized 
Sandmeyer cThemffisttry tto substtffittutte ttThe amffino group of ffindole 3a wffittTh cThloro or bromo as sThown 
ffin Fffig. 3.8. TThese aryl Thalffides alow access tto a varffietty of C-7 substtffittutted ffindoles, sucTh as ttThe 
nACThR alostterffic  modulattors representted  by 7, ttThrougTh  mettal-cattalyzed couplffing reacttffions. 
Second,  we  demonsttratted sulfonamffide couplffing  of ttThe anffilffine  wffittTh  octtanesulfonyl cThlorffide, 
folowed  by alkalffine  nffittrffile  Thydrolysffis tto gffive ttThe  GPAT ffinThffibffittor analog 9a.  A sffimffilar 
sulfonamffide couplffing and  Thydrolysffis sequence can  be envffisffioned tto access ttThe  dffiversffifffiable 
precursor of ttThe BACE1 ffinThffibffittors representted by 6. 
	  
Fffigure 3.8 Functtffional group conversffion of 3a tto precursors of medfficffinal cThemffisttry ttargetts 
3.10 Conclusffions 
In conclusffion,  we  Thave  developed a flexffible and sttep-efffficffientt  mettThod tto  obttaffin  ThffigThly 
functtffionalffized  7-amffinoffindoles from  pyrole-3-carboxaldeThydes.  TThffis  mettThod  uttffilffizes a ttThree-
componentt  Wffittttffig reacttffion  of  pyrole-3-carboxaldeThydes  wffittTh fumaronffittrffile and  PEtt3 tto 
generatte  predomffinanttly cffis-alylffic  nffittrffiles,  wThfficTh can  be  opttffionaly elaboratted furttTher  by a 
cThemoselecttffive alkylattffion att  C-6.   TThese cffis-alylffic  nffittrffiles  undergo cyclffizattffion ttThrougTh an 
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procedure combffinffing ttThe Wffittttffig and Houben-HoescTh reacttffions was also demonsttratted. WThffile 
ttThe  mettThod ffis substtanttffialy lffinear, ttThe stteps are ttypfficaly  ThffigTh yffieldffing  wffittTh cThromattograpThffic 
purffiffficattffion mffinffimffized or elffimffinatted, and ffinttermedffiattes and productts ffisolatted by crysttalffizattffion. 
TThe reacttffions are scalable and requffire  no specffial  precauttffions  or  prottecttffing groups—ffin sum, 
attttrffibuttes favorable for large-scale applfficattffions. FurttTher sttudffies wffil affim tto expand ttThe scope of 
ttThffis mettThod and tto demonsttratte ffitts pottenttffial for ttThe synttThesffis of bffioacttffive ttargetts of ffintterestt. 
3.11 Experffimenttal 
General Informattffion 
Reacttffions requffirffing anThydrous condffittffions  were conductted  under an ffinertt attmospThere  of 
argon  usffing anThydrous solventts.  CH2Cl2, ttoluene, and  MeOH  were  dffisttffiled  over  CaH2.  Ett2O 
and THF were dffisttffiled over Na and benzopThenone. Al reacttffions were monffittored by analyttffical 
ttThffin-layer cThromattograpThy (TLC) usffing ffindfficatted solventt systtems on AnalttecTh Unffiplatte Sffilffica 
Gel TLC plattes (250 mfficrons). Melttffing poffintts were dettermffined on a TThomas-Hoover capffilary 
melttffing  poffintt apparattus and are  uncorectted.  NMR specttra  were recorded  on effittTher  Bruker 
Avance  400  MHz  or  300  MHz specttrometters as ffindfficatted.  CThemffical sThffiftts (δ) are  quotted ffin 
partts  per  mffilffion (ppm) and referenced tto ttThe folowffing resffidual solventt sffignals: 1H δ  =  7.26 
(CDCl3),  2.50 (DMSO-d6),  3.31 (MeOD),  2.05 (acettone-d6); 13C δ  =  77.0 (CDCl3),  39.43 
(DMSO-d6),  49.05 (MeOD),  29.84 (acettone-d6).  Couplffing consttantts (J) are gffiven ffin  Hz. 
Pyrole and ettThyl 4-formylpyrole-2-carboxylatte (2c) were obttaffined from Sffigma-AldrfficTh. 
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Preparattffion of AldeThydes 1a-g 
	  
N-(Trffiffisopropylsffilyl)pyrrole. To a  1.0  M soluttffion  of fresThly  prepared  LDA (72.43 
mmol) ffin  THF att -78 °C  was added  pyrole (5.0  mL,  72.07 mmol).   TThe reacttffion 
mffixtture was alowed tto warm tto room ttemperatture and sttffired for 30 mffin before coolffing tto -78 
°C, folowed  by ttThe slow addffittffion  of cThlorottrffiffisopropylsffilane (16.96  mL,  79.27  mmol).  TThe 
reacttffion soluttffion  was alowed tto  warm tto room ttemperatture and sttffired  overnffigThtt, ttThen 
quencThed  wffittTh  NaHCO3 (200  mL) and exttractted  wffittTh  DCM (3 x  150  mL).  TThe combffined 
organffic layers  were  drffied  over  Na2SO4 and concenttratted ffin vacuo.   Purffiffficattffion  by sffilffica gel 
cThromattograpThy (2% EttOAc ffin Thexanes) aforded ttThe TIPS-prottectted pyrole as a clear offil (15.9 
g, 71.48 mmol, 99%). Al specttral datta mattcThed lffitteratture values.19 
Pyrrole-3-carboxaldeThyde (1a). To a 0.18 M soluttffion of oxalyl cThlorffide (5.99 mL, 
69.82 mmol) ffin DCM att 0 °C was added dropwffise a 2 M soluttffion of DMF (5.41 mL, 
69.82 mmol) ffin DCM. TThe reacttffion mffixtture was sttffired att 0 °C for 30 mffin before rapffid addffittffion 
of a 1.15 M soluttffion of N-ttrffiffisopropylsffilylpyrole (12.00 g, 53.71 mmol) ffin DCM. TThe reacttffion 
mffixtture was Theatted tto reflux and sttffired for 30 mffin. TThe solventt was removed ffin vacuo and ttThe 
crude reacttffion  mffixtture  was resuspended ffin  1  M  NaOH (300  mL) and sttffired att room 
ttemperatture for  12  Th. TThe aqueous  mffixtture  was exttractted  wffittTh  DCM (3 ×  150  mL) and ttThe 
combffined  organffic exttractts  were  drffied  over  Na2SO4.  Purffiffficattffion  by sffilffica gel cThromattograpThy 
(40%  EttOAc ffin  Thexanes) aforded  pyrole–3-carboxaldeThyde as a lffigThtt  brown solffid (5.00 g, 
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5-Bromo-1H-pyrrole-3-carboxaldeThyde (1b). To a sttffirffing soluttffion of pyrole–
3-carboxaldeThyde (250 mg, 2.63 mmol) ffin THF (3.9 mL) att –78 °C was added 
slowly N-bromosuccffinffimffide (473 mg, 2.66 mmol) as a soluttffion ffin DMF (2.0 mL). TThe reacttffion 
mffixtture  was sttffired att –78 °C for  1  Th, ttThen  warmed tto –10 °C  over  2  Th.  TThe reacttffion  was 
quencThed  wffittTh ffice  watter, and ttThe  productt  was exttractted  wffittTh  EttOAc (3 ×  50  mL).  TThe 
combffined organffic exttractts were wasThed wffittTh NaHCO3 and brffine, ttThen drffied over Na2SO4 and 
concenttratted ffin vacuo.  TThe reacttffion  mffixtture  was  purffifffied  by sffilffica gel cThromattograpThy (30% 
EttOAc/Thexanes) tto aford  5-bromopyrole–3-carboxaldeThyde (293  mg,  1.68  mmol,  64%).  Al 
specttral datta mattcThed lffitteratture values.20 
5-PThenyl-1H  pyrrole-3-carboxaldeThyde (1c). 5-Bromopyrole–3-
carboxaldeThyde (50 mg, 0.29 mmol), pThenyl boronffic acffid (42 mg, 0.34 mmol), 
and pottassffium carbonatte (95 mg, 0.69 mmol) were suspended ffin dffioxane (2.6 
mL), and ttThe mffixtture was degassed wffittTh argon. Tettrakffis(ttrffipThenylpThospThffine)paladffium (0) (17 
mg, 5 mol %) was added, ttThen ttThe suspensffion was degassed agaffin wffittTh argon and Theatted tto 105 
°C for  24  Th.  TThe crude  productt  mffixtture  was concenttratted,  parttffittffioned  bettween  EttOAc and 
watter, and exttractted wffittTh EttOAc (3 × 15 mL). TThe combffined organffic exttractts were wasThed wffittTh 
brffine, drffied over Na2SO4, and concenttratted ffin vacuo. Purffiffficattffion by sffilffica gel cThromattograpThy 
(30%  EttOAc/Hexanes) aforded  5-PThenyl-1H pyrole-3-carboxaldeThyde (30  mg,  0.18  mmol, 
61%). Specttral datta mattcThed lffitteratture values.20 
3:1 THF/DMF






























 N-(Trffiffisopropylsffilyl)-3-bromopyrrole. To a sttffired soluttffion  of N-
(ttrffiffisopropylsffilyl)pyrole (214 mg, 0.96 mmol) ffin anThydrous THF (2.1 mL) att -78 °C 
was added N-bromosuccffinffimffide (170 mg, 0.96 mmol). TThe reacttffion mffixtture was keptt att -78 °C 
for  2  Th and ttThen  warmed tto room ttemperatture.  TThe reacttffion  was  quencThed  wffittTh  NaHCO3, 
exttractted wffittTh Ett2O (3 × 20 mL), and ttThe combffined organffic exttractts were wasThed wffittTh brffine, 
drffied over Na2SO4, and concenttratted ffin vacuo. TThe crude productt was fffilttered ttThrougTh a sThortt 
plug  of sffilffica gel,  wThfficTh  was elutted  wffittTh  2%  EttOAc ffin  Thexanes.  Concenttrattffion aforded ttThe 
desffired  productt as a clear  offil (238  mg,  78.7  mmol,  82%).   Specttral  datta  mattcThed lffitteratture 
values.19 
4-Bromo-1H-pyrrole-3-carboxaldeThyde (1g). To a  0.18  M soluttffion  of  oxalyl 
cThlorffide (333 µL, 4.3 mmol) ffin DCM (24 mL) att 0 °C was added dropwffise a 2 M 
soluttffion of DMF (333 µL, 4.3 mmol) ffin DCM (2.2 mL). TThe reacttffion mffixtture was sttffired att 0 
°C for 30 mffin before rapffid addffittffion of a 1.15 M soluttffion of 3-bromo-N-(ttrffiffisopropylsffilyl)pyrole 
(1000 mg, 3.3 mmol) ffin DCM (2.88 mL). TThe reacttffion mffixtture was Theatted tto reflux and sttffired 
for  30  mffin.  TThe solventt  was removed  under reduced  pressure, and ttThe crude  mffixtture  was 
resuspended ffin 1 M NaOH (20 mL) and sttffired att room ttemperatture overnffigThtt. TThe reacttffion 
was quencThed wffittTh satturatted NH4Cl, and ttThe productt was exttractted wffittTh EttOAc (3 × 25 mL). 
TThe combffined organffic exttractts were wasThed wffittTh brffine, drffied over Na2SO4, and concenttratted ffin 































wThffitte solffid (359 mg, 2.06 mmol, 62%). 1H-NMR (400 MHz; acettone-d6): δ 11.12 (s, 1H), 9.80 
(s, 1H), 7.59 (d, J = 2.1 Hz, 1H), 7.04 (d, J = 2.1 Hz, 1H); 13C-NMR (101 MHz, acettone-d6): δ 
184.87,  127.62,  123.83,  121.89,  96.66;  HRMS (FAB) calcd for  C5H4BrNO [M]+,  172.9476; 
found, 172.9473. 
	  
N-(Trffiffisopropylsffilyl)-3-mettThylpyrrole. To a soluttffion  of  3-bromo-N-
(ttrffiffisopropylsffilyl)pyrole (400  mg,  1.32  mmol) ffin  THF (6.6  mL)  was added n-
buttylffittThffium (1.85 M, 1.46 mmol) att –78 °C. TThe mffixtture was sttffired att –78 °C for 10 mffin ttThen 
MeI (107 µL,  1.72  mmol)  was added, and ttThe  mffixtture  was  warmed tto  0 °C  over  1  Th.  TThe 
reacttffion mffixtture was quencThed by addffittffion of satturatted NH4Cl and exttractted wffittTh EttOAc (3 × 
25  mL).  TThe combffined  organffic exttractts  were  wasThed  wffittTh  brffine,  drffied  over  Na2SO4, and 
concenttratted tto dryness tto aford ttThe desffired alkyl pyrole as a yelow offil (306 mg, 97%), wThfficTh 
was used wffittThoutt purffiffficattffion. Specttral datta mattcThed lffitteratture values.15 
N-(Trffiffisopropylsffilyl)-3-ettThylpyrrole. To a soluttffion  of  3-bromo-N-
(ttrffiffisopropylsffilyl)pyrole (400  mg,  1.32  mmol) ffin  THF (6.6  mL)  was added n-
buttylffittThffium (1.85 M, 1.46 mmol) att –78 °C. TThe mffixtture was sttffired att –78 °C for 10 mffin ttThen 
ffiodoettThane (118 µL, 1.72 mmol) was added and ttThe mffixtture was warmed tto 0 °C over 1 Th. TThe 
reacttffion mffixtture was quencThed usffing satturatted NH4Cl and exttractted wffittTh EttOAc (3 × 25 mL). 
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dryness. TThe resffidue was purffifffied by sffilffica gel cThromattograpThy (1% EttOAc ffin Thexanes) tto aford 
ttThe desffired alkyl pyrole as a clear offil (180 mg, 54%). Specttral datta mattcThed lffitteratture values.21 
4-MettThyl-1H-pyrrole-3-carboxaldeThyde (1e). To a  0.18  M soluttffion  of  oxalyl 
cThlorffide (136 µL, 1.58 mmol) ffin DCM (8.8 mL) att 0 °C was added dropwffise a 2 
M soluttffion of DMF (122 µL, 1.58 mmol) ffin DCM (800 µL). TThe reacttffion mffixtture was sttffired att 
0 °C for  30  mffin  before rapffid addffittffion  of a  1.15  M soluttffion of  3-mettThyl-N-
(ttrffiffisopropylsffilyl)pyrole (300  mg,  1.26  mmol) ffin  DCM (1.1  mL).  TThe reacttffion  mffixtture  was 
Theatted tto reflux and sttffired for 30 mffin. TThe solventt was removed ffin vacuo. TThe crude productt 
mffixtture  was resuspended ffin  1  M  NaOH (15  mL) and sttffired att room ttemperatture  overnffigThtt, 
ttThen  quencThed  wffittTh  NH4Cl and exttractted  wffittTh  EttOAc (3 ×  15  mL).  TThe combffined  organffic 
exttractts were wasThed wffittTh brffine, drffied over Na2SO4, and concenttratted ffin vacuo. Purffiffficattffion by 
sffilffica gel cThromattograpThy (20% acettone ffin  pettroleum ettTher) aforded ttThe aldeThyde as an  of-
wThffitte solffid (88 mg, 0.81 mmol, 64%). Specttral datta mattcThed lffitteratture values.22 
4-EttThyl-1H-pyrrole-3-carboxaldeThyde (1f). To a  0.18  M soluttffion  of  oxalyl 
cThlorffide (77 µL, 0.89 mmol) ffin DCM (5 mL) att 0 °C was added dropwffise a 2 
M soluttffion of DMF (69 µL, 0.89 mmol) ffin DCM (450 µL). TThe reacttffion mffixtture was sttffired att 
0 °C for 30 mffin before rapffid addffittffion of a 1.15 M soluttffion of 3-ettThyl-N-(ttrffiffisopropylsffilyl)pyrole 
(180 mg, 0.72 mmol) ffin DCM (650 µL). TThe reacttffion mffixtture was Theatted tto reflux and sttffired 
for  30  mffin.  TThe solventt  was removed ffin vacuo. TThe crude  mffixtture  was resuspended ffin  1  M 
NaOH (5  mL) and sttffired att room ttemperatture  overnffigThtt, ttThen  quencThed  wffittTh  NH4Cl and 
exttractted  wffittTh  EttOAc (3 ×  15  mL).  TThe combffined  organffic exttractts  were  wasThed  wffittTh  brffine, 








acettone ffin  pettroleum ettTher) aforded ttThe aldeThyde as an  of-wThffitte solffid (47  mg,  0.38  mmol, 
53%). Specttral datta mattcThed lffitteratture values.21 
 
One-Pott, TThree-Componentt Wffittttffig Reacttffion 
	  
General Procedure. To a sttffirffing soluttffion of ttThe pyrole–3-carboxaldeThyde (1.0 equffiv.) ffin THF 
(0.25 M) att room ttemperatture was added fumaronffittrffile (1.25 equffiv.) folowed by pThospThffine (X 
equffiv.) dropwffise. TThe reacttffion mffixtture was sttffired att ttThe denotted ttemperatture unttffil ttThe sttarttffing 
matterffial  was  no longer vffisffible  by  TLC, ttThen  quencThed  wffittTh aqueous  NaHCO3 and exttractted 
wffittTh EttOAc (×3). TThe combffined organffic exttractts were wasThed wffittTh brffine, drffied over Na2SO4, 
and concenttratted ffin vacuo.  Generaly,  purffiffficattffion  by sffilffica gel cThromattograpThy aforded a 
mffixtture  of ttThe E and Z olefffin  Wffittttffig  productts  due tto ttThe sffimffilar  Rf values  of ttThe ttwo ffisomers. 
Altternattffively, crysttalffizattffion from EttOAc and Thexanes aforded ttThe pure E ffisomer. Specttral datta 
sThown below are for ttThe pure E ffisomers. 
2-((1H-Pyrrol-3-yl)mettThylene)succffinonffittrffile (2a). yffield: 97%, 3:1 E/Z; mp 
119-120 °C; 1H-NMR (400 MHz; CDCl3): δ 8.73 (s, 1H), 7.34 (s, 1H), 7.11 
(q, J = 2.1 Hz, 1H), 6.92 (q, J = 2.1 Hz, 1H), 6.41 (q, J = 2.1 Hz, 1H), 3.52 (s, 2H); 13C-NMR 
(101  MHz, acettone-d6): δ  1423.11,  125.20,  121.69,  120.75,  118.89,  117.10,  109.58,  95.26, 
19.42; HRMS (FAB) calcd for C9H7N3 [M]+, 157.0640; found, 157.0637. 


























3:1 E/Z; mp 108-109 °C; 1H-NMR (400 MHz; acettone-d6): δ 11.26 (s, 1H), 7.37 (s, 1H), 7.34 
(s, 1H), 6.54 (s, 1H), 3.82 (s, 2H); 13C-NMR (101 MHz, acettone-d6): δ 141.65, 126.21, 120.31, 
120.25,  116.85,  111.16,  102.25,  96.86,  19.32; HRMS (FAB) calcd for  C9H6(79Br)N3 [M]+, 
234.9745; found, 234.9743. 
EttThyl  4-(2,3-dfficyanoprop-1-en-1-yl)-1H-pyrrole-2-carboxylatte (2c). 
yffield: 96%, 5:1 E/Z; mp 134-135 °C; 1H-NMR (400 MHz; acettone-d6): 
δ 11.62 (s, 1H), 7.56 (s, 1H), 7.46 (s, 1H), 7.15 (s, 1H), 4.30 (q, J = 7.1 Hz, 2H), 3.90 (s, 2H), 
1.32 (tt, J = 7.1 Hz, 3H); 13C-NMR (101 MHz, acettone-d6): δ 160.80, 141.91, 128.59, 126.05, 
120.13,  119.90,  116.84,  115.70,  98.57,  61.11,  19.57,  14.66;  HRMS (EI):  Exactt  mass calcd for 
C12H11N3O2 [M]+, 229.0851. Found 229.0854. 
2-((5-PThenyl-1H-pyrrol-3-yl)mettThylene)succffinonffittrffile (2d). yffield: 
88%,  3:1 E/Z;  mp  197-198 °C; 1H-NMR (400  MHz; acettone-d6): δ 
11.26 (s, 1H), 7.72 (dd, J = 8.5, 1.2 Hz, 2H), 7.43-7.41 (m, 4H), 7.27 (tttt, J = 1.2 Hz, 1H), 6.95 
(tt, J =  2.1  Hz,  1H),  3.92 (d, J =  1.2  Hz,  2H); 13C-NMR (101  MHz, acettone-d6): δ 142.59, 
135.55,  132.70,  129.76,  127.81,  126.55,  125.07,  120.66,  120.44,  117.13,  106.63,  96.18,  19.54; 
HRMS (FAB): Exactt mass calcd for C15H11N3 [M]+, 233.0953. Found 233.0954. 
2-((4-MettThyl-1H-pyrrol-3-yl)mettThylene)succffinonffittrffile (2e). yffield:  85%, 
4:1 E/Z; mp 109-111 °C; 1H-NMR (400 MHz; acettone-d6): δ 10.59 (s, 1H), 
7.38 (d, J = 1.3 Hz, 1H), 7.26 (tt, J = 1.2 Hz, 1H), 6.75 (s, 1H), 3.75 (d, J = 1.3 Hz, 2H), 2.14 (s, 
3H); 13C-NMR (101  MHz, acettone-d6): δ 141.32,  122.30,  120.68,  120.56,  118.51,  117.64, 













2-((4-EttThyl-1H-pyrrol-3-yl)mettThylene)succffinonffittrffile (2f). yffield:  85%, 
4:1 E/Z;  mp  108-109 °C; 1H-NMR (400  MHz; acettone-d6): δ 10.63 (s, 
1H), 7.40 (s, 1H), 7.26 (s, 1H), 6.77 (s, 1H), 3.76 (s, 2H), 2.59 (q, J = 7.5 Hz, 2H), 1.18 (tt, J = 
7.5  Hz,  7H); 13C-NMR (101  MHz, acettone-d6): δ  141.23,  127.62,  122.33,  120.67,  117.34, 
117.00, 116.71, 95.92, 19.93, 18.57, 14.90; HRMS (FAB) calcd for C11H11N3 [M]+, 185.0953; 
found, 185.0950. 
2-((4-Bromo-1H-pyrrol-3-yl)mettThylene)succffinonffittrffile (2g). yffield: 93%, 5:3 
E/Z; mp 124-125 °C 1H-NMR (400 MHz; acettone-d6): δ 11.17 (s, 1H), 7.42 
(s, 1H), 7.28 (s, 1H), 7.13 (s, 1H), 3.82 (s, 2H); 13C-NMR (101 MHz, acettone-d6): δ 140.01, 
122.67,  120.84,  119.94,  117.01,  116.62,  100.06,  99.00,  19.93;  HRMS (FAB) calcd for 
C9H6(79Br)N3 [M]+, 234.9745; found, 234.9739. 
 
Dffianffionffic Alkylattffion of 2a 
	  
General Procedure. To a sttffirffing 0.3 M soluttffion of alkene 2a ffin THF att -78 °C was added 2.2 
eq.  of  LDA  dropwffise.  TThe reacttffion  mffixtture  was sttffired for  20  mffin and ttThe electtropThffile (1.05 
equffiv.)  was  quffickly added.  TThe reacttffion  mffixtture  was alowed tto  warm tto  0 °C  over  1  Th, ttThen 
quencThed wffittTh NH4Cl and exttractted wffittTh EttOAc (×3), and ttThe combffined organffic exttractts were 
wasThed  wffittTh  brffine,  drffied  over  Na2SO4, and concenttratted ffin vacuo.  Purffiffficattffion  by sffilffica gel 




















(E)-2-((1H-Pyrrol-3-yl)mettThylene)-3-mettThylsuccffinonffittrffile (4a). yffield: 
77%; 1H-NMR (400  MHz; acettone-d6): δ 10.81 (s,  1H),  7.37 (s,  1H),  7.36 
(dd, J = 2.8, 2.2 Hz, 1H), 7.00 (q, J = 2.2 Hz, 1H), 6.50 (dd, J = 2.8, 2.2 Hz, 1H), 4.33 (q, J = 7.0 
Hz, 1H), 1.61 (d, J = 7.0 Hz, 3H); 13C-NMR (101 MHz, acettone-d6): δ 142.08, 125.50, 121.87, 
120.47,  119.34,  118.63,  109.49,  102.61,  25.97,  18.04;  HRMS (FAB):  Exactt  mass calcd for 
C10H9N3 [M]+, 171.0797. Found 171.0799. 
(E)-2-((1H-Pyrrol-3-yl)mettThylene)-3-ettThylsuccffinonffittrffile (4b). yffield: 
80%; 1H-NMR (400 MHz; acettone-d6): δ 10.79 (s, 1H), 7.41 (s, 1H), 7.36 
(m, 1H), 7.00 (m, 1H), 6.50 (m, 1H), 4.15 (tt, J = 7.5 Hz, 1H), 1.97 (m, 2H), 1.14 (tt, J = 7.5 Hz, 
3H); 13C-NMR (101  MHz, acettone-d6): δ 142.86,  125.62,  121.87,  119.58,  119.54,  118.62, 
109.41,  101.29,  32.98,  26.32,  11.57; HRMS (FAB):  Exactt  mass calcd for  C11H11N3 [M]+, 
185.0953. Found 185.0954. 
(E)-2-((1H-Pyrrol-3-yl)mettThylene)-3-benzylsuccffinonffittrffile (4c). yffield: 
75%; 1H-NMR (400  MHz; acettone-d6): δ 10.77 (s,  1H),  7.43-7.24 (m, 
7H), 6.98 (q, J = 2.5 Hz, 1H), 6.48 (q, J = 2.2 Hz, 1H), 4.51 (tt, J = 7.9 Hz, 1H), 3.34 (dd, J = 
13.7, 7.9 Hz, 1H), 3.22 (dd, J = 13.7, 7.9 Hz, 1H); 13C-NMR (101 MHz, acettone-d6): δ 143.17, 
136.90, 129.96, 129.38, 128.14, 125.60, 121.89, 119.55, 119.26, 118.47, 109.25, 100.80, 38.13, 
33.43; HRMS (FAB): Exactt mass calcd for C16H13N3 [M]+, 247.1110. Found 247.1107. 
(E)-2-((1H-Pyrrol-3-yl)mettThylene)-3-alylsuccffinonffittrffile (4d). yffield: 
67%; 1H-NMR (400 MHz; acettone-d6): δ 10.82 (s, 1H), 7.41 (s, 1H), 7.36 
(dtt, J = 3.1, 1.6 Hz, 1H), 7.00 (q, J = 2.3 Hz, 1H), 6.51-6.49 (m, 1H), 5.90 (ddtt, J = 17.1, 10.2, 
6.9 Hz, 1H), 5.31 (dq, J = 17.1, 1.4 Hz, 1H), 5.20 (dq, J = 10.2, 1.4 Hz, 1H), 4.31 (tt, J = 7.6 Hz, 















119.75, 119.50, 119.21, 118.59, 109.39, 100.91, 36.67, 31.45; HRMS (FAB): Exactt mass calcd 
for C12H11N3 [M]+, 197.0953. Found 197.0958. 
(E)-2-((1H-Pyrrol-3-yl)mettThylene)-3-(prop-2-yn-1-yl)succffinonffittrffile 
(4e). yffield:  72%; 1H-NMR (400  MHz; acettone-d6): δ 10.83 (s,  1H), 7.47 
(s, 1H), 7.38 (q, J = 2.3 Hz, 1H), 7.01 (q, J = 2.3 Hz, 1H), 6.51 (q, J = 2.3 Hz, 1H), 4.48 (tt, J = 
7.4 Hz, 1H), 3.00-2.85 (m, 2H), 2.67 (tt, J = 2.7 Hz, 1H); 13C-NMR (101 MHz, acettone-d6): δ 
143.62,  125.92,  122.07,  119.15,  118.53,  118.49,  109.37,  99.99,  79.11,  73.81,  31.48,  22.52; 
HRMS (FAB): Exactt mass calcd for C12H9N3 [M]+, 195.0797. Found 195.0793. 
EttThyl (E)-3,4-dfficyano-5-(1H-pyrrol-3-yl)pentt-4-enoatte (4f). yffield: 
80%; 1H-NMR (400 MHz; acettone-d6): δ 10.85 (s, 1H), 7.44 (s, 1H), 7.39 
(tt, J = 1.4 Hz, 1H), 7.03 (d, J = 2.4 Hz, 1H), 6.52 (q, J = 2.2 Hz, 1H), 4.60 (tt, J = 7.4 Hz, 1H), 
4.17 (q, J =  7.1  Hz,  2H),  3.15-2.98 (m,  2H),  1.23 (tt, J =  7.1  Hz,  4H); 13C-NMR (101  MHz, 
acettone-d6): δ 169.54,  143.25,  125.90,  122.06,  119.19,  118.84,  118.61,  109.45, 99.85,  61.88, 
36.63, 28.06, 14.34; HRMS (FAB): Exactt mass calcd for C13H13N3O2 [M]+, 243.1008. Found 
243.1004. 
 
Inttramolecular Houben-HoescTh Annulattffion tto Indoles 
	  
General Procedure. To a sttffirffing 0.1 M soluttffion of alkene 2a-g or 4a-4f (1.0 equffiv.) ffin ttThe 1,2-
dfficThloroettThane att room ttemperatture  was added  BF3•OEtt2 (2.5 equffiv.).  TThe reacttffion  mffixtture 




























quencThed  wffittTh  NaHCO3.  TThe reacttffion  mffixtture  was exttractted  wffittTh  EttOAc (×3), and ttThe 
combffined  organffic exttractts  were  wasThed  wffittTh  brffine,  drffied  over  Na2SO4, and concenttratted ffin 
vacuo. Crysttalffizattffion from Thott EttOAc and Thexanes aforded ttThe desffired ffindoles. 
7-Amffino-5-cyano-1H-ffindole (3a). yffield: 91%; mp 158-159 °C; 1H-NMR (400 
MHz; acettone-d6): δ 10.48 (s, 1H), 7.42 (d, J = 3.1 Hz, 1H), 7.37 (d, J = 1.3 Hz, 
1H),  6.70 (d, J =  1.3  Hz,  1H),  6.53 (d, J =  3.1  Hz,  1H),  5.12 (s,  2H); 13C-NMR (101  MHz, 
acettone-d6): δ 134.59, 128.53, 127.84, 125.96, 120.91, 115.53, 106.71, 103.08, 103.00; HRMS 
(FAB) calcd for C9H7N3 [M]+, 157.0640; found, 157.0637. 
7-Amffino-2-bromo-5-cyano-1H-ffindole (3b). yffield: 67%; mp 179-180 °C; 
1H-NMR (400  MHz; acettone-d6): δ  7.30 (s,  1H),  6.72 (s,  1H),  6.61 (s, 
1H), 5.15 (s, 1H); 13C-NMR (101 MHz, acettone-d6): δ 137.84, 130.19, 120.79, 120.54, 114.97, 
113.95, 106.15, 106.10, 104.53; HRMS (FAB) calcd for C9H6(79Br)N3 [M]+, 234.9745; found, 
234.9743. 
EttThyl  7-amffino-5-cyano-1H-ffindole-2-carboxylatte (3c). yffield:  62%; 
mp  202-203 °C; 1H-NMR (400  MHz; acettone-d6): δ  11.02 (s, 1H), 
7.46 (d, J = 1.4 Hz, 1H), 7.21 (d, J = 1.6 Hz, 1H), 6.78 (d, J = 1.4 Hz, 1H), 5.48 (s, 2H), 4.38 (q, 
J = 7.1 Hz, 2H), 1.37 (tt, J = 7.1 Hz, 3H); 13C-NMR (101 MHz, acettone-d6): δ 161.84, 136.40, 
130.05,  129.75,  128.70,  121.09,  117.44,  109.69,  108.83,  105.67,  61.61,  14.63;  HRMS (FAB): 
Exactt mass calcd for C12H11N3O2 [M]+, 229.0851. Found 229.0855. 
7-Amffino-5-cyano-2-pThenyl-1H-ffindole (3d). yffield: 87%; mp 209-210 
°C; 1H-NMR (400 MHz; acettone-d6): δ 10.72 (s, 1H), 7.86 (dd, J = 8.3, 
1.2 Hz, 2H), 7.47 (dd, J = 8.3, 7.1 Hz, 2H), 7.37-7.35 (m, 2H), 6.94 (d, J = 1.4 Hz, 1H), 6.71 (d, 




















130.50,  129.43,  128.82,  126.13,  121.64,  116.02,  108.06,  104.57,  101.09;  HRMS (FAB):  Exactt 
mass calcd for C15H11N3 [M]+, 233.0953. Found 233.0953. 
7-Amffino-5-cyano-3-mettThyl-1H-ffindole (3e). yffield: 94%; mp 181-182 °C; 1H-
NMR (400  MHz; acettone-d6): δ  10.15 (s,  1H),  7.31 (s,  1H),  7.18 (s,  1H), 
6.69 (s, 1H), 5.04 (s, 2H), 2.28 (s, 3H); 13C-NMR (101 MHz, acettone-d6): δ 
135.32,  129.66,  128.99,  124.31,  121.90,  114.72,  112.78,  107.66,  103.28,  9.65;  HRMS (FAB) 
calcd for C10H9N3 [M]+, 171.0797; found, 171.0795. 
7-Amffino-5-cyano-3-ettThyl-1H-ffindole (3f). yffield:  92%;  mp  139-140 °C; 
1H-NMR (400  MHz; acettone-d6): δ 10.16 (s,  1H),  7.35 (s,  1H),  7.20 (s, 
1H), 6.69 (s, 1H), 5.05 (s, 2H), 2.74 (q, J = 7.5 Hz, 2H), 1.29 (tt, J = 7.5 Hz, 
3H); 13C-NMR (101  MHz, acettone-d6): δ  135.39,  129.12,  128.78,  123.17,  121.91,  114.81, 
113.23, 107.65, 103.26, 18.82, 14.96; HRMS (FAB) calcd for C11H11N3 [M]+, 185.0953; found, 
185.0960. 
7-Amffino-3-bromo-5-cyano-1H-ffindole (3g). yffield: 75%; mp 187-189 °C; 1H-
NMR (400 MHz; acettone-d6): δ 10.76 (s, 1H), 7.57 (d, J = 1.3 Hz, 1H), 7.22 
(d, J =  1.3  Hz,  1H),  6.78 (d, J =  1.3  Hz,  1H),  5.27 (s,  2H).; 13C-NMR (101 
MHz, acettone-d6): δ  135.98,  128.22,  128.10,  126.58,  121.11,  113.83,  108.50,  105.26,  91.80; 
HRMS (FAB) calcd for C9H6(79Br)N3 [M]+, 236.9745; found, 236.9747. 
7-Amffino-5-cyano-6-mettThyl-1H-ffindole (5a). yffield: 88%; mp 161-162 °C; 1H-
NMR (400 MHz; acettone-d6): δ 10.32 (s, 1H), 7.39 (s, 1H), 7.37 (d, J = 3.2 
Hz, 1H), 6.47 (d, J = 3.2 Hz, 1H), 4.90 (s, 2H), 2.42 (s, 3H); 13C-NMR (101 MHz, acettone-d6): 
δ 132.77, 129.17, 127.61, 126.49, 121.20, 116.62, 114.06, 105.67, 103.58, 14.92; HRMS (FAB): 






















7-Amffino-5-cyano-6-ettThyl-1H-ffindole (5b). yffield: 95%; mp 165-166 °C; 1H-
NMR (400 MHz; acettone-d6): δ 10.34 (s, 1H), 7.40 (s, 1H), 7.37 (dd, J = 
3.0, 1.8 Hz, 1H), 6.47 (tt, J = 1.8 Hz, 1H), 4.93 (s, 2H), 2.91 (q, J = 7.5 Hz, 2H), 1.22 (tt, J = 7.5 
Hz, 3H); 13C-NMR (101 MHz, acettone-d6): δ 132.05, 129.45, 127.53, 126.54, 121.06, 120.62, 
117.08,  105.01,  103.55,  23.02,  14.31;  HRMS (FAB):  Exactt  mass calcd for  C11H11N3 [M]+, 
185.0953. Found 185.0955. 
7-Amffino-6-benzyl-5-cyano-1H-ffindole (5c). yffield: 96%; mp 170-171 °C; 
1H-NMR (400 MHz; acettone-d6): δ 10.45 (s, 1H), 7.50 (s, 1H), 7.40 (d, J 
= 3.2 Hz, 1H), 7.27-7.24 (m, 4H), 7.18-7.15 (m, 1H), 6.53 (d, J = 3.2 Hz, 1H), 4.87 (s, 2H), 
4.30 (s,  2H); 13C-NMR (101  MHz, acettone-d6): δ 140.55,  133.04,  129.43,  129.17,  128.98, 
127.99,  126.89,  126.85,  121.34,  117.33,  117.02,  106.16,  103.71,  35.30;  HRMS (FAB):  Exactt 
mass calcd for C16H13N3 [M]+, 247.1110. Found 247.1109. 
6-Alyl-7-amffino-5-cyano-1H-ffindole (5d). yffield: 93%; mp 113-115 °C; 1H-
NMR (400 MHz; acettone-d6): δ 10.43 (s, 1H), 7.43 (s, 1H), 7.39 (d, J = 3.1 
Hz, 1H), 6.50 (d, J = 3.1 Hz, 1H), 5.98 (ddtt, J = 17.1, 10.1, 6.0 Hz, 1H), 5.09-5.00 (m, 2H), 4.88 
(s,  2H),  3.65 (dtt, J =  6.0,  1.7  Hz,  2H); 13C-NMR (101  MHz, acettone-d6): δ 136.08,  132.84, 
129.75, 129.03, 127.87, 126.72, 121.00, 117.24, 115.64, 105.66, 103.65, 33.99; HRMS (FAB): 
Exactt mass calcd for C12H11N3 [M]+, 197.0953. Found 197.0960. 
7-Amffino-5-cyano-6-(prop-2-yn-1-yl)-1H-ffindole (5e). yffield:  92%;  mp 
182-183; 1H-NMR (400  MHz; acettone-d6): δ 10.52 (s,  1H),  7.45 (s,  1H), 
7.43 (m, 1H), 6.52 (m, 1H), 5.08 (s, 2H), 3.80 (d, J = 2.8 Hz, 2H), 2.52 (tt, J = 2.8 Hz, 1H); 13C-



















103.77,  81.35,  70.97,  19.32;  HRMS (FAB):  Exactt  mass calcd for  C12H9N3 [M]+,  195.0797. 
Found 195.0796. 
EttThyl  2-(7-amffino-5-cyano-1H-ffindol-6-yl)acettatte (5f). yffield:  72%;  mp 
177-178 °C; 1H-NMR (400  MHz; acettone-d6): δ 10.51 (s,  1H),  7.46 (s, 
1H), 7.42 (tt, J = 2.3 Hz, 1H), 6.52 (tt, J = 2.0 Hz, 1H), 5.07 (s, 2H), 4.12 (q, J = 7.0 Hz, 2H), 3.91 
(s, 2H), 1.21 (tt, J = 7.0 Hz, 3H). 13C-NMR (101 MHz, acettone-d6): δ 171.32, 133.88, 129.43, 
128.24, 127.05, 120.73, 117.41, 111.71, 106.22, 103.81, 61.39, 35.72, 14.49; Exactt mass calcd for 
C13H13N3O2 [M]+, 243.1008. Found 243.1007. 
 
One-Pott Wffittttffig/Houben-HoescTh Indole SynttThesffis 
	  
Procedure. To a sttffirffing soluttffion  of  pyrole-3-carboxaldeThyde (100  mg,  1.05  mmol) ffin  THF 
(2.1  mL) att room ttemperatture  was added fumaronffittrffile (103  mg,  1.31  mmol) folowed  by 
ttrffimettThylpThospThffine (131 µL, 1.26 mmol) dropwffise. TThe reacttffion mffixtture was sttffired for 48 Th, 
ttThen concenttratted on a rottary evaporattor. TThe resffidue was ttThen ttaken up ffin 1,2-DCE (10.5 mL) 
and BF3•OEtt2 (324 µL, 2.63 mmol) was added dropwffise. TThe reacttffion mffixtture was Theatted tto 90 
°C and sttffired for  12  Th, ttThen cooled tto room ttemperatture and  quencThed  wffittTh  NaHCO3.  TThe 
crude  productt  mffixtture  was exttractted  wffittTh  EttOAc (3 ×  20  mL), and ttThe combffined  organffic 
exttractts  were  wasThed  wffittTh  brffine, drffied  over sodffium sulfatte, and concenttratted ffin vacuo.  TThe 
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acettone/pettroleum ettTher, ttThen recrysttalffized from Thott EttOAc and Thexanes tto aford ffindole 3a 
(128 mg, 0.81 mmol, 77%). 
 
Preparattffion of Benzofuran 13a and BenzottThffiopThene 13b 
	  
General  Procedure for  Wffittttffig  Olefffinattffion. To a sttffirffing soluttffion  of ttThe  Thetteroaryl–3-
carboxaldeThyde (1.0 equffiv.) ffin  THF (0.25  M) att room ttemperatture  was added fumaronffittrffile 
(1.25 equffiv.) folowed by ttrffiettThylpThospThffine (1.20 equffiv.) dropwffise. TThe reacttffion mffixtture was 
sttffired att  65 °C  unttffil ttThe sttarttffing  matterffial  was  no longer vffisffible  by  TLC (ttypfficaly  8  Th), ttThen 
quencThed wffittTh NaHCO3 and exttractted wffittTh EttOAc (×3). TThe combffined organffic exttractts were 
wasThed  wffittTh  brffine,  drffied  over  Na2SO4, and concenttratted ffin vacuo.  Purffiffficattffion  by sffilffica gel 
cThromattograpThy aforded a mffixtture of ttThe E- and Z-olefffin Wffittttffig productts due tto ttThe sffimffilar Rf 
values of ttThe ttwo ffisomers. Crysttalffizattffion was unable tto separatte ttThe ttwo ffisomers, wThfficTh were 
used as an E/Z mffixtture (6:1 for 12a, 5:1 for 12b) for ttThe cyclffizattffion reacttffion. TThe specttroscopffic 
datta ffis gffiven for ttThe E-ffisomer. 
2-(Furan-3-ylmettThylene)succffinonffittrffile (12a). 1H-NMR (400 MHz; acettone-
d6): δ 8.10 (s, 1H), 7.77 (d, J = 1.4 Hz, 1H), 7.47 (s, 1H), 6.87 (d, J = 1.4 Hz, 
1H),  3.91 (d, J =  1.2  Hz,  2H); 13C-NMR (101  MHz, acettone-d6): δ 147.62,  146.04,  139.13, 
120.97,  119.42,  116.56,  110.56,  102.43,  19.60;  HRMS (EI):  Exactt  mass calcd for  C9H6N2O 
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2-(TThffiopThen-3-ylmettThylene)succffinonffittrffile (12b). 1H-NMR (400  MHz; 
acettone-d6): δ 7.93 (d, J = 2.8 Hz, 1H), 7.68 (dd, J = 5.1, 2.8 Hz, 1H), 7.61 (s, 
1H), 7.40 (dd, J = 5.1, 1.3 Hz, 1H), 3.96 (d, J = 1.3 Hz, 2H); 13C-NMR (101 MHz, acettone-d6): 
δ 142.24,  135.29,  131.58,  128.88,  128.44,  119.50,  116.60,  102.85,  19.75;  HRMS (EI):  Exactt 
mass calcd for C9H6N2S [M]+, 174.0252; Found 174.0257. 
General Procedure for Annulattffion tto Benzofuran 13a and BenzottThffiopThene 13b. To a sttffirffing 
0.1  M soluttffion  of alkene  12a-b (1.0 equffiv.) ffin  1,2-dfficThloroettThane att room ttemperatture  was 
added  BF3•OEtt2 (2.5 equffiv.).  TThe reacttffion  mffixtture  was  Theatted tto  90 °C and sttffired for  24  Th. 
TThe reacttffion sttaled around 24 Th and dffid nott progress furttTher even wffittTh addffittffion of excess Lewffis 
acffid or exttended reacttffion ttffime. TThe reacttffion mffixtture was ttThen cooled tto room ttemperatture and 
quencThed  wffittTh  NaHCO3.  TThe reacttffion  mffixtture  was exttractted  wffittTh  EttOAc (x3), and ttThe 
combffined  organffic exttractts  were  wasThed  wffittTh  brffine,  drffied  over  Na2SO4, and concenttratted ffin 
vacuo. Recrysttalffizattffion from Thott EttOAc and Thexanes aforded ttThe desffired Thetterocycles 13a-b. 
7-Amffino-5-cyanobenzfuran (13a). yffield: 32%; mp 197-198 °C; 1H-NMR (400 
MHz; MeOD): δ 8.09 (d, J = 2.2 Hz, 1H), 8.03 (d, J = 1.3 Hz, 1H), 7.55 (d, J = 
1.3 Hz, 1H), 7.11 (d, J = 2.2 Hz, 1H); 13C-NMR (101 MHz, MeOD): δ 150.02, 149.94, 131.47, 
125.69,  122.07,  122.04,  120.74,  119.32,  108.61;  HRMS (FAB) calcd for  C9H6N2O [M]+, 
158.0480; found, 158.0479. 
7-Amffino-5-cyanobenzottThffiopThene (13b). yffield:  52%;  mp  123-124 °C; 1H-
NMR (300 MHz; acettone-d6): δ 7.77 (d, J = 5.4 Hz, 1H), 7.63 (d, J = 1.4 Hz, 
1H),  7.48 (d, J =  5.4  Hz,  1H),  6.92 (d, J =  1.4  Hz,  1H),  5.50 (s,  2H); 13C-NMR (101  MHz, 
acettone-d6): δ 144.62, 141.81, 130.72, 128.82, 125.73, 120.43, 117.85, 109.78, 109.60; HRMS 











Elaborattffion of 3a: Sandmeyer Reacttffion 
	  
7-CThloro-5-cyano-1H-ffindole (14a). To a sttffirffing soluttffion  of  7-amffino-5-
cyano[1H]ffindole•HCl (100  mg,  0.52  mmol) ffin  4.3  mL  MeCN and 4.3  mL 
watter att 0 °C was added 0.3 mL concenttratted HCl. Sodffium nffittrffitte (71 mg, 1.03 mmol) was ttThen 
added as a soluttffion ffin  4.3  mL  watter.  TThe reacttffion  mffixtture  was alowed tto  warm tto room 
ttemperatture over 30 mffin before addffittffion of CuCl (256 mg, 2.58 mmol) as a soluttffion ffin 8.6 mL 
watter. TThe reacttffion mffixtture was Theatted tto reflux for 3 Th, ttThen ttThe MeCN was evaporatted. TThe 
reacttffion  mffixtture  was  dffilutted  wffittTh  watter (100  mL) and exttractted  wffittTh  EttOAc (3 ×  30).  TThe 
combffined  organffic exttractts  were  wasThed  wffittTh  brffine,  drffied over  Na2SO4, and concenttratted ffin 
vacuo. Crysttalffizattffion from Thott EttOAc and Thexanes aforded ttThe cThlorffinatted ffindole (71 mg, 0.40 
mmol, 72%). 1H-NMR (400 MHz; acettone-d6): δ 11.15 (s, 1H), 8.06 (s, 1H), 7.64 (tt, J = 3.0 Hz, 
1H), 7.53 (d, J = 1.6 Hz, 1H), 6.76 (dd, J = 3.0, 1.6 Hz, 1H); 13C-NMR (101 MHz, acettone-d6): 
δ 135.10, 129.50, 128.53, 124.94, 122.90, 118.96, 117.25, 103.99, 103.32; HRMS (FAB) calcd 
for C9H5ClN2 [M]+, 176.0141; found, 176.0153. 
7-Bromo-5-cyano-1H-ffindole (14b). To a sttffirffing soluttffion  of ttThe  7-amffino-5-
cyano[1H]ffindole•HCl (100  mg,  0.52  mmol) ffin  4.3  mL  MeCN and  4.3  mL 
watter att 0 °C was added ttThe HBr (48% soluttffion ffin watter, 0.3 mL). Sodffium nffittrffitte (72 mg, 1.03 
mmol) was ttThen added as a soluttffion ffin 4.3 mL watter. TThe reacttffion mffixtture was alowed tto warm 
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8.6 mL watter. TThe reacttffion mffixtture was Theatted tto reflux for 3 Th, ttThen ttThe MeCN was evaporatted. 
TThe reacttffion mffixtture was dffilutted wffittTh watter (100 mL) and exttractted wffittTh EttOAc (3 × 30 mL). 
TThe combffined organffic exttractts were drffied over Na2SO4 and concenttratted ffin vacuo. Purffiffficattffion 
by recrysttalffizattffion from  EttOAc and  Thexanes aforded ttThe  pure  bromoffindole (49  mg,  0.22 
mmol, 43%). 1H-NMR (400 MHz; acettone-d6): δ 11.01 (s, 1H), 8.09 (s, 1H), 7.66 (s, 1H), 7.63 
(s,  1H),  6.79 (s,  1H); 13C-NMR (101  MHz, acettone-d6): δ  136.62,  129.01,  128.51,  125.89, 
125.37, 118.85, 104.73, 104.11, 103.66; HRMS (FAB) calcd for C9H579BrN2 [M]+, 219.9636; 
found, 219.9637; C9H581BrN2 [M]+, 221.9616; found, 221.9615. 
 
Elaborattffion of 3a: Preparattffion of GPAT InThffibffittor Analog 9a. 
	  
N-(5-cyano-1H-ffindol-7-yl)octtane-1-sulfonamffide (15a). To a sttffirffing 
soluttffion  of ffindole 3a (68  mg,  0.43  mmol) ffin  CH2Cl2 (1  mL) att  0 °C  was 
added  octtanesulfonyl cThlorffide (101 µL,  0.52  mmol) folowed  by  NEtt3 (121 
µL, 0.87 mmol) dropwffise. TThe reacttffion mffixtture was alowed tto warm tto room ttemperatture and 
sttffired for 24 Th. TThe reacttffion was quencThed by addffittffion of 20 mL NaHCO3 and exttractted wffittTh 
CH2Cl2 (3 × 15 mL). TThe combffined organffic exttractts were drffied over Na2SO4, and concenttratted 
ffin vacuo.  Purffiffficattffion  by flasTh cThromattograpThy (20%  EttOAc/Hexanes) aforded ttThe  pure 
sulfonamffide (106  mg,  0.32  mmol,  74%). 1H-NMR (400  MHz; acettone-d6): δ  10.71 (s,  1H), 





































J = 3.2, 1.9 Hz, 1H), 3.24-3.20 (m, 2H), 1.84-1.76 (m, 2H), 1.39 (quffinttett, J = 7.1 Hz, 2H), 1.24 
(m, J = 11.5 Hz, 8H), 0.85 (tt, J = 6.9 Hz, 3H); 13C NMR (100 MHz; acettone-d6): δ 132.4, 130.0, 
128.0,  123.6,  123.2,  119.7,  117.5,  103.3,  102.7,  51.0,  31.5,  28.76,  28.74,  27.8,  23.3,  22.3,  13.4; 
HRMS (EI) calcd for C17H23N3O2S [M]+, 333.1511; found, 333.1510. 
7-(octtylsulfonamffido)-1H-ffindole-5-carboxylffic acffid (9a). To a sttffirffing 
soluttffion ttThe cyanoffindole 15a (33 mg, 0.10 mmol) att room ttemperatture was 
added 2 M KOH (1 mL). TThe reacttffion mffixtture was sttffired att 95 °C for 6 Th, 
ttThen  quencThed  wffittTh  1  M  HCl (3  mL).  TThe  wThffitte  precffipffittatte  was fffilttered,  wasThed  wffittTh cold 
watter, and drffied. Purffiffficattffion by flasTh cThromattograpThy (20% acettone/77% pettroleum ettTher/3% 
AcOH) aforded ttThe pure carboxylffic acffid 9a (28 mg, 0.080 mmol, 81%). 1H-NMR (400 MHz; 
acettone-d6): δ 10.60 (s,  1H),  8.28 (s,  1H),  7.90 (s,  1H),  7.50 (s,  1H),  6.67 (s,  1H),  3.15 (m, 
2H), 1.81 (m, 2H), 1.37 (m, 2H), 1.22 (m, 8H), 0.84 (tt, J = 6.8 Hz, 3H); 13C-NMR (101 MHz, 
acettone-d6): δ 168.62,  134.35,  130.56,  127.86,  127.70,  122.73,  122.23,  118.15,  104.44,  51.52, 
32.41,  30.09,  29.89,  28.75,  24.23,  23.22,  14.31;  HRMS (EI) calcd for  C17H24N2O4S [M]+, 
352.1457; found, 352.1456. 
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One-Pott SynttThesffis of HffigThly Substtffittutted N-Fused Hetteroaromattffic Bfficycles 
from Azole AldeThydes 
4.1 Inttroducttffion 
In  CThaptter  3,  new  mettThodology  was  descrffibed for ttThe synttThesffis  of substtffittutted ffindole-
conttaffinffing compounds. TThffis routte was devffised for ttThe rapffid access and dffiversffiffficattffion of ffindole-
based ffinThffibffittors  of glycerol-3-pThospThatte acylttransferase (GPAT). In addffittffion tto ttThe ffindole 
bfficycle, compounds conttaffinffing N-fused Thetteroaromattffic bfficycles, as sThown ffin Fffig. 4.1, were also 
of ffintterestt. AlttThougTh ffisostterffic tto ttThe ffindole sttructture, eacTh N-fused Thetteroaromattffic bfficyclffic core 
presentts a dffisttffinctt aray of H-bond donors and accepttors and a unffique electtronffic sttructture. TThe 
Thetteroaromattffic  bfficycles ttargetted ffincluded ttThe ffindolffizffine, ffimffidazo[1,2-a]pyrffidffine, and 
ffimffidazo[1,5-a]pyrffidffine  nucleffi.  Because  no suffficffientt  mettThod exffistted for ttThe synttThesffis  of ttThese 
5,7-dffisubsttffittutted sttructtures, a routte was devffised for ttTheffir ready preparattffion. 
N-fused aromattffic  Thetterocycles, sucTh as ttThe ffindolffizffine and ffimffidazopyrffidffine classes, are 
attttracttffive synttThettffic ttargetts  owffing tto ttTheffir  pTharmacologffical  pottenttffial and  unffique electtronffic 
properttffies.  TThe  wffide aray  of  bffiologffical efectts elfficffitted  by  members  of ttThese  Thetteroaromattffic 
classes  Thas  been wel  documentted, ffincludffing anttffimfficrobffial,1 anttffivffiral,2 anttffiffinflammattory,3 
anttffittubercular,4 anttfficancer,5 anttffinocfficepttffive,6 anttffiprottozoal,7 and  Thypnoselecttffive8 acttffivffittffies. In 
addffittffion, ttThese scafolds,  nottably ttThe ffimffidazopyrffidffines,  Thave found  uttffilffitty as N-Thetterocyclffic 
carbene (NHC) lffigands ffin complexes wffittTh promffisffing cattalyttffic reacttffivffitty9 or as ffinks and dyes. As 
a consequence  of ttTheffir  dffiverse  uses, several synttThettffic  mettThods  Thave  been  developed for ttTheffir 
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preparattffion.  Tradffittffional synttTheses employ substtffittutted  pyrffidffines tto annulatte ttThe  5-membered 
porttffion of ttThe bfficyclffic systtem.10-11 For example, ttThe mostt common ffindolffizffine synttTheses ffinvolve 
ttThe eupThonffious TscThffittscThffibabffin reacttffion or ffitts concepttual varffiantts, and proceed by reacttffion of 
2-alkylpyrffidffines wffittTh α-Thalo kettones.10a More recenttly, sttrattegffies Thave been developed tto access 
ttThese  bfficycles from ttTheffir  5-membered  Thetterocyclffic  precursors.12 Lee and  Kffim, for example, 
demonsttratted ttThe aldol-ttype cyclffizattffion  of N-substtffittutted  2-acettylpyroles  under alkalffine 
condffittffions tto furnffisTh 6,8-dffisubsttffittutted ffindolffizffines.12c 
	  
Fffigure 4.1 Desffign of GPAT ffinThffibffittors conttaffinffing N-fused Thetteroaromattffic bfficycles 
 
4.2 Desffign of SynttThettffic Routte 
Despffitte recentt  developmentts tto N-fused  Thetteroaromattffic  bfficycles, tto  our knowledge  no 
















































































reportted a flexffible, effficffientt routte tto  ThffigThly substtffittutted  7-amffinoffindoles from  pyrole-3-
carboxaldeThydes.13 TThffis routte  uttffilffized a  one-pott, ttThree componentt  Wffittttffig  olefffinattffion  of ttThe 
aldeThydes  wffittTh a ttrffialkylpThospThffine and fumaronffittrffile tto aford  predomffinanttly E-alkenes, 
folowed by Lewffis acffid-medffiatted ffinttramolecular Houben-HoescTh reacttffion tto ttThe corespondffing 
ffindoles.  We envffisffioned a  mecThanffisttffically relatted routte tto  obttaffin ttThe  5-amffinoffindolffizffine,  5-
amffinoffimffidazo[1,2-a]pyrffidffine, and 5-amffinoffimffidazo[1,5-a]pyrffidffine classes, as sThown ffin Fffig. 4.2. 
In ttThffis case, rattTher ttThan  nucleopThffilffic attttack  of ttThe  pyrolffic α-carbon  on a  Lewffis acffid-acttffivatted 
nffittrffile,  we reasoned ttThatt ttThe relattffive acffidffitty  of ttThe azolffic  N-H  protton  would alow for facffile 
deprottonattffion tto a  nucleopThffilffic azolffide anffion folowed  by cycloaromattffizattffion.  Altternattffively, a 
second  deprottonattffion could furnffisTh an allylffic  dffianffion ttThatt could reactt selecttffively  wffittTh 
electtropThffiles prffior tto cyclffizattffion tto alow for substtffittuentt conttrol att ttThe 6-posffittffion. 
 
	  






































































4.3 Opttffimffizattffion of MettThod 
Exttendffing ttThe condffittffions esttablffisThed ffin our laborattory,14 Wffittttffig olefffinattffion of commercffialy-
avaffilable  pyrole-2-carboxaldeThyde aforded alkene 2a ffin excelentt yffield and good 
dffiasttereoselecttffivffitty as sThown ffin Table 4.1. To esttablffisTh an opttffimal annulattffion procedure, ttThe E-
ffisomer,  purffifffied  by recrysttalffizattffion from ttThe  dffiasttereomerffic  mffixtture,  was ttThen subjectted tto a 
varffietty of condffittffions. Under ttThe Lewffis acffidffic condffittffions employed prevffiously for ttThe Houben-
HoescTh annulattffion tto  7-amffinoffindoles (BF3•OEtt2),  no  desffired cyclffizattffion  was  observed. 
Sffimffilarly, ttreattmentt wffittTh LDA att -78 °C resultted ffin ttThe ffisolattffion of only sttarttffing matterffial. Att 0 
°C,  Thowever, ttreattmentt  wffittTh sttofficThffiomettrffic amountts  of ttThe sttrong  bases  LDA  or  LffiHMDS 
efectted rapffid and complette conversffion tto ttThe ffindolffizffine 3a. TThe weaker bases KOH and K2CO3 
also exThffibffitted ttThe  desffired cyclffizattffion alttThougTh  ThffigTher ttemperattures  were requffired.  For  KOH, 
complette conversffion tto ttThe ffindolffizffine  was  observed att room ttemperatture aftter  15  mffinuttes. 
K2CO3 was far less effficffientt and requffired reflux ttemperatture, longer reacttffion ttffime, and aforded 
lower yffields. We ThypottThesffized ttThatt ttThe ffinffittffial cyclffized productt, an anffilffide anffion, could also actt as 
a base ffittself ttThereby necessffittattffing only a cattalyttffic amountt of base tto ffinffittffiatte ttThe cycle. Indeed, 
ttreattmentt  wffittTh cattalyttffic amountts  of  LDA att  0 °C  or  KOH att room ttemperatture effectted 
complette conversffion tto ttThe cyclffized productt. Due tto ttThe mffilder condffittffions, sThortt reacttffion ttffime, 




Table 4.1	  Opttffimffizattffion of Reacttffion Condffittffions 
 
enttry reagentt X ttemp (°C) ttffime (Th) yffield of 3a (%) 
1 BF3•OEtt2a 2.5 90 12 0 
2 LDA 1.0 -78 1 0 
3 LDA 1.0 0 0.5 98 
4 LDA 0.4 0 0.5 97 
5 LffiHMDS 1.0 0 0.5 97 
6 KOH 4.0 23 0.25 97 
7 KOH 0.4 23 0.25 96 
8 K2CO3 4.0 70 1 86 
aReacttffion run ffin 1,2-dfficThloroettThane rattTher ttThan THF. 
 
4.4 Scope of MettThod 
TThe  mffild and effficffientt cyclffizattffion condffittffions encouraged  us tto combffine ttThe  Wffittttffig 
olefffinattffion and cyclffizattffion stteps ffintto a ttandem, one-pott synttThesffis of ThffigThly substtffittutted N-fused 
Thetteroaromattffic  bfficycles from azole aldeThydes as sThown ffin Fffig. 4.3.  TThe  unadorned  pyrole-2-
carboxaldeThyde 1a was reactted as before wffittTh PEtt3 and fumaronffittrffile att 65 °C, butt for ttThe one-
pott procedure, ttThe E/Z mffixtture was cooled tto room ttemperatture and cattalyttffic KOH was added. 
TThe E-ffisomer was complettely convertted tto 5-amffino-7-cyanoffindolffizffine wffittThffin 30 mffinuttes wThffile 
ttThe Z-ffisomer was leftt unreactted. TThe 74% yffield for ttThffis reacttffion approacThes ttThe sttofficThffiomettrffic 
conversffion  of ttThe  3:1 E/Z mffixtture.  To  demonsttratte ttThe scope  of ttThe  olefffinattffion/cyclffizattffion 
sequence, a varffietty  of substtffittutted  pyrole and ffimffidazole aldeThydes was employed.  Under ttThe 
condffittffions used before, aldeThydes 1b-n underwentt alkene formattffion and cyclffizattffion tto 





















Lffike ttThe unsubsttffittutted pyrole-2-aldeThyde, yffields approacThed ttThe sttofficThffiomettrffic lffimffitt for ttThe E-
ffisomer  presentt ffin ttThe  dffiasttereomerffic mffixtture  of ttThe crude  Wffittttffig reacttffion.  TThe ffimffidazole 
aldeThydes exThffibffitted mucTh fastter reacttffion rattes for ttThe Wffittttffig reacttffion butt mucTh slower rattes of 
annulattffion. TThe addffittffional nffittrogen on ttThe ffimffidazole lffikely acttffivattes ttThe aldeThyde for attttack by 
ttThe  pThospThonffium ylffide  butt ttThe ffincreased acffidffitty  of ttThe ffimffidazole sttabffilffizes ttThe azolffide anffion, 
ttThereby decreasffing ffitts nucleopThffilfficffitty and slowffing cyclffizattffion. 
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TThe condffittffions  were ttolerantt  of a range  of substtffittuentts ffincludffing  Thalffide, estter, and aryl 
functtffionalffittffies, as  wel as alkyl substtffittuentts att eacTh  of ttThe  possffible  posffittffions  on ttThe azole 
aldeThydes.  Deacttffivatted azole aldeThydes, for example ttThose conttaffinffing  Thalogen and estter 
functtffionalffittffies, sThowed a modestt declffine ffin yffield. AldeThydes wffittTh substtffittuentts att ttThe α-posffittffion 
(e.g. 1b,Th,l) sThowed a  moderatte  decrease ffin cyclffizattffion ratte,  pottenttffialy  due tto ttThe  A1,3 sttraffin 
presentt bettween ttThe C–3 and C–5 substtffittuentts ffin ttThe cyclffized productts. 
4.5 Dffianffionffic ApproacTh tto C-6 Substtffittutted Indolffizffines 
WffittTh  no cyclffizattffion  occurffing att -78 °C,  we  ThypottThesffized ttThatt ttThe  dffianffion  of alkene 2a 
formed att low ttemperattures could be reactted wffittTh electtropThffiles regffioselecttffively att ttThe alylffic 
posffittffion.  TThe resulttffing alkylatted  monoanffions  would ttThen cyclffize ffin sffittu upon  warmffing.  TThffis 
mettThod would alow for selecttffive ffinsttalattffion of C–6 substtffittuentts ffin ttThe ffindolffizffine productts. A 
sett of electtropThffiles was cThosen and ttThe resultts are summarffized ffin Table 4.2. Selecttffive addffittffion of 
alkyl-, alyl-,  propargyl-,  benzyl-, and α-ketto  Thalffides  was acThffieved att -78 °C.  Aftter  1  Th  of 
alkylattffion, ttThe acettone/CO2 battTh  was removed efecttffing rapffid cyclffizattffion tto ttThe  5,6,7-
ttrffisubsttffittutted ffindolffizffines 4a-e as ttThe reacttffion  mffixtture  warmed tto room ttemperatture.  TThese 
ttandem alkylattffion/cyclffizattffion reacttffions exThffibffitted excelentt yffields.  TThe acttffivatted electtropThffiles 
aforded slffigThttly  ThffigTher yffields ttThan ttThe  non-acttffivatted  MeI.  Nottably, ttThe reacttffion  wffittTh ettThyl 
bromoacettatte efectted selecttffive alkylattffion  of ttThe  dffianffion, annulattffion tto ttThe ffindolffizffine, and 
furttTher condensattffion tto ttThe ɣ-lacttam 4e ffin a sffingle pott, ThffigThlffigThttffing ttThe effficffiency and synttThettffic 
pottenttffial of ttThffis mettThod. 
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Table 4.2	  Tandem Alkylattffion/Cyclffizattffion Sequence 
 
enttry electtropThffile productt R6 yffield (%) 
1 MeI 4a -CH3 87 
2 BnBr 4b -CH2CH=CH 98 
3 alyl-Br 4c - CH2C≡CH 94 
4 propargyl-Br 4d - CH -CH2PTh 98 
5 BrCH2CO2Ett 4e  90 
 
4.6 Conclusffions 
In conclusffion,  we  Thave  developed a  one-pott,  olefffinattffion/cyclffizattffion sequence for ttThe 
synttThesffis  of  ThffigThly-substtffittutted ffindolffizffines, ffimffidazo[1,2-a]pyrffidffines, and ffimffidazo[1,5-
a]pyrffidffines from pyrole-2-, ffimffidazole-2-, and ffimffidazole-4-carboxaldeThydes, respecttffively. Wffittttffig 
olefffinattffion  of ttThe aldeThydes  wffittTh an ylffide formed ffin sffittu from fumaronffittrffile and 
ttrffiettThylpThospThffine afords E-enrfficThed alkenes, wThfficTh undergo cycloaromattffizattffion wThen ttreatted 
wffittTh cattalyttffic and  mffild  bases, alowffing for conttrol  of ttThe  C–1,  C–2, and  C–3 substtffittuentts. 
Altternattffively, dffianffions formed from ttThe ffisolable E-ffisomers undergo selecttffive alkylattffion att -78 °C 
folowed  by sponttaneous cyclffizattffion  upon  warmffing tto room ttemperatture, alowffing for  C–6 
substtffittuentt conttrol. TThe effficffiency and ttaffilorabffilffitty of ttThffis mettThod sffimplffifffies ttThe generattffion of 
large arays of functtffionalffized Thetteroaromattffic compounds. Isostteres and nffittrogen-rfficTh Thomologs 
of ffindole  presentt geomettrfficaly  defffinable Thydrogen  bond  donors and accepttors ttThatt greattly 





















substtffittuttffion patttterns readffily acThffievable by ttThffis approacTh enrfficTh and complementt ttThose avaffilable 
by curentt mettThods.14 
4.7 Experffimenttal 
General Informattffion 
Reacttffions requffirffing anThydrous condffittffions  were conductted  under an ffinertt attmospThere  of 
argon  usffing anThydrous solventts.  DCM and ttoluene  were  dffisttffiled  over  CaH2.  Ett2O and  THF 
were dffisttffiled over Na and benzopThenone. Al reacttffions were monffittored by analyttffical ttThffin-layer 
cThromattograpThy (TLC) usffing ffindfficatted solventt systtems on AnalttecTh Unffiplatte Sffilffica Gel TLC 
plattes (250 mfficrons). Al NMR specttra were recorded on effittTher Bruker Avance 400 MHz or 300 
MHz specttrometters as ffindfficatted. CThemffical sThffiftts (δ) are quotted ffin partts per mffilffion (ppm) and 
referenced tto ttThe folowffing resffidual solventt sffignals:  1H δ  =  7.26 (CDCl3),  2.50 (DMSO-d6), 
3.31 (MeOD),  2.05 (acettone-d6); 13C δ  =  77.0 (CDCl3),  39.43 (DMSO-d6),  49.05 (MeOD), 
29.84 (acettone-d6).  Couplffing consttantts (J) are gffiven ffin  Hz.  Al IR  datta  were  obttaffined  on 
TrffiettThylpThospThffine, fumaronffittrffile,  pyrole-2-carboxaldeThyde (1a),  3,5-dffimettThylpyrole-2-
carboxaldeThyde (1b),  5-formyl-2,4-dffimettThyl-1H-pyrole-3-carboxylffic acffid,  4-
ffimffidazolecarboxaldeThyde (1ffi),  4-mettThyl-5-ffimffidazolecarboxaldeThyde (1j),  2-mettThyl-1H-
ffimffidazole-4-carboxaldeThyde (1k),  5-cThloro-2-pThenyl-1H-ffimffidazole-4-carboxaldeThyde (1l), 
ffimffidazole-2-carboxaldeThyde (1m), and  4,5-dffimettThyl-1H-ffimffidazole-5-carbaldeThyde (1n)  were 





Preparattffion of AldeThydes 
 
4-Bromo-1H-pyrrole-2-carbaldeThyde (1c). To a sttffired soluttffion of pyrole–2-
carboxaldeThyde (100 mg, 1.05 mmol) ffin THF (1.1 mL) att 0 °C was added N-
bromosuccffinffimffide (187 mg, 1.05 mmol) as a sffingle porttffion. TThe reacttffion mffixtture was sttffired 
for 15 mffin att 0 °C before ttThe solventt was removed ffin vacuo. TThe crude mffixtture was suspended ffin 
watter, ttThe suspensffion was fffilttered, and ttThe fffilttrand was wasThed wffittTh watter. Crysttalffizattffion of ttThe 
fffilttrand from  Thott ettThanol and  watter aforded ttThe  desffired  4-bromopyrole–2-carbaldeThyde as a 
ttan solffid (183 mg, 0.80 mmol, 77%). Specttral datta mattcThed lffitteratture values.15 1H-NMR (400 
MHz; acettone-d6): δ 11.57–11.28 (s, 1H), 9.52 (s, 1H), 7.30 (d, J = 2.5 Hz, 1H), 7.05 (d, J = 2.5 
Hz, 1H). 
4-PThenyl-1H-pyrrole-2-carbaldeThyde (1d). TThe  4-bromopyrole-2-
carbaldeThyde (250  mg,  1.44  mmol),  pThenyl  boronffic acffid (210  mg,  1.72 
mmol), and pottassffium carbonatte (477 mg, 3.45 mmol) were suspended ffin dffioxane (13 mmol), 
and ttThe suspensffion was degassed wffittTh argon. Tettrakffis(ttrffipThenylpThospThffine)paladffium (83 mg, 5 
mol%) was added, and ttThe suspensffion was degassed agaffin wffittTh argon and Theatted tto 105 °C for 
24 Th. TThe reacttffion mffixtture was concenttratted tto dryness, and ttThe resffidue was ttaken up ffin 20 mL 
EttOAc and  20  mL  watter.  TThe  mffixtture  was exttractted  wffittTh  EttOAc (3 ×  20  mL), and ttThe 
combffined organffic exttractts were wasThed wffittTh brffine, drffied over sodffium sulfatte, and concenttratted 
ffin vacuo. Purffiffficattffion by flasTh cThromattograpThy (12→20% acettone/pettroleum ettTher) aforded ttThe 





























re-ffisolatted sttarttffing matterffial (98 mg, 0.56 mmol, 39%). Specttral datta mattcThed lffitteratture values.16 
1H-NMR (400 MHz; acettone-d6): δ 9.59 (s, 1H), 7.68–7.64 (m, 3H), 7.38–7.34 (m, 3H), 7.23–
7.19 (m, 1H). 
 
 Pyrrole-2-carbaldeThyde  dffimettThylamffine  dffimer. A soluttffion  of  pyrole-2-
carboxaldeThyde  3.0 g,  31.55  mmol) ffin  dffimettThylamffine (6.3  mL,  40% ffin 
H2O) was sttffired att room ttemperatture for 3 Th. TThe precffipffittatted solffid was 
colectted by fffilttrattffion and drffied ffin vacuo. TThe crude solffid was recrysttalffized from Thott EttOAc and 
Thexanes tto aford ttThe dffimer as a lffigThtt pffink solffid (3.26 g, 13.3 mmol, 84%). Specttral datta mattcThed 
lffitteratture values.17 
5-MettThyl-1H-pyrrole-2-carbaldeThyde (1e). A  1.7 M soluttffion  of tt-BuLffi ffin 
penttane (1.06 mL, 1.80 mmol) was added dropwffise tto a sttffired soluttffion of ttThe 
pyrole-2-carbaldeThyde dffimettThylamffine dffimer (200 mg, 0.82 mmol) ffin anThydrous THF att –15 
°C. TThe reacttffion mffixtture was sttffired for 15 mffin att ttThffis ttemperatture and ttThen for 30 mffin att 0 °C 
by wThfficTh ttffime ffitt Thad become deep vffiolett ffin color. TThe reacttffion mffixtture was cooled tto –100 °C 
and MeI (204 µL, 3.27 mmol) was added ffin one porttffion. TThe reacttffion mffixtture was alowed tto 
warm tto –30 °C over 1.5 Th and ttThen 23 °C for 1 Th. Watter (20 mL) and satturatted aqueous sodffium 
bfficarbonatte (20 mL) were added and ttThe mffixtture was Theatted tto 80 °C for 15 Th. TThe mffixtture was 
poured ffintto a concenttratted sodffium bfficarbonatte soluttffion and exttractted wffittTh DCM (3 × 20 mL). 
TThe combffined organffic exttractts were drffied over Na2SO4 and concenttratted. Purffiffficattffion by flasTh 
cThromattograpThy (20% acettone ffin  pettroleum ettTher) aforded  5-mettThylpyrole–2-carbaldeThyde 
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as an of-wThffitte solffid (156 mg, 1.43 mmol, 87%). Specttral datta mattcThed lffitteratture values.17 1H-
NMR (400 MHz; acettone-d6): δ 10.86 (s, 1H), 9.37 (s, 1H), 6.87 (s, 1H), 6.03 (s, 1H), 2.33 (s, 
3H). 
5-Alyl-1H-pyrrole-2-carbaldeThyde (1f). A  1.7  M soluttffion  of tt-BuLffi ffin 
penttane (1.06 mL, 1.80 mmol) was added dropwffise tto a sttffired soluttffion of 
ttThe pyrole-2-carbaldeThyde dffimettThylamffine dffimer (200 mg, 0.82 mmol) ffin anThydrous THF att –
15 °C. TThe reacttffion mffixtture was sttffired for 15 mffin att ttThffis ttemperatture and ttThen for 30 mffin att 0 
°C by wThfficTh ttffime ffitt Thad become deep vffiolett In color. TThe reacttffion mffixtture was cooled tto –100 
°C and alyl bromffide (283 µL, 3.27 mmol) was added ffin one porttffion. TThe reacttffion mffixtture was 
alowed tto  warm tto –30 °C  over  1.5  Th and ttThen  23 °C for  1  Th.  Watter (20  mL) and satturatted 
aqueous sodffium bfficarbonatte (20 mL) were added and ttThe mffixtture was Theatted tto 80 °C for 15 Th. 
TThe  mffixtture  was  poured ffintto a concenttratted sodffium  bfficarbonatte soluttffion and exttractted  wffittTh 
DCM (3 × 20 mL). TThe combffined organffic exttractts were drffied over Na2SO4 and concenttratted. 
Crysttalffizattffion from EttOAc and Thexanes aforded 5-alylpyrole–2-carbaldeThyde as an of-wThffitte 
solffid (140  mg,  1.04  mmol,  63%). Specttral  datta  mattcThed lffitteratture values.17  1H-NMR (400 
MHz; acettone-d6): δ 10.92 (s, 1H), 9.41 (s, 1H), 6.91 (s, 1H), 6.09 (s, 1H), 5.99 (ddtt, J = 17.0, 
10.1, 6.7 Hz, 1H), 5.14 (d, J = 17.0 Hz, 1H), 5.07 (d, J = 10.1 Hz, 1H), 3.48 (d, J = 6.7 Hz, 2H). 
5-Benzyl-1H-pyrrole-2-carbaldeThyde (1g). A  1.7  M soluttffion  of tt-BuLffi 
ffin  penttane (1.06  mL,  1.80  mmol)  was added  dropwffise tto a sttffired 
soluttffion  of ttThe  pyrole-2-carbaldeThyde  dffimettThylamffine  dffimer (200  mg,  0.82  mmol) ffin 
anThydrous THF att -15 °C. TThe reacttffion mffixtture was sttffired for 15 mffin att ttThffis ttemperatture and 
ttThen for 30 mffin att 0 °C by wThfficTh ttffime ffitt Thad become deep vffiolett In color. TThe reacttffion mffixtture 








mffixtture was alowed tto warm tto -30 °C over 1.5 Th and ttThen 23 °C for 1 Th. Watter (20 mL) and 
satturatted aqueous sodffium bfficarbonatte (20 mL) were added and ttThe mffixtture was Theatted tto 80 
°C for  15  Th.  TThe  mffixtture  was  poured ffintto a concenttratted sodffium  bfficarbonatte soluttffion and 
exttractted wffittTh DCM (3 × 20 mL). TThe combffined organffic exttractts were drffied over Na2SO4 and 
concenttratted. Crysttalffizattffion from EttOAc and Thexanes aforded 5-benzylpyrole-2-carbaldeThyde 
as an of-wThffitte solffid (208 mg, 1.12 mmol, 69%). 1H-NMR (400 MHz; acettone-d6): δ 10.99 (s, 
1H), 9.41 (s, 1H), 7.31–7.21 (m, 5H), 6.90 (d, J = 1.7 Hz, 1H), 6.07 (d, J = 1.7 Hz, 1H); 13C-
NMR (101 MHz, acettone-d6): δ 178.61, 141.72, 140.04, 133.75, 129.50, 129.32, 127.22, 122.03, 
110.46, 34.42; HRMS (FAB) calcd for C12H11NO [M]+, 185.0841; found, 185.0840; [M+H]+, 
186.0919; found, 186.0914. 
 
MettThyl  5-formyl-2,4-dffimettThyl-1H-pyrrole-3-carboxylatte (1Th). To a 
sttffirffing soluttffion  of  5-formyl–2,4-dffimettThylpyrole–3-carboxylffic acffid (100 
mg,  0.60  mmol) ffin acettone (6.0  mL)  was added  pottassffium carbonatte (91  mg,  0.66  mmol) 
folowed by dffimettThyl sulfatte (60 µL, 0.63 mmol). TThe reacttffion mffixtture was sttffired att 23 °C for 
12  Th, ttThen fffilttered  over  Celffitte.  TThe fffiltter  pad  was  wasThed  wffittTh  EttOAc and ttThe fffilttratte  was 
concenttratted.  Crysttalffizattffion from  Thott  EttOAc and  Thexanes aforded ttThe  desffired  productt as a 
wThffitte solffid (98 mg, 0.54 mmol, 90%). 1H-NMR (400 MHz; acettone-d6): δ 11.06 (s, 1H), 9.68 
(s, 1H), 3.78 (s, 3H), 2.54 (s, 3H), 2.52 (s, 3H); 13C-NMR (101 MHz, acettone-d6): δ 177.97, 
165.80, 143.32, 134.47, 129.54, 114.13, 50.85, 13.89, 10.61; HRMS (FAB) calcd for C9H11NO3 
[M]+, 181.0739; found, 181.0739; [M+H]+, 182.0817; found, 182.0818. 
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Preparattffion of Alkene 2a 
 
(E)-2-((1H-pyrrol-2-yl)mettThylene)succffinonffittrffile (2a). To a sttffirffing soluttffion 
of  pyrole-2-carboxaldeThyde (100  mg,  1.05  mmol) ffin  THF (4.2  mL) att room 
ttemperatture was added fumaronffittrffile (103 mg, 1.31 mmol) folowed by ttrffiettThylpThospThffine (186 
µL, 1.26 mmol) dropwffise. TThe reacttffion mffixtture was sttffired att 65 ̊C for 8 Th, ttThen quencThed wffittTh 
satturatted NaHCO3 (15 mL) and exttractted wffittTh EttOAc (3 × 10 mL). TThe combffined organffic 
exttractts were wasThed wffittTh brffine, drffied over Na2SO4, and concenttratted ffin vacuo. Purffiffficattffion by 
flasTh cThromattograpThy (20% acettone ffin  pettroleum ettTher) aforded a  3:1  mffixtture  of E and Z 
ffisomers as a  wThffitte solffid (161  mg,  1.02  mmol,  97%).  Recrysttalffizattffion from  Thott  EttOAc and 
Thexanes gave 116 mg (70%) of pure E-ffisomer. mp 148-149 °C; 1H-NMR (400 MHz; acettone-
d6): δ 10.76 (s, 1H), 7.39 (s, 1H), 7.20 (m, 1H), 6.75 (m, 1H), 6.39 (m, 1H), 3.83 (s, 2H); 13C-
NMR (101 MHz, acettone-d6): δ 137.17 (CH), 126.95 (C), 124.65 (CH), 120.47 (C), 116.73 
(C),  115.97 (CH),  112.60 (CH),  94.97 (C),  19.80 (CH2);  HRMS (FAB) calcd for  C9H7N3 
[M]+, 157.0640; found, 157.0640. 
Opttffimffizffing Condffittffions for Annulattffion of 2a tto Indolffizffine 3a 
 
General Procedure. To a sttffirffing soluttffion of alkene 2a (50 mg, 0.32 mmol) ffin THF (3.2 mL) 


























unttffil conversffion  was complette as  dettermffined  by  TLC.  TThe reacttffion  was  quencThed  wffittTh 
satturatted  NH4Cl (10  mL) and exttractted  wffittTh  EttOAc (3 ×  10  mL).  TThe combffined  organffic 
exttractts were wasThed wffittTh brffine, drffied over Na2SO4, and concenttratted ffin vacuo. Purffiffficattffion by 
crysttalffizattffion from  Thott  EttOAc and  Thexanes aforded ttThe ffindolffizffine 3a.  See  Table  1 ffin ttThe 
manuscrffiptt for specffifffic ffinformattffion regardffing ttemperatture,  base ffidenttffitty,  number  of  base 
equffivalentts, reacttffions ttffimes, and yffields. 
5-Amffinoffindolffizffine-7-carbonffittrffile (3a). mp 219-200 °C; 1H-NMR (400 MHz; 
acettone-d6): δ 7.63 (d, J = 1.7 Hz, 1H), 7.44 (s, 1H), 6.96 (tt, J = 3.2 Hz, 1H), 
6.69 (d, J = 3.2 Hz, 1H), 6.06 (s, 2H), 5.95 (d, J = 1.7 Hz, 1H); 13C-NMR (101 MHz, acettone-
d6): δ 142.05 (C), 133.18 (C), 120.43 (C), 116.24 (CH), 115.07 (CH), 111.15 (CH), 104.18 
(CH), 102.18 (C), 87.93 (CH); IR (cm-1) 3427, 3335, 3029, 2217, 1651, 1629, 1538; HRMS 
(EI) calcd for C9H7N3 [M]+, 157.0640; found, 157.0641. 
One-Pott Wffittttffig/Annulattffion Sequence 
 
General Procedure. THF att room ttemperatture was added fumaronffittrffile (1.25 equffiv.) followed 
by ttrffiettThylpThospThffine (1.20 equffiv.) dropwffise. TThe reacttffion mffixtture was Theatted tto 65 ̊C. TThe 
reacttffion was monffittored by TLC for dffisappearance of sttarttffing matterffial as descrffibed ffin Fffigure 4.2 
(3-10 Th), ttThen alowed tto cool tto room ttemperatture. KOH (0.40 equffiv.) was added as a sffingle 
porttffion, and ttThe reacttffion mffixtture was sttffired for ttThe ttffime descrffibed ffin Fffigure 4.2 (0.5-16 Th) att 
room ttemperatture. TThe reacttffion was quencThed wffittTh satturatted NH4Cl and exttractted wffittTh EttOAc 





































concenttratted ffin vacuo. Purffiffficattffion by effittTher flasTh cThromattograpThy (elutted wffittTh ~20% acettone 
ffin  pettroleum ettTher for ttThe ffindolffizffines,  ~40% acettone ffin  pettroleum ettTher for ttThe 
ffimffidazopyrffidffines) or crysttalffizattffion aforded ttThe desffired cyclffized productts. 
5-amffino-1,3-dffimettThylffindolffizffine-7-carbonffittrffile (03b). 73% yffield;  mp  156-
158 °C; 1H-NMR (300 MHz; acettone-d6): δ 7.25 (d, J = 1.6 Hz, 1H), 6.42 (s, 
1H), 5.68 (d, J = 1.6 Hz, 1H), 5.42 (s, 2H), 2.96 (s, 3H), 2.26 (s, 3H); 13C-
NMR (101  MHz, acettone-d6): δ 144.65 (C),  131.99 (C),  123.79 (C),  120.61 (C),  119.44 
(CH), 115.98 (CH), 112.77 (C), 98.97 (C), 89.53 (CH), 16.01 (CH3), 10.52 (CH3); IR (cm-1) 
3429,  3347,  3083,  2917,  2203,  1636,  1607,  1558;  HRMS (FAB) calcd for  C11H11N3 [M]+, 
185.0953; found, 185.0955. 
5-Amffino-2-bromoffindolffizffine-7-carbonffittrffile (3c). 67% yffield; mp 202-203 
°C; 1H-NMR (400 MHz; acettone-d6): δ 7.74 (s, 1H), 7.41 (s, 1H), 6.77 (s, 
1H), 6.19 (s, 2H), 6.04 (s, 1H); 13C-NMR (101 MHz, acettone-d6): δ 141.61 (C), 133.65 (C), 
119.84 (C), 113.51 (CH), 110.96 (CH), 105.85 (C), 105.81 (CH), 104.07 (C), 88.97 (CH); 
IR (cm-1)  3438,  3342,  3145,  2221,  1632,  1541,  1322;  HRMS (FAB) calcd for  C9H6(79Br)N3 
[M]+, 234.9745; found, 234.9741; C9H6(81Br)N3 [M]+, 236.9725; found, 236.9737. 
5-Amffino-2-pThenylffindolffizffine-7-carbonffittrffile (3d). 72% yffield; mp 230-
232 °C; 1H-NMR (400 MHz; acettone-d6): δ 8.07 (s, 1H), 7.77 (d, J = 
7.4 Hz, 2H), 7.44–7.40 (m, 3H), 7.28 (tt, J = 7.4 Hz, 1H), 7.06 (s, 1H), 6.13 (s, 2H), 5.99 (s, 
1H); 13C-NMR (101  MHz, acettone-d6): δ  142.01 (C),  135.58 (C),  134.14 (C),  131.92 (C), 
129.73 (CH),  127.86 (CH),  126.87 (CH),  120.31 (C),  114.73 (CH),  108.16 (CH),  102.95 
(C), 101.36 (CH), 88.48 (CH); IR (cm-1) 3429, 3336, 3139, 2217, 1603, 1495; HRMS (FAB) 













5-Amffino-3-mettThylffindolffizffine-7-carbonffittrffile (3e). 74% yffield;  mp  134-135 
°C; 1H-NMR (400 MHz; acettone-d6): δ 7.31 (s, 1H), 6.57 (d, J = 3.9 Hz, 1H), 
6.50 (d, J = 3.9 Hz, 1H), 5.77 (s, 1H), 5.53 (s, 2H), 3.00 (s, 3H); 13C-NMR (101 MHz, acettone-
d6): δ  144.91 (C),  134.75 (C),  124.74 (C),  120.29 (C),  117.97 (CH),  117.48 (CH),  103.76 
(CH), 100.68 (C), 90.08 (CH), 16.23 (CH3); IR (cm-1) 3414, 3343, 2208, 1634, 1542, 1472; 
HRMS (FAB) calcd for C10H9N3 [M]+, 171.0797; found, 171.0794. 
3-Alyl-5-amffinoffindolffizffine-7-carbonffittrffile (3f). 72% yffield; Rf =  0.30 (25% 
acettone/pettroleum ettTher); 1H-NMR (400 MHz; acettone-d6): δ 7.39 (s, 1H), 
6.69 (d, J = 4.0 Hz, 1H), 6.60 (d, J = 4.0 Hz, 1H), 6.23 (ddtt, J = 17.0, 10.5, 5.7 Hz, 1H), 5.86 (s, 
1H), 5.45 (s, 2H), 5.20 (dd, J = 10.5, 1.1 Hz, 1H), 4.98 (dd, J = 17.0, 1.1 Hz, 1H), 4.17 (d, J = 
5.7  Hz,  2H); 13C-NMR (101  MHz, acettone-d6): δ  144.48 (C),  139.11 (CH2),  135.20 (C), 
126.57 (C), 120.15 (C), 118.19 (CH), 117.51 (CH), 117.28 (CH), 104.10 (CH), 101.06 (C), 
90.84 (CH), 34.25 (CH2); IR (cm-1) 3399, 3331, 2208, 1633, 1540, 1440; HRMS (FAB) calcd 
for C12H11N3 [M]+, 197.0953; found, 197.0960. 
5-Amffino-3-benzylffindolffizffine-7-carbonffittrffile (3g). 72% yffield;  mp  121-
122 °C; 1H-NMR (400 MHz; acettone-d6): δ 7.39 (s, 1H), 7.32 (tt, J = 7.5 
Hz, 2H), 7.23 (tt, J = 7.3 Hz, 1H), 7.14 (d, J = 7.6 Hz, 2H), 6.61 (s, 2H), 
5.79 (s, 1H), 5.27 (br. s, 2H), 4.77 (s, 2H); 13C-NMR (101 MHz, acettone-d6): δ 144.47 (C), 
141.47 (C),  135.42 (C),  129.70 (CH),  129.15 (CH),  127.42 (CH),  127.25 (C),  120.08 (C), 
119.42 (CH),  117.58 (CH),  104.11 (CH),  101.22 (C),  90.95 (CH),  35.87 (CH2); IR (cm-1) 












MettThyl  5-amffino-7-cyano-1,3-dffimettThylffindolffizffine-2-carboxylatte (3Th). 
65% yffield; Rf =  0.30 (25% acettone/pettroleum ettTher); 1H-NMR (400 
MHz; acettone-d6): δ 7.42 (s, 1H), 5.80 (s, 1H), 5.62 (br. s, 2H), 3.88 (s, 
3H), 3.26 (s, 3H), 2.44 (s, 3H); 13C-NMR (101 MHz, acettone-d6): δ 166.74 (C), 145.41 (C), 
131.46 (C), 128.62 (C), 119.93 (C), 119.57 (C), 116.97 (CH), 114.72 (C), 101.27 (C), 91.39 
(CH), 51.41 (CH3), 14.20 (CH3), 10.83 (CH3); IR (cm-1) 3428, 3335, 3139, 2983, 2217, 1738, 
1628, 1537, 1220; HRMS (FAB) calcd for C13H13N3O2 [M]+, 243.1008; found, 243.1007. 
5-amffinoffimffidazo[1,5-a]pyrffidffine-7-carbonffittrffile (3ffi). 72% yffield;  mp  226-227 
°C; 1H-NMR (300 MHz; acettone-d6): δ 8.47 (s, 1H), 7.61 (s, 1H), 7.58 (d, J = 
1.3 Hz, 1H), 6.40 (s, 2H), 5.93 (d, J = 1.3 Hz, 1H); 13C-NMR (101 MHz, acettone-d6): δ 140.79 
(C),  130.80 (C),  126.83 (C),  124.46 (CH),  119.60 (C),  114.00 (CH),  105.13 (CH),  88.64 
(CH); IR (cm-1) 3401, 3136, 2222, 1659, 1544, 1118; HRMS (FAB) calcd for C8H6N4 [M]+, 
159.0671; found, 159.0669. 
5-amffino-1-mettThylffimffidazo[1,5-a]pyrffidffine-7-carbonffittrffile (3j). 65% yffield; 
mp 233-234 °C; 1H-NMR (400 MHz; MeOD): δ 8.30 (s, 1H), 7.38 (s, 1H), 
5.75 (s,  1H),  2.47 (s,  3H); 13C-NMR (100  MHz,  MeOD): δ  141.22 (C),  132.51 (C),  127.72 
(C), 125.40 (CH), 120.12 (C), 113.82 (CH), 104.49 (C), 88.51 (CH), 12.37 (CH3); IR (cm-1) 
3398, 3331, 2209, 1633, 1541, 1441; HRMS (FAB) calcd for C9H8N4 [M]+, 172.0749; found, 
172.0744. 
5-amffino-3-mettThylffimffidazo[1,5-a]pyrffidffine-7-carbonffittrffile (3k). 71% yffield; 
mp 214-215 °C; 1H-NMR (400 MHz; MeOD): δ 8.30 (s, 1H), 7.38 (s, 1H), 
5.75 (s,  1H),  2.47 (s,  3H); 13C-NMR (100  MHz,  MeOD): δ 141.22 (C),  132.51 (C),  127.72 





















3437,  3340,  2221,  1645,  1539,  1431;  HRMS (FAB) calcd for  C9H9N4 [M+H]+,  173.0828; 
found, 173.0828. 
5-amffino-1-cThloro-3-pThenylffimffidazo[1,5-a]pyrffidffine-7-carbonffittrffile (3l). 69% 
yffield; mp 201-202 °C; 1H-NMR (400 MHz; acettone-d6): δ 8.04 (d, J = 6.8 Hz, 
2H),  7.53-7.48 (m,  4H),  7.24 (s,  1H),  4.63-4.45 (m,  2H); 13C-NMR (101 
MHz, DMSO-d6): δ 146.75 (C), 133.45 (C), 131.82 (C), 129.71 (CH), 128.90 (CH), 128.56 
(CH), 125.50 (CH), 122.06 (C), 119.21 (C), 117.11 (C), 99.07 (C), 18.44 (CH2); IR (cm-1) 
3190,  2207,  1621,  1479;  HRMS (FAB) calcd for  C14H935ClN4 [M]+,  269.0594; found, 
269.0587; C14H937ClN4 [M]+, 271.0565; found, 271.0566. 
5-amffinoffimffidazo[1,2-a]pyrffidffine-7-carbonffittrffile (3m). 72% yffield; Rf =  0.35 
(40% acettone/pettroleum ettTher); 1H-NMR (400  MHz; acettone-d6): δ 7.98 (s, 
1H), 7.75 (d, J = 1.4 Hz, 1H), 7.43 (s, 1H), 6.52 (s, 1H), 6.24 (d, J = 1.4 Hz, 1H); 13C-NMR 
(101 MHz, MeOD): δ 144.74 (C), 143.53 (C), 133.74 (CH), 117.93 (C), 110.24 (C), 109.22 
(CH), 107.97 (CH), 90.10 (CH); IR (cm-1) 3382, 3152, 2233, 1664, 1544, 1494; HRMS (EI) 
calcd for C8H6N4 [M+H]+, 159.0671; found, 159.0667. 
5-amffino-2,3-dffimettThylffimffidazo[1,2-a]pyrffidffine-7-carbonffittrffile (3n). 73% 
yffield; mp 220-221 °C; 1H-NMR (400 MHz; MeOD): δ 7.09 (s, 1H), 6.01 
(s, 1H), 2.80 (s, 3H), 2.31 (s, 3H); 13C-NMR (101 MHz, MeOD): δ 146.83 (C), 145.52 (C), 
142.59 (C),  119.31 (C),  110.87 (CH),  110.82 (C),  109.74 (C),  93.60 (CH),  12.91 (CH3), 
11.54 (CH3); IR (cm-1)  3443,  2226,  1656,  1532,  1381;  HRMS (FAB) calcd for  C10H10N4 


















One-Pott Alkylattffion/Cyclffizattffion Sequence of 2a tto Indolffizffines 4a-e 
 
General Procedure. To a sttffirffing soluttffion of alkene 2a (100 mg, 0.63 mmol) ffin THF (6.3 mL) 
att -78 °C was added fresThly prepared 1.0 M LDA (1.27 mL, 1.27 mmol) dropwffise. TThe mffixtture 
was alowed tto sttffir att -78 °C for 45 mffin before slow addffittffion of ttThe electtropThffile (1.0 equffiv). TThe 
reacttffion mffixtture was sttffired att -78 °C for 1.5 Th, ttThen alowed tto warm tto room ttemperatture over 
10 mffinuttes. TThe reacttffion was quencThed wffittTh satturatted NH4Cl (15 mL) and ttThe crude mffixtture 
was exttractted wffittTh EttOAc (3 × 15 mL). TThe combffined organffic exttractts were wasThed wffittTh brffine, 
drffied  over  Na2SO4, and concenttratted ffin vacuo.  Purffiffficattffion  by flasTh cThromattograpThy (elutted 
wffittTh ~20% acettone ffin pettroleum ettTher) or crysttalffizattffion from Thott EttOAc and Thexanes aforded 
ttThe desffired ffindolffizffines. 
 5-amffino-6-mettThylffindolffizffine-7-carbonffittrffile (4a). 87% yffield; Rf = 0.30 (20% 
acettone/pettroleum ettTher); 1H-NMR (400 MHz; acettone-d6): δ 7.62-7.62 (m, 
1H), 7.47 (s, 1H), 6.92 (dd, J = 4.0, 2.8 Hz, 1H), 6.63 (dd, J = 4.0, 1.1 Hz, 1H), 5.78 (s, 2H), 
2.34 (s, 3H); 13C-NMR (101 MHz, acettone-d6): δ 132.75 (C), 129.17 (C), 127.60 (C), 126.49 
(CH),  121.21 (CH),  116.63 (CH),  114.07 (C),  105.65 (CH),  103.57 (C),  14.91 (CH3); IR 
(cm-1) 3368, 3326, 2213, 1651, 1529, 1319; HRMS (FAB) calcd for C10H9N3 [M]+, 171.0797; 
found, 171.0794. 
 6-alyl-5-amffinoffindolffizffine-7-carbonffittrffile (4b). 98% yffield; Rf =  0.30 (20% 
acettone/pettroleum ettTher); 1H-NMR (400  MHz; acettone-d6): δ 7.66-7.65 




























(s, 2H), 5.09 (d, J = 17.2 Hz, 1H), 5.04 (d, J = 10.0 Hz, 1H), 3.55 (d, J = 5.9 Hz, 2H); 13C-NMR 
(100  MHz, acettone-d6): δ 138.90 (C),  135.75 (CH),  132.33 (C),  119.63 (C),  116.25 (CH), 
115.93 (CH), 115.74 (CH), 111.10 (CH), 104.61 (C), 103.85 (CH), 96.08 (C), 32.62 (CH2); 
IR (cm-1)  3399,  3331,  2208,  1634,  1540,  1440;  HRMS (FAB) calcd for  C12H11N3 [M]+, 
197.0953; found, 197.0958. 
 5-amffino-6-(prop-2-yn-1-yl)ffindolffizffine-7-carbonffittrffile (4c). 94% yffield; Rf 
= 0.30 (20% acettone/pettroleum ettTher); 1H-NMR (400 MHz; acettone-d6): δ 
7.70 (m, 1H), 7.53 (s, 1H), 6.96 (tt, J = 3.7 Hz, 1H), 6.68 (d, J = 3.7 Hz, 1H), 6.01 (s, 2H), 3.72 
(d, J = 2.6 Hz, 2H), 2.52 (tt, J = 2.6 Hz, 1H); 13C-NMR (101 MHz, acettone-d6): δ 139.08 (C), 
132.31 (C), 119.27 (C), 116.52 (CH), 116.00 (CH), 111.48 (CH), 104.29 (CH), 103.87 (C), 
93.88 (C), 81.32 (C), 71.01 (CH), 18.26 (CH2); IR (cm-1) 3428, 3336, 3309, 2216, 1629, 1536, 
1323; HRMS (FAB) calcd for C12H9N3 [M]+, 195.0796; found, 197.0795. 
 5-amffino-6-benzylffindolffizffine-7-carbonffittrffile (4d). 98% yffield; Rf =  0.25 
(20% acettone/pettroleum ettTher); 1H-NMR (400 MHz; acettone-d6): δ 7.68 
(m, 1H), 7.56 (s, 1H), 7.27 (d, J = 4.3 Hz, 4H), 7.18 (q, J = 4.3 Hz, 1H), 6.96 (tt, J = 3.7 Hz, 1H), 
6.69 (d, J = 3.7 Hz, 1H), 5.86 (s, 2H), 4.20 (s, 2H); 13C-NMR (101 MHz, acettone-d6): δ 140.43, 
139.32, 132.38, 129.22, 128.90, 127.01, 119.87, 116.37, 116.13, 111.35, 105.00, 104.04, 97.52, 
34.01; IR (cm-1)  3340,  2216,  1698,  1639,  1538;  HRMS (FAB) calcd for  C16H13N3 [M]+, 
247.1110; found, 247.1099. 
 2-oxo-2,3-dffiThydro-1H-pyrrolo[2,3-e]ffindolffizffine-4-carbonffittrffile (4e). 90% 
yffield; Rf = 0.30 (25% acettone/pettroleum ettTher); 1H-NMR (300 MHz; acettone-
d6): δ 10.62 (s, 1H), 7.73 (s, 1H), 7.65 (dd, J = 1.7, 0.7 Hz, 1H), 7.04 (dd, J = 












(C),  137.22 (C),  133.31 (C),  118.43 (CH),  118.19 (C),  117.61 (CH),  111.62 (CH),  105.33 
(CH),  98.82 (C),  98.51 (C),  36.07 (CH2); IR (cm-1)  3336,  3231,  2217,  1640,  1539,  1380; 
HRMS (FAB) calcd for C11H7N3O [M]+, 197.0589; found, 197.0595. 
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Summary and Conclusffions 
5.1 Obesffitty Epffidemffic 
TThe prevalence of obesffitty ffin ttThe Thuman populattffion Thas rapffidly ffincreased over ttThe lastt few 
decades.  As a resultt,  obesffitty-relatted  dffiseases, sucTh as  Theartt  dffisease1,2, sttroke3, and ttype  2 
dffiabettes4, are  on ttThe rffise, causffing a sttaggerffing  medffical and fffinancffial  burden.5 Despffitte ttThe 
ffincreased ffincffidence  of  obesffitty, few  pTharmacologffical  opttffions exffistt tto combatt ttThe  dffisease.  TThe 
prffimary mode of acttffion for recentt drugs ffinvolves ttargettffing recepttors wffittThffin ttThe CNS tto elfficffitt ttThe 
feelffing  of sattffietty and reduce food ffinttake.  Unforttunattely, several  of ttThese  drugs  Thave  been 
removed from ttThe markett for ttTheffir severe sffide efectts, sucTh as anxffietty, depressffion, and sufficffidal 
ffinttenttffions.  Outtsffide  of ttThe  CNS,  only  one clffinfficaly-used  drug,  orlffisttatt, actts ffin ttThe  perffipTheral 
ttffissues tto ttreatt  obesffitty.  Orlffisttatt ffinThffibffitts  pancreattffic lffipases tto  preventt ttThe  breakdown and 
absorpttffion  of  dffiettary ttrffiglycerffides.  WThffile ttThffis  promottes modestt  weffigThtt loss, excrettffion  of ttThe 
unabsorbed fatt leads tto undesffirable sffide efectts, sucTh as fecal ffinconttffinence and fatt-soluble 
vffittamffin deffficffiency, ttThatt lffimffitt ttThe ttTherapeuttffic benefffitt of ttThe drug. Due tto ttThe sffide efectts of ttThe 
curentt ttTherapffies, new ttargetts are needed tto ttreatt a growffing obese populattffion. 
5.2 GPAT as a TTherapeuttffic Targett for Obesffitty 
Pottenttffial mettThods for ttreattffing obesffitty ffinclude ttThe ffinThffibffittffion of ttThe bffiosynttThesffis of TAG, ttThe 
major componentt  of anffimal  body fatt, and ttThe sttffimulattffion  of fatttty acffid  mettabolffism.  GPAT 
cattalyzes ttThe fffirstt commffitttted and ratte-lffimffittffing sttep ffin TAG bffiosynttThesffis, ttThe acylattffion of G3P 
wffittTh long cThaffin fatttty acyl-CoAs.6 TThe acttffivffitty  of  GPAT ffis lffinked tto ttThe acttffivffitty  of CPT1, ttThe 
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enzyme responsffible for ttThe ratte-lffimffittffing sttep ffin ttThe β-oxffidattffion of fatttty acffids. GPAT and CPT1 
are bottTh locatted on ttThe outter mffittocThondrffial membrane wThere ttThey compette for fatttty acyl-CoA 
substtrattes.7 Sttudffies Thave sThown ttThatt GPAT plays a major role ffin ttThe parttffittffionffing of fatttty acyl-
CoA substtrattes bettween ttThe TAG bffiosynttThesffis and fatttty acffid mettabolffic pattThways.8, 9 InThffibffittffion 
of GPAT, ttTherefore, Thas ttThe pottenttffial tto lffimffitt TAG bffiosynttThesffis wThffile sttffimulattffing β-oxffidattffion 
ttThrougTh CPT1, makffing ffitt an attttracttffive ttargett for obesffitty ttTherapy. 
Our lab recenttly descrffibed ttThe desffign, synttThesffis, and evaluattffion of sulfonamffidobenzoffic and 
sulfonamffidopThospThonffic acffids as ttThe fffirstt-reportted smal molecule ffinThffibffittors of GPAT.10 TThese 
compounds were desffigned tto mffimffic key ffintteracttffions of ttThe proposed enzymattffic ttransffittffion sttatte. 
TThe o-substtffittutted (nonanesulfonamffido)benzoffic acffid 1b, sThown ffin  Fffig.  5.1, demonsttratted 
modestt ffinThffibffittory acttffivffitty of 24.7 ± 2.1 µM agaffinstt GPAT ffin vffittro and was selectted as ttThe bestt 
candffidatte for sttudffies ffin DIO mffice. TThe ffin vffivo resultts were quffitte promffisffing, wffittTh ttreatted mffice 
sThowffing susttaffined weffigThtt loss of 15.6–17.6% even aftter cessattffion of ttreattmentt.11 TThese resultts 
verffifffied ttThatt  GPAT ffinThffibffittffion, ffin general, and ttThe sulfonamffidobenzoffic acffid scafold, ffin 
parttfficular, Thas pottenttffial as an obesffitty ttTherapeuttffic. 
	  
Fffigure 5.1 Sttructtures and ffin vffittro ffinThffibffittory datta for o-(alkanesulfonamffido)benzoffic acffids 1a–c 
5.3 Second-Generattffion GPAT InThffibffittors: Probffing for an Acttffive Sffitte HydropThobffic Pockett 
Gffiven ttThe encouragffing resultts of 1a-c ffin vffivo, ttThe sulfonamffidobenzoffic acffid scafold was used 







1a (x = 16) IC50 = 18.3 ± 1.9 µM
1b (x = 9) IC50 = 24.7 ± 2.1 µM




ffinThffibffittors, modelffing sttudffies  were  performed  wffittTh ttThe  octtyl analog 1c ffin ttThe acttffive sffitte  of ttThe 
GPAT squasTh Thomolog.12 TThe energy-mffinffimffized docked ffinThffibffittor, sThown ffin Fffig. 5.2, was found 
tto bffind ffin ttThe acttffive sffitte  of  GPAT  wffittTh ffitts carboxylatte anffion posffittffioned ffin ttThe  puttattffive 
pThospThatte  bffindffing  domaffin comprffised  of ttThree conserved cattffionffic resffidues (Lys193,  Arg235, 
and  Arg237).  TThe lffipopThffilffic  C8-ttaffil  of ttThe sulfonamffide was  bound  wffittThffin a long  ThydropThobffic 
ttunnel ThypottThesffized as ttThe fatttty acyl-CoA substtratte bffindffing sffitte. In addffittffion, a complex nettwork 
of ThydropThobffic cavffittffies and ttunnels were observed ttThatt wound ttThrougThoutt ttThe enzyme. One of 
ttThese cavffittffies was posffittffioned exttendffing from ttThe C–4 and C–5 posffittffions of ttThe benzoffic acffid rffing 
and lffined  wffittTh ttThe  ThydropThobffic and aromattffic resffidues PThe98,  Gly99,  Tyr102, Ile103,  Ala143, 
Leu176, Pro179, and PThe180. We dffirectted ttThe desffign of our second-generattffion of ffinThffibffittors tto 
bffind wffittThffin ttThffis cavffitty. 
	  
Fffigure 5.2 (Octtanesulfonamffido)benzoffic acffid docked ffin GPAT and proposed ffinThffibffittor analogs 
A serffies  of analogs  of  docked ffinThffibffittor 1b was  desffigned and synttThesffized  wffittTh aromattffic 
substtffittuentts appended tto ttThe 4- and 5-posffittffions usffing a serffies of lffinker regffions. TThe aryl moffiettffies 
were cThosen tto encourage π-sttackffing  wffittTh aromattffic resffidues ffin ttThe  ThydropThobffic  pockett  wThffile 


























ttThe lffinkers  were cThosen tto sample  dffiferentt  orffienttattffions and geomettrffies for exttensffion  of ttThe 
substtffittuentt ffintto ttThe pockett. TThffis sett of compounds was evaluatted ffin vffittro for GPAT ffinThffibffittffion. 
In general, ThydropThobffic and cThloro substtffittuentts led tto an ffincrease ffin ffinThffibffittory acttffivffitty, as 
sThown ffin  Fffig.  5.3. Conversely, more  polar and  Thydrogen-bondffing substtffittuentts, sucTh as fluoro 
and Thydroxyl moffiettffies, sThowed a decrease ffin ffinThffibffittory acttffivffitty.  WThffile ttThe observed efectts of 
substtffittuttffing att ttThe 4- and 5-posffittffions of ttThe benzoffic acffid were modestt, ttThe datta were consffisttentt 
wffittTh ttThe  presence  of a  ThydropThobffic  pockett as ffidenttffifffied  by ffin sffilffico sttudffies. One ffinThffibffittor, p-
bffipThenylkettone-substtffittutted 5, exThffibffitted a  3-fold ffincrease ffin ffinThffibffittory acttffivffitty and, att 8.5 μM, 
representts ttThe mostt pottentt GPAT ffinThffibffittor reportted tto datte. TThe benzopThenone moffietty ffin ttThffis 
compound could alow for  pThottocrosslffinkffing experffimentts tto ascerttaffin ttThe  bffindffing sffitte  of ttThe 
ffinThffibffittor on GPAT or any of-ttargett protteffins. 
	  
Fffigure 5.3 HydropThobffic- and cThloro-substtffittutted ffinThffibffittors wffittTh mostt pottentt acttffivffitty 
5.4 Developmentt of MettThodology tto Access Substtffittutted Indoles 
WThffile several analogs  of ttThe sulfonamffidobenzoffic acffid scafold  demonsttratted  promffisffing 

































ttThatt  precluded ffin vffivo ttesttffing.  To ffimprove solubffilffitty, a relatted serffies  of compounds  was 
desffigned, replacffing ttThe sffimple  benzoffic acffid  wffittTh carboxylffic acffid-substtffittutted  Thetteroaromattffic 
sttructtures.  TThe fffirstt  Thetteroaromattffic scafold focused  on a  7-amffinoffindole-5-carboxylffic acffid 
sttructture, sThown ffin  Fffig.  5.4.  WffittTh  no exffisttffing  mettThod tto rapffidly synttThesffize ttThffis lffibrary  of 
compounds, we devffised a new, practtffical routte for ttTheffir preparattffion.13 
	  
Fffigure 5.4 Desffign of ffindole-based GPAT ffinThffibffittors and proposed synttThettffic ffinttermedffiatte 
TThe new routte, sThown ffin  Fffig.  5.5, commences  wffittTh a  one-pott, ttThree-componentt  Wffittttffig 
reacttffion  of substtffittutted  pyrole-3-carboxaldeThydes, sucTh as 8, wffittTh fumaronffittrffile and a 
ttrffialkylpThospThffine. TThffis reacttffion was opttffimffized tto aford predomffinanttly ttThe E-alkenes 9, wThfficTh 
are requffired for ttThe subsequentt reacttffion. TThe alylffic  nffittrffiles  undergo a  Lewffis-acffid  medffiatted 
cycloaromattffizattffion tto aford 2- and  3-substtffittutted 7-amffino-5-cyanoffindoles sucTh as 10 ffin  ThffigTh 
yffield. Altternattffively, ttThe E-alkenes can also be furttTher functtffionalffized att ttThe alylffic posffittffion prffior tto 
cyclffizattffion. Dffianffion formattffion, acThffieved by addffittffion of 2 equffivalentts of LDA, reactts wffittTh a Thostt 
of electtropThffiles selecttffively att ttThe alylffic  posffittffion, wThfficTh upon annulattffion, furnffisTh ffindoles 
















































readffily convertted tto GPAT ffinThffibffittors or a number of ottTher medfficffinal cThemffisttry ttargetts ffin ttThe 
lffitteratture. 
	  
Fffigure 5.5 SynttThesffis of 2-, 3-, and 6-substtffittutted 7-amffino-5-cyanoffindoles 
5.5 Developmentt of MettThodology tto Access Substtffittutted N-Fused Hetteroaromattffic Bfficycles 
In addffittffion tto ffindole-based compounds, N-fused Thetteroaromattffic analogs were also desffired. 
TThese sttructtures, ffincludffing ffindolffizffine (13), ffimffidazo[1,2-a]pyrffidffine (14), and ffimffidazo[1,5-
a]pyrffidffine (15) Thetterocycles, are ffisostterffic  wffittTh ffindole,  butt eacTh  provffides a  unffique electtronffic 
sttructture ttThatt can subttly altter ffinThffibffittor bffindffing wffittThffin ttThe  GPAT acttffive sffitte.  Lffike  wffittTh ttThe 
ffindoles,  no suffficffientt  mettThod exffistted for ttThe dffirectt synttThesffis  of ttThe  desffired  5-amffino-7-cyano-








































































Fffigure 5.6 Desffign of N-fused Thetteroaromattffic bfficycle ffinThffibffittors of GPAT 
MecThanffisttfficaly relatted tto ttThe ffindole mettThod menttffioned vffide supra, our routte tto ttThe N-fused 
Thetteroaromattffic  bfficycles ffinvolves a ttThree-componentt  Wffittttffig reacttffion.  RattTher ttThan ttThe  3-
formylpyroles used  prevffiously, substtffittutted azole-2-carboxaldeThydes, sucTh as 16, undergo 
olefffinattffion ffin ttThe  presence  of fumaronffittrffile and ttrffiettThylpThospThffine tto aford  predomffinanttly E-
alkenes. Deprottonattffion of ttThffis ffinttermedffiatte tto ttThe azolffide anffion, promotted by ffin sffittu addffittffion of 
cattalyttffic KOH, folowed by cycloaromattffizattffion, furnffisThed ttThe ttargett Thetteroaromattffic sttructtures 
ffin a sffingle pott ffin good yffield. 
	  
Fffigure 5.7 One-pott synttThesffis of N-fused Thetteroaromattffic bfficycles 
Altternattffively, addffittffion of 2 equffivalentts of sttrong base (e.g., LDA, LffiHMDS) tto ttThe ffisolable 
Wffittttffig  productt promottes a second  deprottonattffion alylffic tto ttThe  nffittrffile.  TThffis formed  dffianffion 
reactts  wffittTh electtropThffiles selecttffively att ttThe alylffic  posffittffion att –78 °C.  TThe resulttffing  monoanffion 































































































ttThen  undergoes ttThe  desffired annulattffion  wThen  warmed tto room ttemperatture tto aford  6-
substtffittutted Thetterocycles. 
	  
Fffigure 5.8 Tandem alkylattffion/cycloaromattffizattffion routte tto 6-substtffittutted ffindolffizffines 
5.6 Conclusffions 
TThe ffinThffibffittffion  of  GPAT remaffins a valffid sttrattegy for combattffing  obesffitty.  Even  modestt 
ffinThffibffittffion  of ttThe enzyme  by sulfonamffidobenzoffic acffids Thas demonsttratted sffignffiffficantt and 
susttaffined weffigThtt loss. TThffis ttThesffis Thas been devotted tto ttThe desffign and synttThesffis of more pottentt 
GPAT ffinThffibffittors. Dockffing sttudffies of compound 1c ffin ttThe GPAT acttffive sffitte Thave suggestted ttThe 
presence  of a  ThydropThobffic  pockett exttendffing from ttThe  4- and  5-posffittffions. SynttThesffis and 
evaluattffion of several analogs substtffittutted att ttThese posffittffions Thave ffindfficatted ttThatt ThydropThobffic and 
cThloro substtffittuentts resultt ffin more efecttffive GPAT ffinThffibffittors ttThan ffincorporattffion of more polar 
groups, pottenttffialy valffidattffing our ffinThffibffittor bffindffing model. 
TThe desffign and synttTheses of relatted Thetterocyclffic analogs, ffincludffing ffindoles, ffindolffizffines, and 
ffimffidazopyrffidffines,  were also  underttaken.  TThffis requffired  new  mettThodology tto  be  developed ffin 
order tto effficffienttly synttThesffize approprffiattely substtffittutted Thetterocycles. WThffile relatted, ttThe routtes 
tto ttThe ffindole and N-fused  Thetteroaromattffic classes  were  mecThanffisttfficaly  dffisttffinctt.  BottTh relffied 
Theavffily  on a  one-pott, ttThree-componentt  Wffittttffig reacttffion  of azole aldeThydes.  For ttThe ffindoles, 
Lewffis acffid-medffiatted acttffivattffion  of ttThe  nffittrffile resultted ffin ttThe ffinttramolecular  Houben-HoescTh-
ttype reacttffion folowed by aromattffizattffion. In conttrastt, base-cattalyzed deprottonattffion of ttThe azole 






















ffinexpensffive, and effficffientt mettThods for ttThe preparattffion of ttThese ffimporttantt classes of Thetterocycles. 
TThe rapffid generattffion of Thetterocyclffic analogs wffil affid ffin our ongoffing researcTh tto dffiscover more 
pottentt  GPAT ffinThffibffittors and furttTher  pursue  our approacTh tto  develop a  new  pTharmacologffical 
ttreattmentt for obesffitty. 
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